"","title","geo_accession","status","submission_date","last_update_date","type","channel_count","source_name_ch1","organism_ch1","characteristics_ch1","characteristics_ch1.1","characteristics_ch1.2","characteristics_ch1.3","characteristics_ch1.4","characteristics_ch1.5","molecule_ch1","extract_protocol_ch1","label_ch1","label_protocol_ch1","taxid_ch1","hyb_protocol","scan_protocol","data_processing","platform_id","contact_name","contact_email","contact_laboratory","contact_institute","contact_address","contact_city","contact_state","contact_zip/postal_code","contact_country","supplementary_file","data_row_count","age:ch1","cmstage:ch1","cnstage:ch1","ctstage:ch1","disease state:ch1","Sex:ch1"
"GSM3063093","BT0010 Biliary Tract Cancer","GSM3063093","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063093/suppl/GSM3063093_SH56954_Cell2_20150820_1327_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063094","BT0022 Biliary Tract Cancer","GSM3063094","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 59","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063094/suppl/GSM3063094_SH56957_Cell2_20150820_1339_1Color_IntegratedResult.txt.gz","2565","59","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063095","BT0043 Biliary Tract Cancer","GSM3063095","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063095/suppl/GSM3063095_SH56B01_Cell3_20150821_1418_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063096","BT0050 Biliary Tract Cancer","GSM3063096","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063096/suppl/GSM3063096_SH56H06_Cell3_20150917_1344_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063097","BT0071 Biliary Tract Cancer","GSM3063097","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 60","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063097/suppl/GSM3063097_SH56B09_Cell3_20150821_1446_1Color_IntegratedResult.txt.gz","2565","60","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063098","BT0075 Biliary Tract Cancer","GSM3063098","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 61","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063098/suppl/GSM3063098_SH56B10_Cell3_20150821_1450_1Color_IntegratedResult.txt.gz","2565","61","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063099","BT0091 Biliary Tract Cancer","GSM3063099","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063099/suppl/GSM3063099_SH56B14_Cell3_20150821_1506_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063100","BT0100 Biliary Tract Cancer","GSM3063100","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063100/suppl/GSM3063100_SH56B16_Cell4_20150825_1552_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063101","BT0105 Biliary Tract Cancer","GSM3063101","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 59","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063101/suppl/GSM3063101_SH56B18_Cell1_20150825_1557_1Color_IntegratedResult.txt.gz","2565","59","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063102","BT0112 Biliary Tract Cancer","GSM3063102","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063102/suppl/GSM3063102_SH56B19_Cell4_20150825_1604_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063103","BT0119 Biliary Tract Cancer","GSM3063103","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063103/suppl/GSM3063103_SH56B21_Cell3_20150825_1611_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063104","BT0127 Biliary Tract Cancer","GSM3063104","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 76","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063104/suppl/GSM3063104_SH56B25_Cell3_20150825_1619_1Color_IntegratedResult.txt.gz","2565","76","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063105","BT0139 Biliary Tract Cancer","GSM3063105","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063105/suppl/GSM3063105_SH56B29_Cell3_20150825_1631_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063106","BT0146 Biliary Tract Cancer","GSM3063106","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063106/suppl/GSM3063106_SH56B31_Cell2_20150825_1638_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063107","BT0149 Biliary Tract Cancer","GSM3063107","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063107/suppl/GSM3063107_SH56B32_Cell1_20150825_1641_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063108","BT0163 Biliary Tract Cancer","GSM3063108","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063108/suppl/GSM3063108_SH56B36_Cell3_20150825_1655_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063109","BT0173 Biliary Tract Cancer","GSM3063109","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063109/suppl/GSM3063109_SH56B39_Cell1_20150825_1705_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063110","BT0174 Biliary Tract Cancer","GSM3063110","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063110/suppl/GSM3063110_SH56B39_Cell2_20150825_1706_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063111","BT0179 Biliary Tract Cancer","GSM3063111","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063111/suppl/GSM3063111_SH56B40_Cell3_20150826_1523_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063112","BT0192 Biliary Tract Cancer","GSM3063112","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063112/suppl/GSM3063112_SH56B43_Cell4_20150826_1536_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063113","BT0194 Biliary Tract Cancer","GSM3063113","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 76","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063113/suppl/GSM3063113_SH56B44_Cell2_20150826_1538_1Color_IntegratedResult.txt.gz","2565","76","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063114","BT0195 Biliary Tract Cancer","GSM3063114","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063114/suppl/GSM3063114_SH56B44_Cell3_20150826_1539_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063115","BT0200 Biliary Tract Cancer","GSM3063115","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063115/suppl/GSM3063115_SH56B45_Cell4_20150826_1544_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063116","BT0203 Biliary Tract Cancer","GSM3063116","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 42","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063116/suppl/GSM3063116_SH56B46_Cell3_20150826_1547_1Color_IntegratedResult.txt.gz","2565","42","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063117","BT0211 Biliary Tract Cancer","GSM3063117","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 26","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063117/suppl/GSM3063117_SH56B50_Cell3_20150826_1555_1Color_IntegratedResult.txt.gz","2565","26","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063118","BT0212 Biliary Tract Cancer","GSM3063118","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063118/suppl/GSM3063118_SH56H07_Cell2_20150917_1347_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063119","BT0232 Biliary Tract Cancer","GSM3063119","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063119/suppl/GSM3063119_SH56B56_Cell4_20150826_1616_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063120","BT0251 Biliary Tract Cancer","GSM3063120","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063120/suppl/GSM3063120_SH5X141_Cell4_20160204_1145_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063121","BT0257 Biliary Tract Cancer","GSM3063121","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 43","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063121/suppl/GSM3063121_SH63Q18_Cell2_20160628_1522_1Color_IntegratedResult.txt.gz","2565","43","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063122","BT0258 Biliary Tract Cancer","GSM3063122","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063122/suppl/GSM3063122_SH63Q18_Cell3_20160628_1523_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063123","BT0278 Biliary Tract Cancer","GSM3063123","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 80","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063123/suppl/GSM3063123_SH63Q24_Cell3_20160629_1517_1Color_IntegratedResult.txt.gz","2565","80","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063124","BT0282 Biliary Tract Cancer","GSM3063124","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063124/suppl/GSM3063124_SH63Q25_Cell3_20160629_1521_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063125","BT0283 Biliary Tract Cancer","GSM3063125","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063125/suppl/GSM3063125_SH63Q25_Cell4_20160629_1522_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063126","BT0292 Biliary Tract Cancer","GSM3063126","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063126/suppl/GSM3063126_SH63Q29_Cell1_20160629_1531_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063127","BT0294 Biliary Tract Cancer","GSM3063127","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063127/suppl/GSM3063127_SH63Q29_Cell3_20160629_1533_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063128","BT0303 Biliary Tract Cancer","GSM3063128","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063128/suppl/GSM3063128_SH63Q45_Cell4_20160629_1542_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063129","BT0307 Biliary Tract Cancer","GSM3063129","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063129/suppl/GSM3063129_SH63W55_Cell3_20160712_1624_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063130","BT0314 Biliary Tract Cancer","GSM3063130","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063130/suppl/GSM3063130_SH63Q34_Cell3_20160629_1553_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063131","BT0316 Biliary Tract Cancer","GSM3063131","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063131/suppl/GSM3063131_SH63Q36_Cell1_20160629_1555_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063132","BT0317 Biliary Tract Cancer","GSM3063132","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063132/suppl/GSM3063132_SH63Q36_Cell2_20160629_1556_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063133","BT0329 Biliary Tract Cancer","GSM3063133","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063133/suppl/GSM3063133_SH63Q40_Cell2_20160629_1608_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063134","BT0338 Biliary Tract Cancer","GSM3063134","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063134/suppl/GSM3063134_SH63Q42_Cell3_20160629_1617_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063135","BT0353 Biliary Tract Cancer","GSM3063135","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063135/suppl/GSM3063135_SH63Q48_Cell2_20160701_1511_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063136","BT0369 Biliary Tract Cancer","GSM3063136","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063136/suppl/GSM3063136_SH63Q52_Cell2_20160701_1527_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063137","BT0372 Biliary Tract Cancer","GSM3063137","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063137/suppl/GSM3063137_SH63Q54_Cell1_20160701_1530_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063138","BT0380 Biliary Tract Cancer","GSM3063138","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063138/suppl/GSM3063138_SH63Q57_Cell1_20160701_1538_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063139","BT0390 Biliary Tract Cancer","GSM3063139","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 86","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063139/suppl/GSM3063139_SH63Q59_Cell3_20160701_1548_1Color_IntegratedResult.txt.gz","2565","86","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063140","BT0396 Biliary Tract Cancer","GSM3063140","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063140/suppl/GSM3063140_SH63Q61_Cell1_20160701_1554_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063141","BT0398 Biliary Tract Cancer","GSM3063141","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063141/suppl/GSM3063141_SH63Q61_Cell3_20160701_1556_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063142","BT0401 Biliary Tract Cancer","GSM3063142","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Biliary Tract Cancer","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063142/suppl/GSM3063142_SH63Q62_Cell2_20160701_1559_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Biliary Tract Cancer","Male"
"GSM3063143","BL0013 Bladder Cancer","GSM3063143","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063143/suppl/GSM3063143_SH63W03_Cell4_20160701_1617_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063144","BL0030 Bladder Cancer","GSM3063144","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063144/suppl/GSM3063144_SH63W11_Cell1_20160705_1427_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063145","BL0046 Bladder Cancer","GSM3063145","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 53","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063145/suppl/GSM3063145_SH63W15_Cell1_20160705_1443_1Color_IntegratedResult.txt.gz","2565","53","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063146","BL0051 Bladder Cancer","GSM3063146","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 60","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063146/suppl/GSM3063146_SH63W16_Cell2_20160705_1448_1Color_IntegratedResult.txt.gz","2565","60","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063147","BL0056 Bladder Cancer","GSM3063147","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063147/suppl/GSM3063147_SH63W18_Cell3_20160705_1453_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063148","BL0061 Bladder Cancer","GSM3063148","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063148/suppl/GSM3063148_SH63W19_Cell4_20160705_1458_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063149","BL0075 Bladder Cancer","GSM3063149","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 41","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063149/suppl/GSM3063149_SH63W25_Cell2_20160705_1512_1Color_IntegratedResult.txt.gz","2565","41","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063150","BL0078 Bladder Cancer","GSM3063150","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 81","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063150/suppl/GSM3063150_SH63W26_Cell1_20160705_1515_1Color_IntegratedResult.txt.gz","2565","81","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063151","BL0094 Bladder Cancer","GSM3063151","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063151/suppl/GSM3063151_SH63W31_Cell1_20160705_1531_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063152","BL0114 Bladder Cancer","GSM3063152","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 35","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063152/suppl/GSM3063152_SH63W39_Cell1_20160712_1526_1Color_IntegratedResult.txt.gz","2565","35","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063153","BL0118 Bladder Cancer","GSM3063153","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 44","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063153/suppl/GSM3063153_SH63W40_Cell1_20160712_1530_1Color_IntegratedResult.txt.gz","2565","44","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063154","BL0123 Bladder Cancer","GSM3063154","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063154/suppl/GSM3063154_SH63W41_Cell2_20160712_1535_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063155","BL0127 Bladder Cancer","GSM3063155","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063155/suppl/GSM3063155_SH63H14_Cell4_20160810_1549_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063156","BL0134 Bladder Cancer","GSM3063156","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 56","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063156/suppl/GSM3063156_SH63W44_Cell1_20160712_1546_1Color_IntegratedResult.txt.gz","2565","56","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063157","BL0136 Bladder Cancer","GSM3063157","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 82","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063157/suppl/GSM3063157_SH63W44_Cell3_20160712_1548_1Color_IntegratedResult.txt.gz","2565","82","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063158","BL0155 Bladder Cancer","GSM3063158","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063158/suppl/GSM3063158_SH63W57_Cell3_20160720_1247_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063159","BL0158 Bladder Cancer","GSM3063159","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063159/suppl/GSM3063159_SH63W58_Cell2_20160720_1250_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063160","BL0179 Bladder Cancer","GSM3063160","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063160/suppl/GSM3063160_SH63X01_Cell3_20160720_1311_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063161","BL0184 Bladder Cancer","GSM3063161","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 61","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063161/suppl/GSM3063161_SH63H18_Cell2_20160810_1559_1Color_IntegratedResult.txt.gz","2565","61","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063162","BL0198 Bladder Cancer","GSM3063162","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063162/suppl/GSM3063162_SH63X09_Cell2_20160720_1256_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063163","BL0199 Bladder Cancer","GSM3063163","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063163/suppl/GSM3063163_SH63X09_Cell3_20160720_1257_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063164","BL0206 Bladder Cancer","GSM3063164","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 50","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063164/suppl/GSM3063164_SH63X12_Cell2_20160720_1304_1Color_IntegratedResult.txt.gz","2565","50","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063165","BL0246 Bladder Cancer","GSM3063165","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 50","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063165/suppl/GSM3063165_SH63X36_Cell2_20160721_1533_1Color_IntegratedResult.txt.gz","2565","50","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063166","BL0267 Bladder Cancer","GSM3063166","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063166/suppl/GSM3063166_SH63X44_Cell3_20160721_1554_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063167","BL0275 Bladder Cancer","GSM3063167","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063167/suppl/GSM3063167_SH63X47_Cell3_20160721_1602_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063168","BL0283 Bladder Cancer","GSM3063168","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063168/suppl/GSM3063168_SH63X49_Cell3_20160721_1610_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063169","BL0288 Bladder Cancer","GSM3063169","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 80","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063169/suppl/GSM3063169_SH63X50_Cell4_20160721_1615_1Color_IntegratedResult.txt.gz","2565","80","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063170","BL0315 Bladder Cancer","GSM3063170","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 54","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063170/suppl/GSM3063170_SH64R59_Cell4_20160818_1649_1Color_IntegratedResult.txt.gz","2565","54","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063171","BL0348 Bladder Cancer","GSM3063171","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063171/suppl/GSM3063171_SH63Y30_Cell1_20160727_1605_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063172","BL0361 Bladder Cancer","GSM3063172","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063172/suppl/GSM3063172_SH63Y33_Cell2_20160727_1618_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063173","BL0375 Bladder Cancer","GSM3063173","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 40","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063173/suppl/GSM3063173_SH63Y37_Cell4_20160727_1632_1Color_IntegratedResult.txt.gz","2565","40","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063174","BL0407 Bladder Cancer","GSM3063174","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 82","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063174/suppl/GSM3063174_SH63Y47_Cell4_20160810_1457_1Color_IntegratedResult.txt.gz","2565","82","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063175","BL0418 Bladder Cancer","GSM3063175","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063175/suppl/GSM3063175_SH63H03_Cell3_20160810_1508_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063176","BL0428 Bladder Cancer","GSM3063176","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063176/suppl/GSM3063176_SH63H06_Cell1_20160810_1518_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063177","BL0433 Bladder Cancer","GSM3063177","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063177/suppl/GSM3063177_SH63H07_Cell2_20160810_1523_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063178","BL0437 Bladder Cancer","GSM3063178","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063178/suppl/GSM3063178_SH63H08_Cell2_20160810_1527_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063179","BL0442 Bladder Cancer","GSM3063179","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063179/suppl/GSM3063179_SH63H09_Cell3_20160810_1532_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063180","BL0449 Bladder Cancer","GSM3063180","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 56","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063180/suppl/GSM3063180_SH63H12_Cell2_20160810_1539_1Color_IntegratedResult.txt.gz","2565","56","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063181","BL0457 Bladder Cancer","GSM3063181","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063181/suppl/GSM3063181_SH63H21_Cell3_20160816_1500_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063182","BL0459 Bladder Cancer","GSM3063182","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 55","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063182/suppl/GSM3063182_SH63H22_Cell1_20160816_1502_1Color_IntegratedResult.txt.gz","2565","55","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063183","BL0461 Bladder Cancer","GSM3063183","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 83","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063183/suppl/GSM3063183_SH63H22_Cell3_20160816_1504_1Color_IntegratedResult.txt.gz","2565","83","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063184","BL0465 Bladder Cancer","GSM3063184","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 79","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063184/suppl/GSM3063184_SH63H23_Cell3_20160816_1508_1Color_IntegratedResult.txt.gz","2565","79","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063185","BL0466 Bladder Cancer","GSM3063185","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063185/suppl/GSM3063185_SH66229_Cell4_20160909_1641_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063186","BL0484 Bladder Cancer","GSM3063186","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 48","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063186/suppl/GSM3063186_SH63H28_Cell2_20160816_1527_1Color_IntegratedResult.txt.gz","2565","48","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063187","BL0488 Bladder Cancer","GSM3063187","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063187/suppl/GSM3063187_SH63H29_Cell2_20160816_1531_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063188","BL0492 Bladder Cancer","GSM3063188","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063188/suppl/GSM3063188_SH63P30_Cell2_20160816_1535_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063189","BL0496 Bladder Cancer","GSM3063189","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063189/suppl/GSM3063189_SH63X22_Cell2_20160816_1539_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063190","BL0502 Bladder Cancer","GSM3063190","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063190/suppl/GSM3063190_SH63X26_Cell4_20160816_1545_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063191","BL0509 Bladder Cancer","GSM3063191","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 53","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063191/suppl/GSM3063191_SH66231_Cell4_20160909_1649_1Color_IntegratedResult.txt.gz","2565","53","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063192","BL0513 Bladder Cancer","GSM3063192","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Bladder Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063192/suppl/GSM3063192_SH63X30_Cell3_20160816_1556_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Bladder Cancer","Male"
"GSM3063193","CC0065 Colorectal Cancer","GSM3063193","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063193/suppl/GSM3063193_SH52109_Cell1_20150407_1642_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063194","CC0092 Colorectal Cancer","GSM3063194","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063194/suppl/GSM3063194_SH52R31_Cell4_20150408_1322_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063195","CC0114 Colorectal Cancer","GSM3063195","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063195/suppl/GSM3063195_SH52T10_Cell2_20150408_1344_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063196","CC0133 Colorectal Cancer","GSM3063196","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063196/suppl/GSM3063196_SH52T15_Cell1_20150408_1834_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063197","CC0135 Colorectal Cancer","GSM3063197","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063197/suppl/GSM3063197_SH52T15_Cell3_20150408_1836_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063198","CC0140 Colorectal Cancer","GSM3063198","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 61","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063198/suppl/GSM3063198_SH52T16_Cell4_20150408_1841_1Color_IntegratedResult.txt.gz","2565","61","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063199","CC0147 Colorectal Cancer","GSM3063199","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063199/suppl/GSM3063199_SH52T19_Cell3_20150408_1848_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063200","CC0225 Colorectal Cancer","GSM3063200","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063200/suppl/GSM3063200_SH52T45_Cell1_20150409_1329_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063201","CC0306 Colorectal Cancer","GSM3063201","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063201/suppl/GSM3063201_SH4YJ38_Cell3_20150428_1731_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063202","CC0368 Colorectal Cancer","GSM3063202","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063202/suppl/GSM3063202_SH4YJ58_Cell1_20150428_1604_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063203","CC0390 Colorectal Cancer","GSM3063203","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063203/suppl/GSM3063203_SH4YL06_Cell3_20150501_1609_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063204","CC0469 Colorectal Cancer","GSM3063204","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063204/suppl/GSM3063204_SH4YL39_Cell2_20150508_1515_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063205","CC0564 Colorectal Cancer","GSM3063205","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063205/suppl/GSM3063205_SH4YE57_Cell1_20150515_1543_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063206","CC0608 Colorectal Cancer","GSM3063206","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063206/suppl/GSM3063206_SH52J31_Cell3_20150508_1429_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063207","CC0615 Colorectal Cancer","GSM3063207","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 46","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063207/suppl/GSM3063207_SH52P14_Cell2_20150512_1544_1Color_IntegratedResult.txt.gz","2565","46","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063208","CC0624 Colorectal Cancer","GSM3063208","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063208/suppl/GSM3063208_SH53217_Cell3_20150512_1553_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063209","CC0672 Colorectal Cancer","GSM3063209","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063209/suppl/GSM3063209_SH53A16_Cell3_20150512_1641_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063210","CC0684 Colorectal Cancer","GSM3063210","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 60","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063210/suppl/GSM3063210_SH53A24_Cell3_20150512_1653_1Color_IntegratedResult.txt.gz","2565","60","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063211","CC0707 Colorectal Cancer","GSM3063211","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063211/suppl/GSM3063211_SH53A32_Cell2_20150513_1536_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063212","CC0710 Colorectal Cancer","GSM3063212","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063212/suppl/GSM3063212_SH53A35_Cell1_20150513_1539_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063213","CC0723 Colorectal Cancer","GSM3063213","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063213/suppl/GSM3063213_SH53A38_Cell2_20150513_1552_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063214","CC0752 Colorectal Cancer","GSM3063214","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063214/suppl/GSM3063214_SH56F27_Cell4_20150910_1431_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063215","CC0780 Colorectal Cancer","GSM3063215","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 46","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063215/suppl/GSM3063215_SH56F35_Cell4_20150910_1459_1Color_IntegratedResult.txt.gz","2565","46","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063216","CC0784 Colorectal Cancer","GSM3063216","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063216/suppl/GSM3063216_SH56G01_Cell4_20150910_1503_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063217","CC0797 Colorectal Cancer","GSM3063217","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063217/suppl/GSM3063217_SH56G07_Cell1_20150911_1549_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063218","CC0799 Colorectal Cancer","GSM3063218","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063218/suppl/GSM3063218_SH56G07_Cell3_20150911_1551_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063219","CC0801 Colorectal Cancer","GSM3063219","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063219/suppl/GSM3063219_SH56G08_Cell1_20150911_1553_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063220","CC0844 Colorectal Cancer","GSM3063220","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063220/suppl/GSM3063220_SH56G19_Cell4_20150911_1636_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063221","CC0847 Colorectal Cancer","GSM3063221","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063221/suppl/GSM3063221_SH56G20_Cell3_20150911_1639_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063222","CC0875 Colorectal Cancer","GSM3063222","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063222/suppl/GSM3063222_SH56G28_Cell3_20150915_1531_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063223","CC0896 Colorectal Cancer","GSM3063223","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 46","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063223/suppl/GSM3063223_SH56G33_Cell4_20150915_1552_1Color_IntegratedResult.txt.gz","2565","46","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063224","CC0922 Colorectal Cancer","GSM3063224","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063224/suppl/GSM3063224_SH56G43_Cell2_20150915_1618_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063225","CC0948 Colorectal Cancer","GSM3063225","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063225/suppl/GSM3063225_SH56G49_Cell4_20150915_1644_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063226","CC1007 Colorectal Cancer","GSM3063226","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063226/suppl/GSM3063226_SH56G66_Cell3_20150916_1615_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063227","CC1044 Colorectal Cancer","GSM3063227","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 79","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063227/suppl/GSM3063227_SH56H13_Cell2_20150917_1359_1Color_IntegratedResult.txt.gz","2565","79","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063228","CC1112 Colorectal Cancer","GSM3063228","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 82","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063228/suppl/GSM3063228_SH56H35_Cell2_20150930_1538_1Color_IntegratedResult.txt.gz","2565","82","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063229","CC1174 Colorectal Cancer","GSM3063229","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063229/suppl/GSM3063229_SH5X555_Cell2_20160210_1629_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063230","CC1185 Colorectal Cancer","GSM3063230","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063230/suppl/GSM3063230_SH5X558_Cell1_20160210_1640_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063231","CC1188 Colorectal Cancer","GSM3063231","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 50","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063231/suppl/GSM3063231_SH5X558_Cell4_20160210_1643_1Color_IntegratedResult.txt.gz","2565","50","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063232","CC1262 Colorectal Cancer","GSM3063232","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063232/suppl/GSM3063232_SH5YL63_Cell4_20160301_1435_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063233","CC1300 Colorectal Cancer","GSM3063233","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063233/suppl/GSM3063233_SH5YQ12_Cell2_20160301_1513_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063234","CC1350 Colorectal Cancer","GSM3063234","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063234/suppl/GSM3063234_SH5YQ27_Cell3_20160302_1607_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063235","CC1369 Colorectal Cancer","GSM3063235","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063235/suppl/GSM3063235_SH5YQ34_Cell2_20160302_1626_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063236","CC1404 Colorectal Cancer","GSM3063236","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063236/suppl/GSM3063236_SH5YQ45_Cell1_20160302_1701_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063237","CC1419 Colorectal Cancer","GSM3063237","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063237/suppl/GSM3063237_SH5YQ49_Cell4_20160303_1505_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063238","CC1485 Colorectal Cancer","GSM3063238","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063238/suppl/GSM3063238_SH5YR07_Cell2_20160303_1611_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063239","CC1497 Colorectal Cancer","GSM3063239","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 83","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063239/suppl/GSM3063239_SH5YR10_Cell2_20160310_1502_1Color_IntegratedResult.txt.gz","2565","83","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063240","CC1498 Colorectal Cancer","GSM3063240","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 46","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063240/suppl/GSM3063240_SH5YR10_Cell3_20160310_1503_1Color_IntegratedResult.txt.gz","2565","46","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063241","CC1514 Colorectal Cancer","GSM3063241","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063241/suppl/GSM3063241_SH5YR16_Cell3_20160310_1519_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063242","CC1522 Colorectal Cancer","GSM3063242","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Colorectal Cancer","Sex: Male","age: 36","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063242/suppl/GSM3063242_SH5YR19_Cell3_20160310_1527_1Color_IntegratedResult.txt.gz","2565","36","uncertain","uncertain","uncertain","Colorectal Cancer","Male"
"GSM3063243","EC0014 Esophageal Cancer","GSM3063243","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 80","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063243/suppl/GSM3063243_SH56B62_Cell3_20150826_1635_1Color_IntegratedResult.txt.gz","2565","80","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063244","EC0021 Esophageal Cancer","GSM3063244","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063244/suppl/GSM3063244_SH56B64_Cell2_20150827_1526_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063245","EC0025 Esophageal Cancer","GSM3063245","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 48","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063245/suppl/GSM3063245_SH56B65_Cell2_20150827_1530_1Color_IntegratedResult.txt.gz","2565","48","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063246","EC0037 Esophageal Cancer","GSM3063246","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063246/suppl/GSM3063246_SH56F01_Cell2_20150827_1542_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063247","EC0045 Esophageal Cancer","GSM3063247","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063247/suppl/GSM3063247_SH56F03_Cell2_20150827_1550_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063248","EC0064 Esophageal Cancer","GSM3063248","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063248/suppl/GSM3063248_SH56F09_Cell1_20150827_1609_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063249","EC0083 Esophageal Cancer","GSM3063249","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 56","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063249/suppl/GSM3063249_SH56F13_Cell4_20150827_1628_1Color_IntegratedResult.txt.gz","2565","56","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063250","EC0087 Esophageal Cancer","GSM3063250","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 60","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063250/suppl/GSM3063250_SH56F14_Cell4_20150827_1632_1Color_IntegratedResult.txt.gz","2565","60","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063251","EC0095 Esophageal Cancer","GSM3063251","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063251/suppl/GSM3063251_SH56F16_Cell4_20150827_1640_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063252","EC0097 Esophageal Cancer","GSM3063252","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063252/suppl/GSM3063252_SH56F17_Cell2_20150827_1642_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063253","EC0162 Esophageal Cancer","GSM3063253","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063253/suppl/GSM3063253_SH57M62_Cell3_20151020_1502_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063254","EC0180 Esophageal Cancer","GSM3063254","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063254/suppl/GSM3063254_SH57M67_Cell1_20151020_1520_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063255","EC0199 Esophageal Cancer","GSM3063255","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 81","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063255/suppl/GSM3063255_SH57N04_Cell4_20151020_1539_1Color_IntegratedResult.txt.gz","2565","81","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063256","EC0209 Esophageal Cancer","GSM3063256","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063256/suppl/GSM3063256_SH57N07_Cell2_20151021_1648_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063257","EC0210 Esophageal Cancer","GSM3063257","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063257/suppl/GSM3063257_SH57N07_Cell3_20151021_1521_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063258","EC0211 Esophageal Cancer","GSM3063258","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 61","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063258/suppl/GSM3063258_SH57N07_Cell4_20151021_1522_1Color_IntegratedResult.txt.gz","2565","61","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063259","EC0213 Esophageal Cancer","GSM3063259","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063259/suppl/GSM3063259_SH57N08_Cell2_20151021_1524_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063260","EC0217 Esophageal Cancer","GSM3063260","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063260/suppl/GSM3063260_SH57N09_Cell2_20151021_1528_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063261","EC0231 Esophageal Cancer","GSM3063261","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063261/suppl/GSM3063261_SH57N15_Cell4_20151021_1542_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063262","EC0291 Esophageal Cancer","GSM3063262","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063262/suppl/GSM3063262_SH57P18_Cell3_20151105_1449_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063263","EC0295 Esophageal Cancer","GSM3063263","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063263/suppl/GSM3063263_SH57P19_Cell3_20151105_1453_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063264","EC0302 Esophageal Cancer","GSM3063264","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063264/suppl/GSM3063264_SH57P21_Cell2_20151105_1500_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063265","EC0316 Esophageal Cancer","GSM3063265","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063265/suppl/GSM3063265_SH57P24_Cell4_20151105_1514_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063266","EC0327 Esophageal Cancer","GSM3063266","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 48","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063266/suppl/GSM3063266_SH57P29_Cell3_20151105_1529_1Color_IntegratedResult.txt.gz","2565","48","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063267","EC0351 Esophageal Cancer","GSM3063267","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063267/suppl/GSM3063267_SH57P38_Cell3_20151105_1549_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063268","EC0363 Esophageal Cancer","GSM3063268","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 59","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063268/suppl/GSM3063268_SH57P43_Cell3_20151106_1512_1Color_IntegratedResult.txt.gz","2565","59","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063269","EC0368 Esophageal Cancer","GSM3063269","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063269/suppl/GSM3063269_SH57P44_Cell4_20151106_1517_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063270","EC0373 Esophageal Cancer","GSM3063270","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063270/suppl/GSM3063270_SH57Y26_Cell2_20151126_1130_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063271","EC0376 Esophageal Cancer","GSM3063271","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063271/suppl/GSM3063271_SH57P46_Cell4_20151106_1525_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063272","EC0378 Esophageal Cancer","GSM3063272","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063272/suppl/GSM3063272_SH57P47_Cell2_20151106_1527_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063273","EC0385 Esophageal Cancer","GSM3063273","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063273/suppl/GSM3063273_SH57P49_Cell1_20151106_1534_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063274","EC0399 Esophageal Cancer","GSM3063274","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063274/suppl/GSM3063274_SH57Y26_Cell3_20151126_1131_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063275","EC0417 Esophageal Cancer","GSM3063275","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 60","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063275/suppl/GSM3063275_SH57P57_Cell1_20151106_1606_1Color_IntegratedResult.txt.gz","2565","60","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063276","EC0423 Esophageal Cancer","GSM3063276","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063276/suppl/GSM3063276_SH57P58_Cell3_20151106_1612_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063277","EC0426 Esophageal Cancer","GSM3063277","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063277/suppl/GSM3063277_SH57P59_Cell2_20151106_1615_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063278","EC0429 Esophageal Cancer","GSM3063278","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 87","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063278/suppl/GSM3063278_SH57P60_Cell1_20151106_1618_1Color_IntegratedResult.txt.gz","2565","87","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063279","EC0436 Esophageal Cancer","GSM3063279","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063279/suppl/GSM3063279_SH57P61_Cell4_20151106_1625_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063280","EC0450 Esophageal Cancer","GSM3063280","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063280/suppl/GSM3063280_SH57P66_Cell2_20151117_1508_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063281","EC0457 Esophageal Cancer","GSM3063281","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063281/suppl/GSM3063281_SH57T01_Cell1_20151117_1515_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063282","EC0483 Esophageal Cancer","GSM3063282","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 60","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063282/suppl/GSM3063282_SH57T09_Cell3_20151117_1541_1Color_IntegratedResult.txt.gz","2565","60","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063283","EC0499 Esophageal Cancer","GSM3063283","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063283/suppl/GSM3063283_SH57T16_Cell3_20151117_1557_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063284","EC0500 Esophageal Cancer","GSM3063284","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 81","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063284/suppl/GSM3063284_SH57T16_Cell4_20151117_1558_1Color_IntegratedResult.txt.gz","2565","81","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063285","EC0502 Esophageal Cancer","GSM3063285","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063285/suppl/GSM3063285_SH57T17_Cell2_20151117_1720_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063286","EC0515 Esophageal Cancer","GSM3063286","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063286/suppl/GSM3063286_SH57T21_Cell3_20151117_1613_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063287","EC0525 Esophageal Cancer","GSM3063287","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063287/suppl/GSM3063287_SH57T24_Cell1_20151118_1533_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063288","EC0526 Esophageal Cancer","GSM3063288","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063288/suppl/GSM3063288_SH57T24_Cell2_20151118_1534_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063289","EC0562 Esophageal Cancer","GSM3063289","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 81","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063289/suppl/GSM3063289_SH57X01_Cell2_20151118_1610_1Color_IntegratedResult.txt.gz","2565","81","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063290","EC0567 Esophageal Cancer","GSM3063290","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063290/suppl/GSM3063290_SH57X03_Cell3_20151118_1615_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063291","EC0581 Esophageal Cancer","GSM3063291","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063291/suppl/GSM3063291_SH57X07_Cell1_20151118_1629_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063292","EC0588 Esophageal Cancer","GSM3063292","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Esophageal Cancer","Sex: Male","age: 61","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063292/suppl/GSM3063292_SH57X08_Cell4_20151118_1636_1Color_IntegratedResult.txt.gz","2565","61","uncertain","uncertain","uncertain","Esophageal Cancer","Male"
"GSM3063293","GC0047 Gastric Cancer","GSM3063293","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 52","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063293/suppl/GSM3063293_SH59X49_Cell4_20160126_1518_1Color_IntegratedResult.txt.gz","2565","52","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063294","GC0168 Gastric Cancer","GSM3063294","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063294/suppl/GSM3063294_SH59Y20_Cell1_20160128_1504_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063295","GC0171 Gastric Cancer","GSM3063295","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063295/suppl/GSM3063295_SH59Y20_Cell4_20160128_1507_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063296","GC0182 Gastric Cancer","GSM3063296","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 61","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063296/suppl/GSM3063296_SH59Y23_Cell3_20160128_1518_1Color_IntegratedResult.txt.gz","2565","61","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063297","GC0209 Gastric Cancer","GSM3063297","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063297/suppl/GSM3063297_SH59Y31_Cell2_20160128_1545_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063298","GC0284 Gastric Cancer","GSM3063298","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063298/suppl/GSM3063298_SH59Y52_Cell1_20160129_1645_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063299","GC0285 Gastric Cancer","GSM3063299","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 83","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063299/suppl/GSM3063299_SH59Y52_Cell2_20160129_1646_1Color_IntegratedResult.txt.gz","2565","83","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063300","GC0295 Gastric Cancer","GSM3063300","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063300/suppl/GSM3063300_SH59Y54_Cell4_20160129_1656_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063301","GC0307 Gastric Cancer","GSM3063301","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063301/suppl/GSM3063301_SH59Y59_Cell4_20160129_1708_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063302","GC0339 Gastric Cancer","GSM3063302","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 82","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063302/suppl/GSM3063302_SH5X106_Cell4_20160203_1527_1Color_IntegratedResult.txt.gz","2565","82","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063303","GC0374 Gastric Cancer","GSM3063303","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063303/suppl/GSM3063303_SH5X117_Cell3_20160203_1602_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063304","GC0382 Gastric Cancer","GSM3063304","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 53","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063304/suppl/GSM3063304_SH5X119_Cell3_20160203_1610_1Color_IntegratedResult.txt.gz","2565","53","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063305","GC0400 Gastric Cancer","GSM3063305","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063305/suppl/GSM3063305_SH5X126_Cell1_20160204_1521_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063306","GC0404 Gastric Cancer","GSM3063306","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 86","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063306/suppl/GSM3063306_SH5X127_Cell1_20160204_1525_1Color_IntegratedResult.txt.gz","2565","86","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063307","GC0405 Gastric Cancer","GSM3063307","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063307/suppl/GSM3063307_SH5X127_Cell2_20160204_1526_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063308","GC0417 Gastric Cancer","GSM3063308","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063308/suppl/GSM3063308_SH5X130_Cell2_20160204_1538_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063309","GC0422 Gastric Cancer","GSM3063309","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063309/suppl/GSM3063309_SH5X131_Cell3_20160204_1543_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063310","GC0442 Gastric Cancer","GSM3063310","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063310/suppl/GSM3063310_SH5X136_Cell3_20160204_1603_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063311","GC0480 Gastric Cancer","GSM3063311","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063311/suppl/GSM3063311_SH61C55_Cell2_20160511_1556_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063312","GC0486 Gastric Cancer","GSM3063312","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063312/suppl/GSM3063312_SH61C56_Cell4_20160511_1602_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063313","GC0490 Gastric Cancer","GSM3063313","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 76","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063313/suppl/GSM3063313_SH61C57_Cell4_20160511_1606_1Color_IntegratedResult.txt.gz","2565","76","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063314","GC0525 Gastric Cancer","GSM3063314","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063314/suppl/GSM3063314_SH61E04_Cell3_20160512_1513_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063315","GC0558 Gastric Cancer","GSM3063315","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 54","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063315/suppl/GSM3063315_SH61E12_Cell4_20160512_1546_1Color_IntegratedResult.txt.gz","2565","54","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063316","GC0570 Gastric Cancer","GSM3063316","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 83","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063316/suppl/GSM3063316_SH61E15_Cell4_20160512_1558_1Color_IntegratedResult.txt.gz","2565","83","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063317","GC0573 Gastric Cancer","GSM3063317","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063317/suppl/GSM3063317_SH61E16_Cell3_20160512_1601_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063318","GC0604 Gastric Cancer","GSM3063318","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063318/suppl/GSM3063318_SH61E29_Cell1_20160513_1607_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063319","GC0627 Gastric Cancer","GSM3063319","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063319/suppl/GSM3063319_SH61E36_Cell4_20160513_1630_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063320","GC0642 Gastric Cancer","GSM3063320","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 56","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063320/suppl/GSM3063320_SH61E40_Cell3_20160513_1645_1Color_IntegratedResult.txt.gz","2565","56","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063321","GC0676 Gastric Cancer","GSM3063321","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063321/suppl/GSM3063321_SH61E51_Cell1_20160518_1524_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063322","GC0702 Gastric Cancer","GSM3063322","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063322/suppl/GSM3063322_SH61E57_Cell3_20160518_1550_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063323","GC0705 Gastric Cancer","GSM3063323","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 54","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063323/suppl/GSM3063323_SH61E59_Cell2_20160518_1553_1Color_IntegratedResult.txt.gz","2565","54","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063324","GC0742 Gastric Cancer","GSM3063324","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 86","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063324/suppl/GSM3063324_SH61F16_Cell3_20160519_1316_1Color_IntegratedResult.txt.gz","2565","86","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063325","GC0761 Gastric Cancer","GSM3063325","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063325/suppl/GSM3063325_SH61F21_Cell2_20160519_1335_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063326","GC0836 Gastric Cancer","GSM3063326","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063326/suppl/GSM3063326_SH61F43_Cell1_20160520_1626_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063327","GC0879 Gastric Cancer","GSM3063327","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063327/suppl/GSM3063327_SH61F55_Cell4_20160524_1441_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063328","GC0885 Gastric Cancer","GSM3063328","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 82","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063328/suppl/GSM3063328_SH61F57_Cell2_20160524_1447_1Color_IntegratedResult.txt.gz","2565","82","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063329","GC0910 Gastric Cancer","GSM3063329","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063329/suppl/GSM3063329_SH62A01_Cell3_20160524_1512_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063330","GC0938 Gastric Cancer","GSM3063330","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063330/suppl/GSM3063330_SH62A13_Cell2_20160526_1508_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063331","GC0962 Gastric Cancer","GSM3063331","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063331/suppl/GSM3063331_SH62A19_Cell2_20160526_1532_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063332","GC0994 Gastric Cancer","GSM3063332","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063332/suppl/GSM3063332_SH62A27_Cell2_20160526_1604_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063333","GC0996 Gastric Cancer","GSM3063333","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063333/suppl/GSM3063333_SH62A27_Cell4_20160526_1606_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063334","GC0998 Gastric Cancer","GSM3063334","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 76","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063334/suppl/GSM3063334_SH62A28_Cell2_20160526_1608_1Color_IntegratedResult.txt.gz","2565","76","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063335","GC1036 Gastric Cancer","GSM3063335","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063335/suppl/GSM3063335_SH62F03_Cell2_20160531_1505_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063336","GC1143 Gastric Cancer","GSM3063336","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063336/suppl/GSM3063336_SH63P43_Cell2_20160624_1440_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063337","GC1145 Gastric Cancer","GSM3063337","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063337/suppl/GSM3063337_SH62G04_Cell2_20160607_1211_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063338","GC1153 Gastric Cancer","GSM3063338","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063338/suppl/GSM3063338_SH63P44_Cell2_20160624_1615_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063339","GC1183 Gastric Cancer","GSM3063339","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063339/suppl/GSM3063339_SH63P46_Cell4_20160624_1454_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063340","GC1300 Gastric Cancer","GSM3063340","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063340/suppl/GSM3063340_SH63P15_Cell1_20160610_1629_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063341","GC1375 Gastric Cancer","GSM3063341","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 52","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063341/suppl/GSM3063341_SH63P51_Cell1_20160624_1511_1Color_IntegratedResult.txt.gz","2565","52","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063342","GC1464 Gastric Cancer","GSM3063342","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Gastric Cancer","Sex: Male","age: 48","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063342/suppl/GSM3063342_SH63Q16_Cell2_20160628_1514_1Color_IntegratedResult.txt.gz","2565","48","uncertain","uncertain","uncertain","Gastric Cancer","Male"
"GSM3063343","GL0004 Glioma","GSM3063343","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063343/suppl/GSM3063343_SH6XC13_Cell3_20170421_1545_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063344","GL0009 Glioma","GSM3063344","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 42","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063344/suppl/GSM3063344_SH6XC14_Cell2_20170421_1548_1Color_IntegratedResult.txt.gz","2565","42","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063345","GL0011 Glioma","GSM3063345","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063345/suppl/GSM3063345_SH6XC14_Cell3_20170421_1831_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063346","GL0017 Glioma","GSM3063346","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063346/suppl/GSM3063346_SH6XK20_Cell1_20170523_1551_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063347","GL0019 Glioma","GSM3063347","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063347/suppl/GSM3063347_SH6XK20_Cell3_20170523_1747_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063348","GL0025 Glioma","GSM3063348","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 26","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063348/suppl/GSM3063348_SH6XK22_Cell4_20170523_1558_1Color_IntegratedResult.txt.gz","2565","26","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063349","GL0034 Glioma","GSM3063349","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 17","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063349/suppl/GSM3063349_SH6XK25_Cell4_20170523_1606_1Color_IntegratedResult.txt.gz","2565","17","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063350","GL0048 Glioma","GSM3063350","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 60","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063350/suppl/GSM3063350_SH6XK30_Cell3_20170523_1617_1Color_IntegratedResult.txt.gz","2565","60","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063351","GL0053 Glioma","GSM3063351","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 31","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063351/suppl/GSM3063351_SH6XK32_Cell3_20170523_1621_1Color_IntegratedResult.txt.gz","2565","31","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063352","GL0056 Glioma","GSM3063352","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 17","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063352/suppl/GSM3063352_SH6XK38_Cell2_20170523_1750_1Color_IntegratedResult.txt.gz","2565","17","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063353","GL0067 Glioma","GSM3063353","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063353/suppl/GSM3063353_SH6XK46_Cell1_20170523_1635_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063354","GL0068 Glioma","GSM3063354","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063354/suppl/GSM3063354_SH6XK46_Cell2_20170523_1636_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063355","GL0070 Glioma","GSM3063355","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 44","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063355/suppl/GSM3063355_SH6XK46_Cell4_20170523_1638_1Color_IntegratedResult.txt.gz","2565","44","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063356","GL0071 Glioma","GSM3063356","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063356/suppl/GSM3063356_SH6XK50_Cell1_20170523_1639_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063357","GL0075 Glioma","GSM3063357","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063357/suppl/GSM3063357_SH6XK51_Cell1_20170523_1643_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063358","GL0076 Glioma","GSM3063358","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 25","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063358/suppl/GSM3063358_SH6XK51_Cell2_20170523_1644_1Color_IntegratedResult.txt.gz","2565","25","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063359","GL0086 Glioma","GSM3063359","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 54","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063359/suppl/GSM3063359_SH6XK55_Cell3_20170523_1653_1Color_IntegratedResult.txt.gz","2565","54","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063360","GL0088 Glioma","GSM3063360","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 49","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063360/suppl/GSM3063360_SH6XK56_Cell1_20170523_1655_1Color_IntegratedResult.txt.gz","2565","49","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063361","GL0089 Glioma","GSM3063361","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063361/suppl/GSM3063361_SH6XK56_Cell2_20170523_1656_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063362","GL0100 Glioma","GSM3063362","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063362/suppl/GSM3063362_SH6XK60_Cell1_20170524_1601_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063363","GL0103 Glioma","GSM3063363","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063363/suppl/GSM3063363_SH6XK60_Cell4_20170524_1604_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063364","GL0105 Glioma","GSM3063364","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 48","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063364/suppl/GSM3063364_SH6XC16_Cell2_20170421_1556_1Color_IntegratedResult.txt.gz","2565","48","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063365","GL0107 Glioma","GSM3063365","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 61","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063365/suppl/GSM3063365_SH6XK62_Cell3_20170524_1607_1Color_IntegratedResult.txt.gz","2565","61","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063366","GL0109 Glioma","GSM3063366","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063366/suppl/GSM3063366_SH6XL02_Cell1_20170524_1609_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063367","GL0112 Glioma","GSM3063367","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 17","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063367/suppl/GSM3063367_SH6XL02_Cell4_20170524_1612_1Color_IntegratedResult.txt.gz","2565","17","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063368","GL0114 Glioma","GSM3063368","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 84","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063368/suppl/GSM3063368_SH6XL03_Cell2_20170524_1614_1Color_IntegratedResult.txt.gz","2565","84","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063369","GL0117 Glioma","GSM3063369","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 45","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063369/suppl/GSM3063369_SH6XL04_Cell1_20170524_1617_1Color_IntegratedResult.txt.gz","2565","45","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063370","GL0120 Glioma","GSM3063370","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 46","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063370/suppl/GSM3063370_SH6XL04_Cell4_20170524_1620_1Color_IntegratedResult.txt.gz","2565","46","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063371","GL0124 Glioma","GSM3063371","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 83","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063371/suppl/GSM3063371_SH6XL05_Cell4_20170524_1624_1Color_IntegratedResult.txt.gz","2565","83","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063372","GL0126 Glioma","GSM3063372","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 82","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063372/suppl/GSM3063372_SH6XL06_Cell2_20170524_1626_1Color_IntegratedResult.txt.gz","2565","82","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063373","GL0130 Glioma","GSM3063373","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063373/suppl/GSM3063373_SH6XL07_Cell2_20170524_1630_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063374","GL0132 Glioma","GSM3063374","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063374/suppl/GSM3063374_SH6XL07_Cell4_20170524_1632_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063375","GL0140 Glioma","GSM3063375","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 46","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063375/suppl/GSM3063375_SH6XL10_Cell4_20170524_1734_1Color_IntegratedResult.txt.gz","2565","46","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063376","GL0145 Glioma","GSM3063376","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 33","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063376/suppl/GSM3063376_SH6XL11_Cell4_20170524_1644_1Color_IntegratedResult.txt.gz","2565","33","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063377","GL0149 Glioma","GSM3063377","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 29","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063377/suppl/GSM3063377_SH6XC16_Cell4_20170421_1558_1Color_IntegratedResult.txt.gz","2565","29","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063378","GL0150 Glioma","GSM3063378","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 45","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063378/suppl/GSM3063378_SH6XL13_Cell4_20170529_1454_1Color_IntegratedResult.txt.gz","2565","45","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063379","GL0158 Glioma","GSM3063379","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 24","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063379/suppl/GSM3063379_SH6XL15_Cell3_20170524_1655_1Color_IntegratedResult.txt.gz","2565","24","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063380","GL0159 Glioma","GSM3063380","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063380/suppl/GSM3063380_SH6XL15_Cell4_20170524_1656_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063381","GL0168 Glioma","GSM3063381","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063381/suppl/GSM3063381_SH6XL17_Cell3_20170524_1703_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063382","GL0174 Glioma","GSM3063382","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063382/suppl/GSM3063382_SH6XL18_Cell4_20170524_1708_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063383","GL0176 Glioma","GSM3063383","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 42","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063383/suppl/GSM3063383_SH6XL19_Cell2_20170524_1710_1Color_IntegratedResult.txt.gz","2565","42","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063384","GL0179 Glioma","GSM3063384","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063384/suppl/GSM3063384_SH6XL20_Cell1_20170524_1713_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063385","GL0183 Glioma","GSM3063385","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 40","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063385/suppl/GSM3063385_SH6XL21_Cell1_20170525_1524_1Color_IntegratedResult.txt.gz","2565","40","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063386","GL0188 Glioma","GSM3063386","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063386/suppl/GSM3063386_SH6XL22_Cell1_20170525_1528_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063387","GL0194 Glioma","GSM3063387","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 42","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063387/suppl/GSM3063387_SH6XC18_Cell2_20170421_1604_1Color_IntegratedResult.txt.gz","2565","42","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063388","GL0198 Glioma","GSM3063388","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 50","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063388/suppl/GSM3063388_SH6XC18_Cell3_20170421_1605_1Color_IntegratedResult.txt.gz","2565","50","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063389","GL0204 Glioma","GSM3063389","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 59","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063389/suppl/GSM3063389_SH6XC20_Cell1_20170421_1611_1Color_IntegratedResult.txt.gz","2565","59","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063390","GL0206 Glioma","GSM3063390","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063390/suppl/GSM3063390_SH6XC20_Cell3_20170421_1613_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063391","GL0210 Glioma","GSM3063391","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 10","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063391/suppl/GSM3063391_SH6XC21_Cell3_20170421_1617_1Color_IntegratedResult.txt.gz","2565","10","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063392","GL0216 Glioma","GSM3063392","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Glioma","Sex: Male","age: 76","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063392/suppl/GSM3063392_SH6XC23_Cell1_20170421_1623_1Color_IntegratedResult.txt.gz","2565","76","uncertain","uncertain","uncertain","Glioma","Male"
"GSM3063393","HC0004 Hepatocellular Carcinoma","GSM3063393","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 52","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063393/suppl/GSM3063393_SH54N25_Cell4_20150722_1520_1Color_IntegratedResult.txt.gz","2565","52","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063394","HC0009 Hepatocellular Carcinoma","GSM3063394","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063394/suppl/GSM3063394_SH54N27_Cell1_20150722_1525_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063395","HC0015 Hepatocellular Carcinoma","GSM3063395","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063395/suppl/GSM3063395_SH56963_Cell1_20150821_1236_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063396","HC0020 Hepatocellular Carcinoma","GSM3063396","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063396/suppl/GSM3063396_SH54N29_Cell4_20150722_1536_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063397","HC0028 Hepatocellular Carcinoma","GSM3063397","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063397/suppl/GSM3063397_SH54N32_Cell4_20150722_1544_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063398","HC0042 Hepatocellular Carcinoma","GSM3063398","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063398/suppl/GSM3063398_SH54N36_Cell2_20150722_1558_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063399","HC0059 Hepatocellular Carcinoma","GSM3063399","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063399/suppl/GSM3063399_SH54N41_Cell3_20150722_1615_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063400","HC0061 Hepatocellular Carcinoma","GSM3063400","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063400/suppl/GSM3063400_SH54N43_Cell1_20150722_1617_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063401","HC0065 Hepatocellular Carcinoma","GSM3063401","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063401/suppl/GSM3063401_SH54N44_Cell1_20150722_1621_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063402","HC0074 Hepatocellular Carcinoma","GSM3063402","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063402/suppl/GSM3063402_SH54N51_Cell2_20150722_1630_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063403","HC0087 Hepatocellular Carcinoma","GSM3063403","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 61","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063403/suppl/GSM3063403_SH54N55_Cell3_20150723_1527_1Color_IntegratedResult.txt.gz","2565","61","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063404","HC0089 Hepatocellular Carcinoma","GSM3063404","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063404/suppl/GSM3063404_SH54N56_Cell1_20150723_1529_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063405","HC0093 Hepatocellular Carcinoma","GSM3063405","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 82","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063405/suppl/GSM3063405_SH54N57_Cell1_20150723_1533_1Color_IntegratedResult.txt.gz","2565","82","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063406","HC0097 Hepatocellular Carcinoma","GSM3063406","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063406/suppl/GSM3063406_SH54N58_Cell1_20150723_1537_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063407","HC0109 Hepatocellular Carcinoma","GSM3063407","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 60","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063407/suppl/GSM3063407_SH55T24_Cell1_20150723_1549_1Color_IntegratedResult.txt.gz","2565","60","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063408","HC0115 Hepatocellular Carcinoma","GSM3063408","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063408/suppl/GSM3063408_SH55T25_Cell3_20150723_1555_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063409","HC0126 Hepatocellular Carcinoma","GSM3063409","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063409/suppl/GSM3063409_SH55T28_Cell2_20150723_1606_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063410","HC0131 Hepatocellular Carcinoma","GSM3063410","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063410/suppl/GSM3063410_SH55T31_Cell3_20150723_1611_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063411","HC0141 Hepatocellular Carcinoma","GSM3063411","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063411/suppl/GSM3063411_SH55T36_Cell1_20150723_1718_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063412","HC0150 Hepatocellular Carcinoma","GSM3063412","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063412/suppl/GSM3063412_SH55T38_Cell2_20150723_1630_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063413","HC0171 Hepatocellular Carcinoma","GSM3063413","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063413/suppl/GSM3063413_SH56966_Cell1_20150821_1248_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063414","HC0176 Hepatocellular Carcinoma","GSM3063414","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063414/suppl/GSM3063414_SH55T50_Cell4_20150806_1545_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063415","HC0178 Hepatocellular Carcinoma","GSM3063415","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063415/suppl/GSM3063415_SH56967_Cell1_20150821_1252_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063416","HC0183 Hepatocellular Carcinoma","GSM3063416","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063416/suppl/GSM3063416_SH56967_Cell4_20150821_1255_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063417","HC0188 Hepatocellular Carcinoma","GSM3063417","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063417/suppl/GSM3063417_SH56968_Cell2_20150821_1257_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063418","HC0196 Hepatocellular Carcinoma","GSM3063418","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063418/suppl/GSM3063418_SH55T62_Cell4_20150806_1605_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063419","HC0198 Hepatocellular Carcinoma","GSM3063419","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063419/suppl/GSM3063419_SH55T63_Cell2_20150806_1607_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063420","HC0204 Hepatocellular Carcinoma","GSM3063420","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 79","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063420/suppl/GSM3063420_SH5X144_Cell4_20160204_1211_1Color_IntegratedResult.txt.gz","2565","79","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063421","HC0208 Hepatocellular Carcinoma","GSM3063421","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063421/suppl/GSM3063421_SH5X145_Cell4_20160204_1215_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063422","HC0213 Hepatocellular Carcinoma","GSM3063422","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063422/suppl/GSM3063422_SH5X148_Cell2_20160205_1517_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063423","HC0222 Hepatocellular Carcinoma","GSM3063423","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 48","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063423/suppl/GSM3063423_SH5X152_Cell3_20160205_1526_1Color_IntegratedResult.txt.gz","2565","48","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063424","HC0227 Hepatocellular Carcinoma","GSM3063424","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063424/suppl/GSM3063424_SH5X153_Cell4_20160205_1531_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063425","HC0228 Hepatocellular Carcinoma","GSM3063425","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063425/suppl/GSM3063425_SH5X154_Cell1_20160205_1532_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063426","HC0240 Hepatocellular Carcinoma","GSM3063426","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063426/suppl/GSM3063426_SH5X501_Cell1_20160205_1544_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063427","HC0243 Hepatocellular Carcinoma","GSM3063427","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063427/suppl/GSM3063427_SH5X501_Cell4_20160205_1547_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063428","HC0244 Hepatocellular Carcinoma","GSM3063428","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 76","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063428/suppl/GSM3063428_SH5X504_Cell1_20160205_1548_1Color_IntegratedResult.txt.gz","2565","76","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063429","HC0275 Hepatocellular Carcinoma","GSM3063429","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063429/suppl/GSM3063429_SH5X513_Cell4_20160205_1619_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063430","HC0282 Hepatocellular Carcinoma","GSM3063430","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 60","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063430/suppl/GSM3063430_SH5X516_Cell3_20160205_1626_1Color_IntegratedResult.txt.gz","2565","60","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063431","HC0283 Hepatocellular Carcinoma","GSM3063431","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 61","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063431/suppl/GSM3063431_SH5X516_Cell4_20160205_1627_1Color_IntegratedResult.txt.gz","2565","61","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063432","HC0286 Hepatocellular Carcinoma","GSM3063432","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063432/suppl/GSM3063432_SH5X517_Cell3_20160209_1410_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063433","HC0319 Hepatocellular Carcinoma","GSM3063433","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 79","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063433/suppl/GSM3063433_SH5X526_Cell4_20160209_1443_1Color_IntegratedResult.txt.gz","2565","79","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063434","HC0320 Hepatocellular Carcinoma","GSM3063434","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 45","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063434/suppl/GSM3063434_SH5X527_Cell1_20160209_1444_1Color_IntegratedResult.txt.gz","2565","45","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063435","HC0331 Hepatocellular Carcinoma","GSM3063435","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063435/suppl/GSM3063435_SH5X529_Cell4_20160209_1455_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063436","HC0334 Hepatocellular Carcinoma","GSM3063436","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 81","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063436/suppl/GSM3063436_SH5X530_Cell3_20160209_1458_1Color_IntegratedResult.txt.gz","2565","81","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063437","HC0340 Hepatocellular Carcinoma","GSM3063437","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 43","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063437/suppl/GSM3063437_SH5X532_Cell1_20160209_1504_1Color_IntegratedResult.txt.gz","2565","43","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063438","HC0347 Hepatocellular Carcinoma","GSM3063438","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063438/suppl/GSM3063438_SH5X533_Cell4_20160209_1511_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063439","HC0351 Hepatocellular Carcinoma","GSM3063439","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 84","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063439/suppl/GSM3063439_SH5X534_Cell4_20160209_1515_1Color_IntegratedResult.txt.gz","2565","84","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063440","HC0354 Hepatocellular Carcinoma","GSM3063440","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063440/suppl/GSM3063440_SH5X535_Cell3_20160209_1518_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063441","HC0355 Hepatocellular Carcinoma","GSM3063441","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063441/suppl/GSM3063441_SH5X535_Cell4_20160209_1519_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063442","HC0356 Hepatocellular Carcinoma","GSM3063442","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Hepatocellular Carcinoma","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063442/suppl/GSM3063442_SH5X537_Cell1_20160209_1520_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Hepatocellular Carcinoma","Male"
"GSM3063443","LK0011 Lung Cancer","GSM3063443","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063443/suppl/GSM3063443_SH57X20_Cell2_20151119_1536_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063444","LK0041 Lung Cancer","GSM3063444","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 83","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063444/suppl/GSM3063444_SH57X27_Cell4_20151119_1606_1Color_IntegratedResult.txt.gz","2565","83","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063445","LK0104 Lung Cancer","GSM3063445","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063445/suppl/GSM3063445_SH57X58_Cell3_20151125_1805_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063446","LK0158 Lung Cancer","GSM3063446","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 76","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063446/suppl/GSM3063446_SH57Y15_Cell4_20151126_1525_1Color_IntegratedResult.txt.gz","2565","76","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063447","LK0198 Lung Cancer","GSM3063447","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 60","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063447/suppl/GSM3063447_SH59Q22_Cell4_20151218_1126_1Color_IntegratedResult.txt.gz","2565","60","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063448","LK0315 Lung Cancer","GSM3063448","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 49","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063448/suppl/GSM3063448_SH5X603_Cell2_20160218_1201_1Color_IntegratedResult.txt.gz","2565","49","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063449","LK0334 Lung Cancer","GSM3063449","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063449/suppl/GSM3063449_SH58L02_Cell4_20151209_1433_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063450","LK0347 Lung Cancer","GSM3063450","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063450/suppl/GSM3063450_SH58L09_Cell1_20151209_1446_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063451","LK0398 Lung Cancer","GSM3063451","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 43","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063451/suppl/GSM3063451_SH59F03_Cell4_20151211_1602_1Color_IntegratedResult.txt.gz","2565","43","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063452","LK0399 Lung Cancer","GSM3063452","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063452/suppl/GSM3063452_SH59F04_Cell1_20151211_1603_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063453","LK0405 Lung Cancer","GSM3063453","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063453/suppl/GSM3063453_SH59F05_Cell3_20151211_1609_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063454","LK0442 Lung Cancer","GSM3063454","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063454/suppl/GSM3063454_SH59F22_Cell4_20151215_1431_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063455","LK0503 Lung Cancer","GSM3063455","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 39","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063455/suppl/GSM3063455_SH59H06_Cell1_20151215_1532_1Color_IntegratedResult.txt.gz","2565","39","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063456","LK0583 Lung Cancer","GSM3063456","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 81","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063456/suppl/GSM3063456_SH59H33_Cell1_20151216_1629_1Color_IntegratedResult.txt.gz","2565","81","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063457","LK0589 Lung Cancer","GSM3063457","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063457/suppl/GSM3063457_SH59H34_Cell3_20151216_1635_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063458","LK0603 Lung Cancer","GSM3063458","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063458/suppl/GSM3063458_SH59H38_Cell1_20151217_1504_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063459","LK0630 Lung Cancer","GSM3063459","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 49","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063459/suppl/GSM3063459_SH59H46_Cell4_20151217_1531_1Color_IntegratedResult.txt.gz","2565","49","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063460","LK0649 Lung Cancer","GSM3063460","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063460/suppl/GSM3063460_SH59H53_Cell3_20151217_1550_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063461","LK0691 Lung Cancer","GSM3063461","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 59","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063461/suppl/GSM3063461_SH59H66_Cell1_20151218_1538_1Color_IntegratedResult.txt.gz","2565","59","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063462","LK0794 Lung Cancer","GSM3063462","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 76","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063462/suppl/GSM3063462_SH5YS23_Cell4_20160315_1543_1Color_IntegratedResult.txt.gz","2565","76","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063463","LK0841 Lung Cancer","GSM3063463","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063463/suppl/GSM3063463_SH5YS40_Cell3_20160315_1510_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063464","LK0850 Lung Cancer","GSM3063464","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063464/suppl/GSM3063464_SH5YS42_Cell4_20160315_1519_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063465","LK0857 Lung Cancer","GSM3063465","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063465/suppl/GSM3063465_SH5YS44_Cell3_20160316_1600_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063466","LK0866 Lung Cancer","GSM3063466","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063466/suppl/GSM3063466_SH5YS46_Cell4_20160316_1738_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063467","LK0931 Lung Cancer","GSM3063467","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063467/suppl/GSM3063467_SH5YY05_Cell1_20160316_1714_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063468","LK0944 Lung Cancer","GSM3063468","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063468/suppl/GSM3063468_SH5YY08_Cell2_20160317_1509_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063469","LK1076 Lung Cancer","GSM3063469","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 51","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063469/suppl/GSM3063469_SH5YY53_Cell2_20160329_1421_1Color_IntegratedResult.txt.gz","2565","51","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063470","LK1104 Lung Cancer","GSM3063470","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063470/suppl/GSM3063470_SH5Z104_Cell2_20160329_1449_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063471","LK1105 Lung Cancer","GSM3063471","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 56","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063471/suppl/GSM3063471_SH5Z104_Cell3_20160329_1450_1Color_IntegratedResult.txt.gz","2565","56","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063472","LK1121 Lung Cancer","GSM3063472","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063472/suppl/GSM3063472_SH5Z115_Cell3_20160329_1506_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063473","LK1172 Lung Cancer","GSM3063473","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063473/suppl/GSM3063473_SH5Z139_Cell2_20160330_1517_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063474","LK1190 Lung Cancer","GSM3063474","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 76","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063474/suppl/GSM3063474_SH5Z148_Cell4_20160330_1535_1Color_IntegratedResult.txt.gz","2565","76","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063475","LK1230 Lung Cancer","GSM3063475","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063475/suppl/GSM3063475_SH5Z234_Cell4_20160405_1415_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063476","LK1308 Lung Cancer","GSM3063476","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063476/suppl/GSM3063476_SH5Z311_Cell2_20160413_1542_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063477","LK1327 Lung Cancer","GSM3063477","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 46","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063477/suppl/GSM3063477_SH5Z317_Cell1_20160413_1601_1Color_IntegratedResult.txt.gz","2565","46","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063478","LK1419 Lung Cancer","GSM3063478","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063478/suppl/GSM3063478_SH61606_Cell4_20160419_1453_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063479","LK1428 Lung Cancer","GSM3063479","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063479/suppl/GSM3063479_SH61610_Cell1_20160419_1502_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063480","LK1462 Lung Cancer","GSM3063480","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063480/suppl/GSM3063480_SH61618_Cell3_20160419_1536_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063481","LK1464 Lung Cancer","GSM3063481","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063481/suppl/GSM3063481_SH61619_Cell1_20160420_1510_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063482","LK1478 Lung Cancer","GSM3063482","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 60","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063482/suppl/GSM3063482_SH61622_Cell3_20160420_1524_1Color_IntegratedResult.txt.gz","2565","60","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063483","LK1493 Lung Cancer","GSM3063483","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 53","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063483/suppl/GSM3063483_SH61804_Cell2_20160420_1539_1Color_IntegratedResult.txt.gz","2565","53","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063484","LK1550 Lung Cancer","GSM3063484","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063484/suppl/GSM3063484_SH61854_Cell3_20160422_1525_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063485","LK1570 Lung Cancer","GSM3063485","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 47","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063485/suppl/GSM3063485_SH61F11_Cell1_20160519_1241_1Color_IntegratedResult.txt.gz","2565","47","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063486","LK1585 Lung Cancer","GSM3063486","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063486/suppl/GSM3063486_SH61C03_Cell2_20160422_1600_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063487","LK1633 Lung Cancer","GSM3063487","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063487/suppl/GSM3063487_SH61C16_Cell2_20160426_1434_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063488","LK1649 Lung Cancer","GSM3063488","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063488/suppl/GSM3063488_SH61C20_Cell2_20160426_1549_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063489","LK1660 Lung Cancer","GSM3063489","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063489/suppl/GSM3063489_SH61C24_Cell1_20160426_1501_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063490","LK1693 Lung Cancer","GSM3063490","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063490/suppl/GSM3063490_SH61C33_Cell2_20160426_1534_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063491","LK1700 Lung Cancer","GSM3063491","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063491/suppl/GSM3063491_SH61C36_Cell1_20160511_1459_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063492","LK1714 Lung Cancer","GSM3063492","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Lung Cancer","Sex: Male","age: 83","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063492/suppl/GSM3063492_SH61C40_Cell3_20160511_1513_1Color_IntegratedResult.txt.gz","2565","83","uncertain","uncertain","uncertain","Lung Cancer","Male"
"GSM3063493","PR1045 Negative prostate biopsy","GSM3063493","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 73","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063493/suppl/GSM3063493_SH77Q03_Cell1_20171024_1615_1Color_IntegratedResult.txt.gz","2565","73","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063494","PR1046 Negative prostate biopsy","GSM3063494","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063494/suppl/GSM3063494_SH77Q03_Cell2_20171024_1616_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063495","PR1047 Negative prostate biopsy","GSM3063495","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063495/suppl/GSM3063495_SH77Q03_Cell3_20171024_1617_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063496","PR1048 Negative prostate biopsy","GSM3063496","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 62","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063496/suppl/GSM3063496_SH77Q03_Cell4_20171024_1618_1Color_IntegratedResult.txt.gz","2565","62","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063497","PR1049 Negative prostate biopsy","GSM3063497","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063497/suppl/GSM3063497_SH77Q05_Cell1_20171024_1619_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063498","PR1050 Negative prostate biopsy","GSM3063498","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063498/suppl/GSM3063498_SH77Q05_Cell2_20171024_1620_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063499","PR1051 Negative prostate biopsy","GSM3063499","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063499/suppl/GSM3063499_SH77Q05_Cell3_20171024_1621_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063500","PR1052 Negative prostate biopsy","GSM3063500","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 73","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063500/suppl/GSM3063500_SH77Q05_Cell4_20171024_1622_1Color_IntegratedResult.txt.gz","2565","73","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063501","PR1053 Negative prostate biopsy","GSM3063501","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 75","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063501/suppl/GSM3063501_SH77Q06_Cell1_20171024_1623_1Color_IntegratedResult.txt.gz","2565","75","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063502","PR1054 Negative prostate biopsy","GSM3063502","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 74","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063502/suppl/GSM3063502_SH77Q06_Cell2_20171024_1624_1Color_IntegratedResult.txt.gz","2565","74","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063503","PR1055 Negative prostate biopsy","GSM3063503","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 55","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063503/suppl/GSM3063503_SH77Q06_Cell3_20171024_1625_1Color_IntegratedResult.txt.gz","2565","55","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063504","PR1056 Negative prostate biopsy","GSM3063504","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 63","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063504/suppl/GSM3063504_SH77Q06_Cell4_20171024_1626_1Color_IntegratedResult.txt.gz","2565","63","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063505","PR1057 Negative prostate biopsy","GSM3063505","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 60","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063505/suppl/GSM3063505_SH77Q08_Cell1_20171024_1627_1Color_IntegratedResult.txt.gz","2565","60","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063506","PR1058 Negative prostate biopsy","GSM3063506","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 57","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063506/suppl/GSM3063506_SH77Q08_Cell2_20171024_1628_1Color_IntegratedResult.txt.gz","2565","57","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063507","PR1059 Negative prostate biopsy","GSM3063507","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 67","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063507/suppl/GSM3063507_SH77Q08_Cell3_20171024_1629_1Color_IntegratedResult.txt.gz","2565","67","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063508","PR1060 Negative prostate biopsy","GSM3063508","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063508/suppl/GSM3063508_SH77Q08_Cell4_20171024_1630_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063509","PR1061 Negative prostate biopsy","GSM3063509","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 66","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063509/suppl/GSM3063509_SH77Q09_Cell1_20171024_1734_1Color_IntegratedResult.txt.gz","2565","66","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063510","PR1062 Negative prostate biopsy","GSM3063510","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063510/suppl/GSM3063510_SH77Q09_Cell2_20171024_1632_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063511","PR1063 Negative prostate biopsy","GSM3063511","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 66","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063511/suppl/GSM3063511_SH77Q09_Cell3_20171024_1633_1Color_IntegratedResult.txt.gz","2565","66","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063512","PR1064 Negative prostate biopsy","GSM3063512","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 56","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063512/suppl/GSM3063512_SH77Q09_Cell4_20171024_1634_1Color_IntegratedResult.txt.gz","2565","56","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063513","PR1065 Negative prostate biopsy","GSM3063513","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063513/suppl/GSM3063513_SH77Q11_Cell1_20171024_1635_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063514","PR1066 Negative prostate biopsy","GSM3063514","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 66","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063514/suppl/GSM3063514_SH78P54_Cell1_20171128_1515_1Color_IntegratedResult.txt.gz","2565","66","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063515","PR1067 Negative prostate biopsy","GSM3063515","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 74","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063515/suppl/GSM3063515_SH77Q11_Cell3_20171024_1637_1Color_IntegratedResult.txt.gz","2565","74","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063516","PR1068 Negative prostate biopsy","GSM3063516","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063516/suppl/GSM3063516_SH77Q11_Cell4_20171024_1638_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063517","PR1069 Negative prostate biopsy","GSM3063517","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 62","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063517/suppl/GSM3063517_SH77Q12_Cell1_20171024_1639_1Color_IntegratedResult.txt.gz","2565","62","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063518","PR1070 Negative prostate biopsy","GSM3063518","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 75","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063518/suppl/GSM3063518_SH78P54_Cell2_20171128_1516_1Color_IntegratedResult.txt.gz","2565","75","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063519","PR1071 Negative prostate biopsy","GSM3063519","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063519/suppl/GSM3063519_SH77Q12_Cell3_20171024_1641_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063520","PR1072 Negative prostate biopsy","GSM3063520","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063520/suppl/GSM3063520_SH77Q12_Cell4_20171024_1642_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063521","PR1073 Negative prostate biopsy","GSM3063521","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063521/suppl/GSM3063521_SH77Q13_Cell1_20171024_1643_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063522","PR1074 Negative prostate biopsy","GSM3063522","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 59","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063522/suppl/GSM3063522_SH78P54_Cell3_20171128_1643_1Color_IntegratedResult.txt.gz","2565","59","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063523","PR1075 Negative prostate biopsy","GSM3063523","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 62","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063523/suppl/GSM3063523_SH77Q13_Cell3_20171024_1645_1Color_IntegratedResult.txt.gz","2565","62","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063524","PR1076 Negative prostate biopsy","GSM3063524","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 76","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063524/suppl/GSM3063524_SH77Q13_Cell4_20171024_1646_1Color_IntegratedResult.txt.gz","2565","76","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063525","PR1077 Negative prostate biopsy","GSM3063525","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 74","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063525/suppl/GSM3063525_SH77Q16_Cell1_20171024_1647_1Color_IntegratedResult.txt.gz","2565","74","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063526","PR1078 Negative prostate biopsy","GSM3063526","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 59","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063526/suppl/GSM3063526_SH77Q16_Cell2_20171024_1648_1Color_IntegratedResult.txt.gz","2565","59","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063527","PR1079 Negative prostate biopsy","GSM3063527","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063527/suppl/GSM3063527_SH77Q16_Cell3_20171024_1649_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063528","PR1080 Negative prostate biopsy","GSM3063528","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 63","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063528/suppl/GSM3063528_SH77Q16_Cell4_20171024_1650_1Color_IntegratedResult.txt.gz","2565","63","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063529","PR1081 Negative prostate biopsy","GSM3063529","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063529/suppl/GSM3063529_SH77Q17_Cell1_20171024_1651_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063530","PR1082 Negative prostate biopsy","GSM3063530","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 50","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063530/suppl/GSM3063530_SH77Q17_Cell2_20171024_1652_1Color_IntegratedResult.txt.gz","2565","50","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063531","PR1083 Negative prostate biopsy","GSM3063531","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063531/suppl/GSM3063531_SH77Q17_Cell3_20171024_1653_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063532","PR1084 Negative prostate biopsy","GSM3063532","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 51","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063532/suppl/GSM3063532_SH77Q17_Cell4_20171024_1654_1Color_IntegratedResult.txt.gz","2565","51","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063533","PR1085 Negative prostate biopsy","GSM3063533","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 63","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063533/suppl/GSM3063533_SH77Q22_Cell1_20171024_1655_1Color_IntegratedResult.txt.gz","2565","63","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063534","PR1086 Negative prostate biopsy","GSM3063534","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 76","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063534/suppl/GSM3063534_SH77Q22_Cell2_20171024_1656_1Color_IntegratedResult.txt.gz","2565","76","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063535","PR1087 Negative prostate biopsy","GSM3063535","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 58","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063535/suppl/GSM3063535_SH77Q22_Cell3_20171024_1657_1Color_IntegratedResult.txt.gz","2565","58","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063536","PR1088 Negative prostate biopsy","GSM3063536","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 55","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063536/suppl/GSM3063536_SH77Q22_Cell4_20171024_1658_1Color_IntegratedResult.txt.gz","2565","55","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063537","PR1089 Negative prostate biopsy","GSM3063537","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 52","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063537/suppl/GSM3063537_SH77Q29_Cell1_20171024_1659_1Color_IntegratedResult.txt.gz","2565","52","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063538","PR1090 Negative prostate biopsy","GSM3063538","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 57","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063538/suppl/GSM3063538_SH78P54_Cell4_20171128_1518_1Color_IntegratedResult.txt.gz","2565","57","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063539","PR1091 Negative prostate biopsy","GSM3063539","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 71","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063539/suppl/GSM3063539_SH77Q29_Cell3_20171024_1701_1Color_IntegratedResult.txt.gz","2565","71","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063540","PR1092 Negative prostate biopsy","GSM3063540","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063540/suppl/GSM3063540_SH77Q29_Cell4_20171024_1702_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063541","PR1093 Negative prostate biopsy","GSM3063541","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 57","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063541/suppl/GSM3063541_SH77Q30_Cell1_20171024_1703_1Color_IntegratedResult.txt.gz","2565","57","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063542","PR1094 Negative prostate biopsy","GSM3063542","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 57","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063542/suppl/GSM3063542_SH78P55_Cell1_20171128_1519_1Color_IntegratedResult.txt.gz","2565","57","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063543","PR1095 Negative prostate biopsy","GSM3063543","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063543/suppl/GSM3063543_SH77Q30_Cell3_20171024_1705_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063544","PR1096 Negative prostate biopsy","GSM3063544","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063544/suppl/GSM3063544_SH77Q30_Cell4_20171024_1706_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063545","PR1097 Negative prostate biopsy","GSM3063545","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063545/suppl/GSM3063545_SH77Q31_Cell1_20171024_1707_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063546","PR1098 Negative prostate biopsy","GSM3063546","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 85","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063546/suppl/GSM3063546_SH77Q31_Cell2_20171024_1708_1Color_IntegratedResult.txt.gz","2565","85","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063547","PR1099 Negative prostate biopsy","GSM3063547","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 73","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063547/suppl/GSM3063547_SH77Q31_Cell3_20171024_1709_1Color_IntegratedResult.txt.gz","2565","73","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063548","PR1100 Negative prostate biopsy","GSM3063548","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 58","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063548/suppl/GSM3063548_SH77Q31_Cell4_20171024_1710_1Color_IntegratedResult.txt.gz","2565","58","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063549","PR1101 Negative prostate biopsy","GSM3063549","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 63","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063549/suppl/GSM3063549_SH77Q32_Cell1_20171024_1711_1Color_IntegratedResult.txt.gz","2565","63","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063550","PR1102 Negative prostate biopsy","GSM3063550","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063550/suppl/GSM3063550_SH77Q32_Cell2_20171024_1712_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063551","PR1103 Negative prostate biopsy","GSM3063551","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 74","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063551/suppl/GSM3063551_SH77Q32_Cell3_20171024_1713_1Color_IntegratedResult.txt.gz","2565","74","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063552","PR1104 Negative prostate biopsy","GSM3063552","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 76","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063552/suppl/GSM3063552_SH77Q32_Cell4_20171024_1714_1Color_IntegratedResult.txt.gz","2565","76","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063553","PR1105 Negative prostate biopsy","GSM3063553","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 60","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063553/suppl/GSM3063553_SH77Q37_Cell1_20171024_1715_1Color_IntegratedResult.txt.gz","2565","60","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063554","PR1106 Negative prostate biopsy","GSM3063554","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 60","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063554/suppl/GSM3063554_SH77Q37_Cell2_20171024_1716_1Color_IntegratedResult.txt.gz","2565","60","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063555","PR1107 Negative prostate biopsy","GSM3063555","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063555/suppl/GSM3063555_SH77Q37_Cell3_20171024_1717_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063556","PR1108 Negative prostate biopsy","GSM3063556","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063556/suppl/GSM3063556_SH77Q37_Cell4_20171024_1718_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063557","PR1109 Negative prostate biopsy","GSM3063557","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 53","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063557/suppl/GSM3063557_SH77Q40_Cell1_20171026_1602_1Color_IntegratedResult.txt.gz","2565","53","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063558","PR1110 Negative prostate biopsy","GSM3063558","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 71","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063558/suppl/GSM3063558_SH77Q40_Cell2_20171026_1603_1Color_IntegratedResult.txt.gz","2565","71","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063559","PR1111 Negative prostate biopsy","GSM3063559","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 66","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063559/suppl/GSM3063559_SH77Q40_Cell3_20171026_1604_1Color_IntegratedResult.txt.gz","2565","66","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063560","PR1112 Negative prostate biopsy","GSM3063560","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063560/suppl/GSM3063560_SH77Q40_Cell4_20171026_1605_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063561","PR1113 Negative prostate biopsy","GSM3063561","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063561/suppl/GSM3063561_SH77Q43_Cell1_20171026_1606_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063562","PR1114 Negative prostate biopsy","GSM3063562","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 50","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063562/suppl/GSM3063562_SH77Q43_Cell2_20171026_1607_1Color_IntegratedResult.txt.gz","2565","50","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063563","PR1115 Negative prostate biopsy","GSM3063563","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063563/suppl/GSM3063563_SH77Q43_Cell3_20171026_1608_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063564","PR1116 Negative prostate biopsy","GSM3063564","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 77","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063564/suppl/GSM3063564_SH77Q43_Cell4_20171026_1609_1Color_IntegratedResult.txt.gz","2565","77","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063565","PR1117 Negative prostate biopsy","GSM3063565","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063565/suppl/GSM3063565_SH78P55_Cell2_20171128_1520_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063566","PR1118 Negative prostate biopsy","GSM3063566","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 74","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063566/suppl/GSM3063566_SH78P55_Cell3_20171128_1521_1Color_IntegratedResult.txt.gz","2565","74","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063567","PR1119 Negative prostate biopsy","GSM3063567","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063567/suppl/GSM3063567_SH77Q44_Cell3_20171026_1612_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063568","PR1120 Negative prostate biopsy","GSM3063568","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063568/suppl/GSM3063568_SH77Q44_Cell4_20171026_1613_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063569","PR1121 Negative prostate biopsy","GSM3063569","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 49","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063569/suppl/GSM3063569_SH78215_Cell1_20171026_1614_1Color_IntegratedResult.txt.gz","2565","49","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063570","PR1122 Negative prostate biopsy","GSM3063570","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063570/suppl/GSM3063570_SH78215_Cell2_20171026_1615_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063571","PR1123 Negative prostate biopsy","GSM3063571","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 62","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063571/suppl/GSM3063571_SH78215_Cell3_20171026_1616_1Color_IntegratedResult.txt.gz","2565","62","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063572","PR1124 Negative prostate biopsy","GSM3063572","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 74","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063572/suppl/GSM3063572_SH78P55_Cell4_20171128_1522_1Color_IntegratedResult.txt.gz","2565","74","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063573","PR1125 Negative prostate biopsy","GSM3063573","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 57","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063573/suppl/GSM3063573_SH78216_Cell1_20171026_1618_1Color_IntegratedResult.txt.gz","2565","57","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063574","PR1126 Negative prostate biopsy","GSM3063574","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063574/suppl/GSM3063574_SH78216_Cell2_20171026_1619_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063575","PR1127 Negative prostate biopsy","GSM3063575","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 62","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063575/suppl/GSM3063575_SH78216_Cell3_20171026_1620_1Color_IntegratedResult.txt.gz","2565","62","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063576","PR1128 Negative prostate biopsy","GSM3063576","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063576/suppl/GSM3063576_SH78216_Cell4_20171026_1621_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063577","PR1129 Negative prostate biopsy","GSM3063577","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 75","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063577/suppl/GSM3063577_SH78217_Cell1_20171026_1622_1Color_IntegratedResult.txt.gz","2565","75","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063578","PR1130 Negative prostate biopsy","GSM3063578","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 63","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063578/suppl/GSM3063578_SH78217_Cell2_20171026_1623_1Color_IntegratedResult.txt.gz","2565","63","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063579","PR1131 Negative prostate biopsy","GSM3063579","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 67","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063579/suppl/GSM3063579_SH78P56_Cell1_20171128_1523_1Color_IntegratedResult.txt.gz","2565","67","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063580","PR1132 Negative prostate biopsy","GSM3063580","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 59","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063580/suppl/GSM3063580_SH78217_Cell4_20171026_1625_1Color_IntegratedResult.txt.gz","2565","59","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063581","PR1133 Negative prostate biopsy","GSM3063581","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 54","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063581/suppl/GSM3063581_SH78218_Cell1_20171026_1626_1Color_IntegratedResult.txt.gz","2565","54","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063582","PR1134 Negative prostate biopsy","GSM3063582","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 49","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063582/suppl/GSM3063582_SH78218_Cell2_20171026_1627_1Color_IntegratedResult.txt.gz","2565","49","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063583","PR1135 Negative prostate biopsy","GSM3063583","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 63","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063583/suppl/GSM3063583_SH78218_Cell3_20171026_1628_1Color_IntegratedResult.txt.gz","2565","63","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063584","PR1136 Negative prostate biopsy","GSM3063584","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 63","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063584/suppl/GSM3063584_SH78218_Cell4_20171026_1629_1Color_IntegratedResult.txt.gz","2565","63","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063585","PR1137 Negative prostate biopsy","GSM3063585","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063585/suppl/GSM3063585_SH78220_Cell1_20171026_1733_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063586","PR1138 Negative prostate biopsy","GSM3063586","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 74","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063586/suppl/GSM3063586_SH78220_Cell2_20171026_1631_1Color_IntegratedResult.txt.gz","2565","74","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063587","PR1139 Negative prostate biopsy","GSM3063587","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 71","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063587/suppl/GSM3063587_SH78220_Cell3_20171026_1632_1Color_IntegratedResult.txt.gz","2565","71","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063588","PR1140 Negative prostate biopsy","GSM3063588","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 67","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063588/suppl/GSM3063588_SH78220_Cell4_20171026_1734_1Color_IntegratedResult.txt.gz","2565","67","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063589","PR1141 Negative prostate biopsy","GSM3063589","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 66","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063589/suppl/GSM3063589_SH78222_Cell1_20171026_1634_1Color_IntegratedResult.txt.gz","2565","66","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063590","PR1142 Negative prostate biopsy","GSM3063590","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063590/suppl/GSM3063590_SH78222_Cell2_20171026_1635_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063591","PR1143 Negative prostate biopsy","GSM3063591","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 62","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063591/suppl/GSM3063591_SH78222_Cell3_20171026_1636_1Color_IntegratedResult.txt.gz","2565","62","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063592","PR1144 Negative prostate biopsy","GSM3063592","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 60","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063592/suppl/GSM3063592_SH78222_Cell4_20171026_1637_1Color_IntegratedResult.txt.gz","2565","60","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063593","PR1145 Negative prostate biopsy","GSM3063593","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 79","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063593/suppl/GSM3063593_SH78223_Cell1_20171026_1638_1Color_IntegratedResult.txt.gz","2565","79","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063594","PR1146 Negative prostate biopsy","GSM3063594","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063594/suppl/GSM3063594_SH78223_Cell2_20171026_1639_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063595","PR1147 Negative prostate biopsy","GSM3063595","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063595/suppl/GSM3063595_SH78223_Cell3_20171026_1640_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063596","PR1148 Negative prostate biopsy","GSM3063596","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063596/suppl/GSM3063596_SH78223_Cell4_20171026_1641_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063597","PR1149 Negative prostate biopsy","GSM3063597","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 55","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063597/suppl/GSM3063597_SH78225_Cell1_20171026_1642_1Color_IntegratedResult.txt.gz","2565","55","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063598","PR1150 Negative prostate biopsy","GSM3063598","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063598/suppl/GSM3063598_SH78225_Cell2_20171026_1643_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063599","PR1151 Negative prostate biopsy","GSM3063599","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 66","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063599/suppl/GSM3063599_SH78225_Cell3_20171026_1644_1Color_IntegratedResult.txt.gz","2565","66","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063600","PR1152 Negative prostate biopsy","GSM3063600","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 66","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063600/suppl/GSM3063600_SH78225_Cell4_20171026_1645_1Color_IntegratedResult.txt.gz","2565","66","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063601","PR1153 Negative prostate biopsy","GSM3063601","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063601/suppl/GSM3063601_SH78P56_Cell2_20171128_1524_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063602","PR1154 Negative prostate biopsy","GSM3063602","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063602/suppl/GSM3063602_SH78227_Cell2_20171026_1647_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063603","PR1155 Negative prostate biopsy","GSM3063603","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063603/suppl/GSM3063603_SH78227_Cell3_20171026_1648_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063604","PR1156 Negative prostate biopsy","GSM3063604","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063604/suppl/GSM3063604_SH78227_Cell4_20171026_1649_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063605","PR1157 Negative prostate biopsy","GSM3063605","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063605/suppl/GSM3063605_SH78228_Cell1_20171026_1650_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063606","PR1158 Negative prostate biopsy","GSM3063606","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 55","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063606/suppl/GSM3063606_SH78P56_Cell3_20171128_1525_1Color_IntegratedResult.txt.gz","2565","55","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063607","PR1159 Negative prostate biopsy","GSM3063607","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 75","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063607/suppl/GSM3063607_SH78228_Cell3_20171026_1652_1Color_IntegratedResult.txt.gz","2565","75","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063608","PR1160 Negative prostate biopsy","GSM3063608","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063608/suppl/GSM3063608_SH78228_Cell4_20171026_1653_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063609","PR1161 Negative prostate biopsy","GSM3063609","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 45","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063609/suppl/GSM3063609_SH78230_Cell1_20171026_1654_1Color_IntegratedResult.txt.gz","2565","45","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063610","PR1162 Negative prostate biopsy","GSM3063610","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 45","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063610/suppl/GSM3063610_SH78230_Cell2_20171026_1655_1Color_IntegratedResult.txt.gz","2565","45","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063611","PR1163 Negative prostate biopsy","GSM3063611","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 63","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063611/suppl/GSM3063611_SH78230_Cell3_20171026_1656_1Color_IntegratedResult.txt.gz","2565","63","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063612","PR1164 Negative prostate biopsy","GSM3063612","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063612/suppl/GSM3063612_SH78230_Cell4_20171026_1657_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063613","PR1165 Negative prostate biopsy","GSM3063613","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 67","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063613/suppl/GSM3063613_SH78231_Cell1_20171026_1658_1Color_IntegratedResult.txt.gz","2565","67","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063614","PR1166 Negative prostate biopsy","GSM3063614","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063614/suppl/GSM3063614_SH78231_Cell2_20171026_1659_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063615","PR1167 Negative prostate biopsy","GSM3063615","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063615/suppl/GSM3063615_SH78231_Cell3_20171026_1700_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063616","PR1168 Negative prostate biopsy","GSM3063616","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 74","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063616/suppl/GSM3063616_SH78231_Cell4_20171026_1701_1Color_IntegratedResult.txt.gz","2565","74","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063617","PR1169 Negative prostate biopsy","GSM3063617","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063617/suppl/GSM3063617_SH78232_Cell1_20171026_1702_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063618","PR1170 Negative prostate biopsy","GSM3063618","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 76","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063618/suppl/GSM3063618_SH78232_Cell2_20171026_1703_1Color_IntegratedResult.txt.gz","2565","76","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063619","PR1171 Negative prostate biopsy","GSM3063619","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 58","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063619/suppl/GSM3063619_SH78232_Cell3_20171026_1704_1Color_IntegratedResult.txt.gz","2565","58","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063620","PR1172 Negative prostate biopsy","GSM3063620","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063620/suppl/GSM3063620_SH78P56_Cell4_20171128_1526_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063621","PR1173 Negative prostate biopsy","GSM3063621","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063621/suppl/GSM3063621_SH78234_Cell1_20171026_1706_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063622","PR1174 Negative prostate biopsy","GSM3063622","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 73","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063622/suppl/GSM3063622_SH78234_Cell2_20171026_1707_1Color_IntegratedResult.txt.gz","2565","73","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063623","PR1175 Negative prostate biopsy","GSM3063623","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063623/suppl/GSM3063623_SH78234_Cell3_20171026_1708_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063624","PR1176 Negative prostate biopsy","GSM3063624","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063624/suppl/GSM3063624_SH78234_Cell4_20171026_1709_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063625","PR1177 Negative prostate biopsy","GSM3063625","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063625/suppl/GSM3063625_SH78235_Cell1_20171026_1710_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063626","PR1178 Negative prostate biopsy","GSM3063626","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 58","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063626/suppl/GSM3063626_SH78235_Cell2_20171026_1711_1Color_IntegratedResult.txt.gz","2565","58","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063627","PR1179 Negative prostate biopsy","GSM3063627","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 73","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063627/suppl/GSM3063627_SH78235_Cell3_20171026_1712_1Color_IntegratedResult.txt.gz","2565","73","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063628","PR1180 Negative prostate biopsy","GSM3063628","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063628/suppl/GSM3063628_SH78235_Cell4_20171026_1713_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063629","PR1181 Negative prostate biopsy","GSM3063629","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 55","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063629/suppl/GSM3063629_SH78236_Cell1_20171026_1714_1Color_IntegratedResult.txt.gz","2565","55","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063630","PR1182 Negative prostate biopsy","GSM3063630","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 71","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063630/suppl/GSM3063630_SH78236_Cell2_20171026_1715_1Color_IntegratedResult.txt.gz","2565","71","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063631","PR1183 Negative prostate biopsy","GSM3063631","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063631/suppl/GSM3063631_SH78236_Cell3_20171026_1716_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063632","PR1184 Negative prostate biopsy","GSM3063632","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063632/suppl/GSM3063632_SH78236_Cell4_20171026_1717_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063633","PR1185 Negative prostate biopsy","GSM3063633","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 67","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063633/suppl/GSM3063633_SH78237_Cell1_20171026_1718_1Color_IntegratedResult.txt.gz","2565","67","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063634","PR1186 Negative prostate biopsy","GSM3063634","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 56","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063634/suppl/GSM3063634_SH78237_Cell2_20171026_1719_1Color_IntegratedResult.txt.gz","2565","56","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063635","PR1187 Negative prostate biopsy","GSM3063635","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063635/suppl/GSM3063635_SH78237_Cell3_20171026_1720_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063636","PR1188 Negative prostate biopsy","GSM3063636","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 63","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063636/suppl/GSM3063636_SH78237_Cell4_20171026_1721_1Color_IntegratedResult.txt.gz","2565","63","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063637","PR1189 Negative prostate biopsy","GSM3063637","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063637/suppl/GSM3063637_SH78260_Cell1_20171031_1647_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063638","PR1190 Negative prostate biopsy","GSM3063638","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063638/suppl/GSM3063638_SH78260_Cell2_20171031_1648_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063639","PR1191 Negative prostate biopsy","GSM3063639","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063639/suppl/GSM3063639_SH78260_Cell3_20171031_1625_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063640","PR1192 Negative prostate biopsy","GSM3063640","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 75","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063640/suppl/GSM3063640_SH78260_Cell4_20171031_1626_1Color_IntegratedResult.txt.gz","2565","75","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063641","PR1193 Negative prostate biopsy","GSM3063641","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063641/suppl/GSM3063641_SH78261_Cell1_20171031_1649_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063642","PR1194 Negative prostate biopsy","GSM3063642","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063642/suppl/GSM3063642_SH78261_Cell2_20171031_1628_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063643","PR1195 Negative prostate biopsy","GSM3063643","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063643/suppl/GSM3063643_SH78261_Cell3_20171031_1629_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063644","PR1196 Negative prostate biopsy","GSM3063644","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 66","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063644/suppl/GSM3063644_SH78261_Cell4_20171031_1630_1Color_IntegratedResult.txt.gz","2565","66","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063645","PR1197 Negative prostate biopsy","GSM3063645","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063645/suppl/GSM3063645_SH78349_Cell3_20171107_1608_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063646","PR1198 Negative prostate biopsy","GSM3063646","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 79","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063646/suppl/GSM3063646_SH78349_Cell4_20171107_1609_1Color_IntegratedResult.txt.gz","2565","79","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063647","PR1199 Negative prostate biopsy","GSM3063647","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 55","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063647/suppl/GSM3063647_SH78350_Cell1_20171107_1610_1Color_IntegratedResult.txt.gz","2565","55","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063648","PR1200 Negative prostate biopsy","GSM3063648","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 73","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063648/suppl/GSM3063648_SH78350_Cell2_20171107_1611_1Color_IntegratedResult.txt.gz","2565","73","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063649","PR1201 Negative prostate biopsy","GSM3063649","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063649/suppl/GSM3063649_SH78350_Cell3_20171107_1612_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063650","PR1202 Negative prostate biopsy","GSM3063650","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063650/suppl/GSM3063650_SH78350_Cell4_20171107_1613_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063651","PR1203 Negative prostate biopsy","GSM3063651","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063651/suppl/GSM3063651_SH78730_Cell3_20171121_1527_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063652","PR1204 Negative prostate biopsy","GSM3063652","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063652/suppl/GSM3063652_SH78351_Cell1_20171107_1614_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063653","PR1205 Negative prostate biopsy","GSM3063653","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 57","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063653/suppl/GSM3063653_SH78351_Cell2_20171107_1615_1Color_IntegratedResult.txt.gz","2565","57","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063654","PR1206 Negative prostate biopsy","GSM3063654","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063654/suppl/GSM3063654_SH78351_Cell3_20171107_1616_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063655","PR1207 Negative prostate biopsy","GSM3063655","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063655/suppl/GSM3063655_SH78351_Cell4_20171107_1617_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063656","PR1208 Negative prostate biopsy","GSM3063656","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063656/suppl/GSM3063656_SH78352_Cell1_20171107_1618_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063657","PR1209 Negative prostate biopsy","GSM3063657","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 66","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063657/suppl/GSM3063657_SH78352_Cell2_20171107_1619_1Color_IntegratedResult.txt.gz","2565","66","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063658","PR1210 Negative prostate biopsy","GSM3063658","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063658/suppl/GSM3063658_SH78352_Cell3_20171107_1620_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063659","PR1211 Negative prostate biopsy","GSM3063659","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063659/suppl/GSM3063659_SH78352_Cell4_20171107_1621_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063660","PR1212 Negative prostate biopsy","GSM3063660","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 80","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063660/suppl/GSM3063660_SH78701_Cell1_20171107_1622_1Color_IntegratedResult.txt.gz","2565","80","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063661","PR1213 Negative prostate biopsy","GSM3063661","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063661/suppl/GSM3063661_SH78701_Cell2_20171107_1630_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063662","PR1214 Negative prostate biopsy","GSM3063662","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 62","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063662/suppl/GSM3063662_SH78701_Cell3_20171107_1624_1Color_IntegratedResult.txt.gz","2565","62","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063663","PR1215 Negative prostate biopsy","GSM3063663","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 48","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063663/suppl/GSM3063663_SH78701_Cell4_20171107_1625_1Color_IntegratedResult.txt.gz","2565","48","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063664","PR1216 Negative prostate biopsy","GSM3063664","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063664/suppl/GSM3063664_SH78P57_Cell1_20171128_1527_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063665","PR1217 Negative prostate biopsy","GSM3063665","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063665/suppl/GSM3063665_SH78P57_Cell2_20171128_1528_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063666","PR1218 Negative prostate biopsy","GSM3063666","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 66","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063666/suppl/GSM3063666_SH78P57_Cell3_20171128_1529_1Color_IntegratedResult.txt.gz","2565","66","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063667","PR1219 Negative prostate biopsy","GSM3063667","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063667/suppl/GSM3063667_SH78706_Cell1_20171114_1536_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063668","PR1220 Negative prostate biopsy","GSM3063668","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 62","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063668/suppl/GSM3063668_SH78706_Cell2_20171114_1537_1Color_IntegratedResult.txt.gz","2565","62","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063669","PR1221 Negative prostate biopsy","GSM3063669","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063669/suppl/GSM3063669_SH78P57_Cell4_20171128_1530_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063670","PR1222 Negative prostate biopsy","GSM3063670","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063670/suppl/GSM3063670_SH78706_Cell4_20171114_1539_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063671","PR1223 Negative prostate biopsy","GSM3063671","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 67","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063671/suppl/GSM3063671_SH78707_Cell1_20171114_1540_1Color_IntegratedResult.txt.gz","2565","67","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063672","PR1224 Negative prostate biopsy","GSM3063672","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063672/suppl/GSM3063672_SH78707_Cell2_20171114_1541_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063673","PR1225 Negative prostate biopsy","GSM3063673","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063673/suppl/GSM3063673_SH78707_Cell3_20171114_1542_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063674","PR1226 Negative prostate biopsy","GSM3063674","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063674/suppl/GSM3063674_SH78P58_Cell1_20171128_1531_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063675","PR1227 Negative prostate biopsy","GSM3063675","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 55","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063675/suppl/GSM3063675_SH78708_Cell1_20171114_1544_1Color_IntegratedResult.txt.gz","2565","55","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063676","PR1228 Negative prostate biopsy","GSM3063676","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063676/suppl/GSM3063676_SH78P58_Cell2_20171128_1532_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063677","PR1229 Negative prostate biopsy","GSM3063677","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063677/suppl/GSM3063677_SH78708_Cell3_20171114_1546_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063678","PR1230 Negative prostate biopsy","GSM3063678","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063678/suppl/GSM3063678_SH78708_Cell4_20171114_1547_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063679","PR1231 Negative prostate biopsy","GSM3063679","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 57","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063679/suppl/GSM3063679_SH78709_Cell1_20171114_1548_1Color_IntegratedResult.txt.gz","2565","57","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063680","PR1232 Negative prostate biopsy","GSM3063680","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063680/suppl/GSM3063680_SH78709_Cell2_20171114_1549_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063681","PR1233 Negative prostate biopsy","GSM3063681","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 63","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063681/suppl/GSM3063681_SH78P58_Cell3_20171128_1533_1Color_IntegratedResult.txt.gz","2565","63","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063682","PR1234 Negative prostate biopsy","GSM3063682","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 55","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063682/suppl/GSM3063682_SH78709_Cell4_20171114_1551_1Color_IntegratedResult.txt.gz","2565","55","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063683","PR1235 Negative prostate biopsy","GSM3063683","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 67","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063683/suppl/GSM3063683_SH78P58_Cell4_20171128_1534_1Color_IntegratedResult.txt.gz","2565","67","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063684","PR1236 Negative prostate biopsy","GSM3063684","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 56","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063684/suppl/GSM3063684_SH78711_Cell2_20171114_1553_1Color_IntegratedResult.txt.gz","2565","56","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063685","PR1237 Negative prostate biopsy","GSM3063685","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 76","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063685/suppl/GSM3063685_SH78711_Cell3_20171114_1554_1Color_IntegratedResult.txt.gz","2565","76","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063686","PR1238 Negative prostate biopsy","GSM3063686","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063686/suppl/GSM3063686_SH78711_Cell4_20171114_1555_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063687","PR1239 Negative prostate biopsy","GSM3063687","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063687/suppl/GSM3063687_SH78P59_Cell1_20171128_1535_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063688","PR1240 Negative prostate biopsy","GSM3063688","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 42","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063688/suppl/GSM3063688_SH78P59_Cell2_20171128_1536_1Color_IntegratedResult.txt.gz","2565","42","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063689","PR1241 Negative prostate biopsy","GSM3063689","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 66","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063689/suppl/GSM3063689_SH78P59_Cell3_20171128_1537_1Color_IntegratedResult.txt.gz","2565","66","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063690","PR1242 Negative prostate biopsy","GSM3063690","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 77","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063690/suppl/GSM3063690_SH78712_Cell4_20171114_1559_1Color_IntegratedResult.txt.gz","2565","77","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063691","PR1243 Negative prostate biopsy","GSM3063691","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063691/suppl/GSM3063691_SH78713_Cell1_20171114_1600_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063692","PR1244 Negative prostate biopsy","GSM3063692","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 59","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063692/suppl/GSM3063692_SH78713_Cell2_20171114_1601_1Color_IntegratedResult.txt.gz","2565","59","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063693","PR1245 Negative prostate biopsy","GSM3063693","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 62","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063693/suppl/GSM3063693_SH78713_Cell3_20171114_1602_1Color_IntegratedResult.txt.gz","2565","62","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063694","PR1246 Negative prostate biopsy","GSM3063694","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063694/suppl/GSM3063694_SH78713_Cell4_20171114_1603_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063695","PR1247 Negative prostate biopsy","GSM3063695","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063695/suppl/GSM3063695_SH78714_Cell1_20171114_1604_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063696","PR1248 Negative prostate biopsy","GSM3063696","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063696/suppl/GSM3063696_SH78P59_Cell4_20171128_1538_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063697","PR1249 Negative prostate biopsy","GSM3063697","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 67","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063697/suppl/GSM3063697_SH78714_Cell3_20171114_1606_1Color_IntegratedResult.txt.gz","2565","67","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063698","PR1250 Negative prostate biopsy","GSM3063698","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 80","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063698/suppl/GSM3063698_SH78714_Cell4_20171114_1607_1Color_IntegratedResult.txt.gz","2565","80","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063699","PR1251 Negative prostate biopsy","GSM3063699","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063699/suppl/GSM3063699_SH78715_Cell1_20171114_1608_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063700","PR1252 Negative prostate biopsy","GSM3063700","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063700/suppl/GSM3063700_SH78715_Cell2_20171114_1609_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063701","PR1253 Negative prostate biopsy","GSM3063701","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 58","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063701/suppl/GSM3063701_SH78715_Cell3_20171114_1610_1Color_IntegratedResult.txt.gz","2565","58","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063702","PR1254 Negative prostate biopsy","GSM3063702","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063702/suppl/GSM3063702_SH78715_Cell4_20171114_1611_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063703","PR1255 Negative prostate biopsy","GSM3063703","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063703/suppl/GSM3063703_SH78716_Cell1_20171114_1612_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063704","PR1256 Negative prostate biopsy","GSM3063704","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 67","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063704/suppl/GSM3063704_SH78716_Cell2_20171114_1613_1Color_IntegratedResult.txt.gz","2565","67","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063705","PR1257 Negative prostate biopsy","GSM3063705","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 56","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063705/suppl/GSM3063705_SH78716_Cell3_20171114_1614_1Color_IntegratedResult.txt.gz","2565","56","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063706","PR1258 Negative prostate biopsy","GSM3063706","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 67","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063706/suppl/GSM3063706_SH78716_Cell4_20171114_1615_1Color_IntegratedResult.txt.gz","2565","67","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063707","PR1259 Negative prostate biopsy","GSM3063707","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 78","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063707/suppl/GSM3063707_SH78717_Cell1_20171114_1616_1Color_IntegratedResult.txt.gz","2565","78","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063708","PR1260 Negative prostate biopsy","GSM3063708","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 64","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063708/suppl/GSM3063708_SH78717_Cell2_20171114_1617_1Color_IntegratedResult.txt.gz","2565","64","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063709","PR1261 Negative prostate biopsy","GSM3063709","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063709/suppl/GSM3063709_SH78717_Cell3_20171114_1618_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063710","PR1262 Negative prostate biopsy","GSM3063710","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063710/suppl/GSM3063710_SH78717_Cell4_20171114_1619_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063711","PR1263 Negative prostate biopsy","GSM3063711","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 67","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063711/suppl/GSM3063711_SH78718_Cell1_20171114_1620_1Color_IntegratedResult.txt.gz","2565","67","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063712","PR1264 Negative prostate biopsy","GSM3063712","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 57","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063712/suppl/GSM3063712_SH78718_Cell2_20171114_1621_1Color_IntegratedResult.txt.gz","2565","57","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063713","PR1265 Negative prostate biopsy","GSM3063713","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063713/suppl/GSM3063713_SH78718_Cell3_20171114_1622_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063714","PR1266 Negative prostate biopsy","GSM3063714","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063714/suppl/GSM3063714_SH78718_Cell4_20171114_1623_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063715","PR1267 Negative prostate biopsy","GSM3063715","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 59","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063715/suppl/GSM3063715_SH78719_Cell1_20171114_1624_1Color_IntegratedResult.txt.gz","2565","59","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063716","PR1268 Negative prostate biopsy","GSM3063716","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 61","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063716/suppl/GSM3063716_SH78719_Cell2_20171114_1625_1Color_IntegratedResult.txt.gz","2565","61","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063717","PR1269 Negative prostate biopsy","GSM3063717","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 62","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063717/suppl/GSM3063717_SH78719_Cell3_20171114_1626_1Color_IntegratedResult.txt.gz","2565","62","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063718","PR1270 Negative prostate biopsy","GSM3063718","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063718/suppl/GSM3063718_SH78719_Cell4_20171114_1627_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063719","PR1271 Negative prostate biopsy","GSM3063719","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 55","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063719/suppl/GSM3063719_SH78720_Cell1_20171114_1628_1Color_IntegratedResult.txt.gz","2565","55","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063720","PR1272 Negative prostate biopsy","GSM3063720","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 60","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063720/suppl/GSM3063720_SH78720_Cell2_20171114_1629_1Color_IntegratedResult.txt.gz","2565","60","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063721","PR1273 Negative prostate biopsy","GSM3063721","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 66","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063721/suppl/GSM3063721_SH78720_Cell3_20171114_1630_1Color_IntegratedResult.txt.gz","2565","66","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063722","PR1274 Negative prostate biopsy","GSM3063722","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 63","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063722/suppl/GSM3063722_SH78720_Cell4_20171114_1631_1Color_IntegratedResult.txt.gz","2565","63","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063723","PR1275 Negative prostate biopsy","GSM3063723","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 71","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063723/suppl/GSM3063723_SH78721_Cell1_20171114_1632_1Color_IntegratedResult.txt.gz","2565","71","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063724","PR1276 Negative prostate biopsy","GSM3063724","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 71","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063724/suppl/GSM3063724_SH78721_Cell2_20171114_1633_1Color_IntegratedResult.txt.gz","2565","71","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063725","PR1277 Negative prostate biopsy","GSM3063725","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 47","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063725/suppl/GSM3063725_SH78721_Cell3_20171114_1634_1Color_IntegratedResult.txt.gz","2565","47","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063726","PR1278 Negative prostate biopsy","GSM3063726","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 65","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063726/suppl/GSM3063726_SH78721_Cell4_20171114_1635_1Color_IntegratedResult.txt.gz","2565","65","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063727","PR1279 Negative prostate biopsy","GSM3063727","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 71","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063727/suppl/GSM3063727_SH78724_Cell1_20171114_1636_1Color_IntegratedResult.txt.gz","2565","71","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063728","PR1280 Negative prostate biopsy","GSM3063728","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 71","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063728/suppl/GSM3063728_SH78724_Cell2_20171114_1637_1Color_IntegratedResult.txt.gz","2565","71","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063729","PR1281 Negative prostate biopsy","GSM3063729","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 56","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063729/suppl/GSM3063729_SH78724_Cell3_20171114_1638_1Color_IntegratedResult.txt.gz","2565","56","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063730","PR1282 Negative prostate biopsy","GSM3063730","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 69","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063730/suppl/GSM3063730_SH78724_Cell4_20171114_1639_1Color_IntegratedResult.txt.gz","2565","69","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063731","PR1283 Negative prostate biopsy","GSM3063731","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 68","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063731/suppl/GSM3063731_SH78726_Cell1_20171114_1640_1Color_IntegratedResult.txt.gz","2565","68","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063732","PR1284 Negative prostate biopsy","GSM3063732","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 59","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063732/suppl/GSM3063732_SH78726_Cell2_20171114_1641_1Color_IntegratedResult.txt.gz","2565","59","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063733","PR1285 Negative prostate biopsy","GSM3063733","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Negative prostate biopsy","Sex: Male","age: 54","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063733/suppl/GSM3063733_SH78726_Cell3_20171114_1642_1Color_IntegratedResult.txt.gz","2565","54","NA","NA","NA","Negative prostate biopsy","Male"
"GSM3063734","CHC895 non-Cancer","GSM3063734","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 70","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063734/suppl/GSM3063734_SH6XQ19_Cell1_20170120_1849_1Color_IntegratedResult.txt.gz","2565","70","NA","NA","NA","non-Cancer","Male"
"GSM3063735","M10121402 non-Cancer","GSM3063735","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 48","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063735/suppl/GSM3063735_SH64L53_Cell2_20161101_2022_1Color_IntegratedResult.txt.gz","2565","48","NA","NA","NA","non-Cancer","Male"
"GSM3063736","M11031802 non-Cancer","GSM3063736","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 67","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063736/suppl/GSM3063736_SH66E30_Cell4_20160916_1932_1Color_IntegratedResult.txt.gz","2565","67","NA","NA","NA","non-Cancer","Male"
"GSM3063737","M11051803 non-Cancer","GSM3063737","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 81","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063737/suppl/GSM3063737_SH64L29_Cell1_20161101_1251_1Color_IntegratedResult.txt.gz","2565","81","NA","NA","NA","non-Cancer","Male"
"GSM3063738","M11053103 non-Cancer","GSM3063738","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063738/suppl/GSM3063738_SH64733_Cell1_20160921_1526_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","non-Cancer","Male"
"GSM3063739","M12012302 non-Cancer","GSM3063739","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 92","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063739/suppl/GSM3063739_SH64601_Cell1_20160913_2007_1Color_IntegratedResult.txt.gz","2565","92","NA","NA","NA","non-Cancer","Male"
"GSM3063740","NB12022205 non-Cancer","GSM3063740","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 77","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063740/suppl/GSM3063740_SH66N28_Cell2_20161125_1604_1Color_IntegratedResult.txt.gz","2565","77","NA","NA","NA","non-Cancer","Male"
"GSM3063741","NB12040304 non-Cancer","GSM3063741","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 87","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063741/suppl/GSM3063741_SH66N50_Cell2_20161129_1549_1Color_IntegratedResult.txt.gz","2565","87","NA","NA","NA","non-Cancer","Male"
"GSM3063742","NB12072701 non-Cancer","GSM3063742","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 75","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063742/suppl/GSM3063742_SH66P44_Cell1_20161201_1811_1Color_IntegratedResult.txt.gz","2565","75","NA","NA","NA","non-Cancer","Male"
"GSM3063743","NB12081301 non-Cancer","GSM3063743","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 78","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063743/suppl/GSM3063743_SH66P55_Cell2_20161201_1844_1Color_IntegratedResult.txt.gz","2565","78","NA","NA","NA","non-Cancer","Male"
"GSM3063744","NB12091403 non-Cancer","GSM3063744","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 82","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063744/suppl/GSM3063744_SH66T07_Cell3_20161202_1548_1Color_IntegratedResult.txt.gz","2565","82","NA","NA","NA","non-Cancer","Male"
"GSM3063745","NB12111604 non-Cancer","GSM3063745","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 75","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063745/suppl/GSM3063745_SH66X07_Cell3_20161207_1913_1Color_IntegratedResult.txt.gz","2565","75","NA","NA","NA","non-Cancer","Male"
"GSM3063746","NB12112003 non-Cancer","GSM3063746","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 93","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063746/suppl/GSM3063746_SH66X11_Cell2_20161207_1924_1Color_IntegratedResult.txt.gz","2565","93","NA","NA","NA","non-Cancer","Male"
"GSM3063747","NB13010802 non-Cancer","GSM3063747","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 80","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063747/suppl/GSM3063747_SH66X31_Cell3_20161208_1826_1Color_IntegratedResult.txt.gz","2565","80","NA","NA","NA","non-Cancer","Male"
"GSM3063748","NB13070807 non-Cancer","GSM3063748","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 77","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063748/suppl/GSM3063748_SH68952_Cell1_20161216_1617_1Color_IntegratedResult.txt.gz","2565","77","NA","NA","NA","non-Cancer","Male"
"GSM3063749","NB13082605 non-Cancer","GSM3063749","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 79","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063749/suppl/GSM3063749_SH68Z24_Cell1_20170105_1608_1Color_IntegratedResult.txt.gz","2565","79","NA","NA","NA","non-Cancer","Male"
"GSM3063750","NB13112003 non-Cancer","GSM3063750","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 76","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063750/suppl/GSM3063750_SH69509_Cell3_20170111_1533_1Color_IntegratedResult.txt.gz","2565","76","NA","NA","NA","non-Cancer","Male"
"GSM3063751","NB13120904 non-Cancer","GSM3063751","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 77","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063751/suppl/GSM3063751_SH69522_Cell4_20170111_1618_1Color_IntegratedResult.txt.gz","2565","77","NA","NA","NA","non-Cancer","Male"
"GSM3063752","NB14020503 non-Cancer","GSM3063752","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 49","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063752/suppl/GSM3063752_SH69556_Cell3_20170112_1903_1Color_IntegratedResult.txt.gz","2565","49","NA","NA","NA","non-Cancer","Male"
"GSM3063753","NB14050201 non-Cancer","GSM3063753","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 81","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063753/suppl/GSM3063753_SH69807_Cell4_20170118_1814_1Color_IntegratedResult.txt.gz","2565","81","NA","NA","NA","non-Cancer","Male"
"GSM3063754","NB14050703 non-Cancer","GSM3063754","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 79","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063754/suppl/GSM3063754_SH69813_Cell1_20170118_1827_1Color_IntegratedResult.txt.gz","2565","79","NA","NA","NA","non-Cancer","Male"
"GSM3063755","NB14051207 non-Cancer","GSM3063755","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 74","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063755/suppl/GSM3063755_SH69818_Cell4_20170118_1842_1Color_IntegratedResult.txt.gz","2565","74","NA","NA","NA","non-Cancer","Male"
"GSM3063756","NB14051208 non-Cancer","GSM3063756","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 74","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063756/suppl/GSM3063756_SH69819_Cell1_20170118_1843_1Color_IntegratedResult.txt.gz","2565","74","NA","NA","NA","non-Cancer","Male"
"GSM3063757","XB0284 non-Cancer","GSM3063757","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 47","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063757/suppl/GSM3063757_SH56N45_Cell1_20150903_2202_1Color_IntegratedResult.txt.gz","2565","47","NA","NA","NA","non-Cancer","Male"
"GSM3063758","XB0347 non-Cancer","GSM3063758","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 50","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063758/suppl/GSM3063758_SH53Z49_Cell4_20150604_1334_1Color_IntegratedResult.txt.gz","2565","50","NA","NA","NA","non-Cancer","Male"
"GSM3063759","XB0403 non-Cancer","GSM3063759","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 72","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063759/suppl/GSM3063759_SH53S02_Cell1_20150603_1520_1Color_IntegratedResult.txt.gz","2565","72","NA","NA","NA","non-Cancer","Male"
"GSM3063760","XB0414 non-Cancer","GSM3063760","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 44","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063760/suppl/GSM3063760_SH55B19_Cell4_20150707_1600_1Color_IntegratedResult.txt.gz","2565","44","NA","NA","NA","non-Cancer","Male"
"GSM3063761","XB0453 non-Cancer","GSM3063761","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 52","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063761/suppl/GSM3063761_SH53S29_Cell2_20150603_1609_1Color_IntegratedResult.txt.gz","2565","52","NA","NA","NA","non-Cancer","Male"
"GSM3063762","XB0574 non-Cancer","GSM3063762","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 44","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063762/suppl/GSM3063762_SH54E07_Cell1_20150702_1615_1Color_IntegratedResult.txt.gz","2565","44","NA","NA","NA","non-Cancer","Male"
"GSM3063763","XB0620 non-Cancer","GSM3063763","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 40","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063763/suppl/GSM3063763_SH54E22_Cell3_20150707_1327_1Color_IntegratedResult.txt.gz","2565","40","NA","NA","NA","non-Cancer","Male"
"GSM3063764","XB0629 non-Cancer","GSM3063764","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 49","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063764/suppl/GSM3063764_SH54E24_Cell4_20150707_1336_1Color_IntegratedResult.txt.gz","2565","49","NA","NA","NA","non-Cancer","Male"
"GSM3063765","XB0637 non-Cancer","GSM3063765","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 42","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063765/suppl/GSM3063765_SH54G07_Cell4_20150707_1344_1Color_IntegratedResult.txt.gz","2565","42","NA","NA","NA","non-Cancer","Male"
"GSM3063766","XB0653 non-Cancer","GSM3063766","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 37","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063766/suppl/GSM3063766_SH55B08_Cell4_20150707_1400_1Color_IntegratedResult.txt.gz","2565","37","NA","NA","NA","non-Cancer","Male"
"GSM3063767","XB0656 non-Cancer","GSM3063767","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 54","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063767/suppl/GSM3063767_SH55B27_Cell3_20150714_1535_1Color_IntegratedResult.txt.gz","2565","54","NA","NA","NA","non-Cancer","Male"
"GSM3063768","XB0666 non-Cancer","GSM3063768","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 47","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063768/suppl/GSM3063768_SH55B33_Cell1_20150714_1545_1Color_IntegratedResult.txt.gz","2565","47","NA","NA","NA","non-Cancer","Male"
"GSM3063769","XB0773 non-Cancer","GSM3063769","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 38","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063769/suppl/GSM3063769_SH55C60_Cell4_20150717_1649_1Color_IntegratedResult.txt.gz","2565","38","NA","NA","NA","non-Cancer","Male"
"GSM3063770","XB0832 non-Cancer","GSM3063770","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 42","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063770/suppl/GSM3063770_SH55M68_Cell3_20150723_1255_1Color_IntegratedResult.txt.gz","2565","42","NA","NA","NA","non-Cancer","Male"
"GSM3063771","XB0833 non-Cancer","GSM3063771","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 49","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063771/suppl/GSM3063771_SH55M68_Cell4_20150723_1256_1Color_IntegratedResult.txt.gz","2565","49","NA","NA","NA","non-Cancer","Male"
"GSM3063772","XB0923 non-Cancer","GSM3063772","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 53","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063772/suppl/GSM3063772_SH55M40_Cell2_20150728_1317_1Color_IntegratedResult.txt.gz","2565","53","NA","NA","NA","non-Cancer","Male"
"GSM3063773","XB0925 non-Cancer","GSM3063773","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 37","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063773/suppl/GSM3063773_SH55M40_Cell4_20150728_1319_1Color_IntegratedResult.txt.gz","2565","37","NA","NA","NA","non-Cancer","Male"
"GSM3063774","XB0969 non-Cancer","GSM3063774","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: non-Cancer","Sex: Male","age: 52","ctstage: NA","cnstage: NA","cmstage: NA","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063774/suppl/GSM3063774_SH55M65_Cell4_20150731_1505_1Color_IntegratedResult.txt.gz","2565","52","NA","NA","NA","non-Cancer","Male"
"GSM3063775","PC0026 Pancreatic Cancer","GSM3063775","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063775/suppl/GSM3063775_SH51Q09_Cell4_20150610_1618_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063776","PC0059 Pancreatic Cancer","GSM3063776","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063776/suppl/GSM3063776_SH51Q55_Cell1_20150616_1513_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063777","PC0076 Pancreatic Cancer","GSM3063777","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 79","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063777/suppl/GSM3063777_SH51Q66_Cell2_20150616_1530_1Color_IntegratedResult.txt.gz","2565","79","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063778","PC0085 Pancreatic Cancer","GSM3063778","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063778/suppl/GSM3063778_SH51T03_Cell3_20150616_1539_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063779","PC0088 Pancreatic Cancer","GSM3063779","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 43","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063779/suppl/GSM3063779_SH51T05_Cell2_20150616_1542_1Color_IntegratedResult.txt.gz","2565","43","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063780","PC0112 Pancreatic Cancer","GSM3063780","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 59","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063780/suppl/GSM3063780_SH51T15_Cell2_20150616_1446_1Color_IntegratedResult.txt.gz","2565","59","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063781","PC0115 Pancreatic Cancer","GSM3063781","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063781/suppl/GSM3063781_SH51T17_Cell1_20150616_1449_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063782","PC0130 Pancreatic Cancer","GSM3063782","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063782/suppl/GSM3063782_SH51T23_Cell4_20150616_1504_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063783","PC0133 Pancreatic Cancer","GSM3063783","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063783/suppl/GSM3063783_SH51T25_Cell3_20150616_1507_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063784","PC0164 Pancreatic Cancer","GSM3063784","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 44","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063784/suppl/GSM3063784_SH51T37_Cell2_20150624_1526_1Color_IntegratedResult.txt.gz","2565","44","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063785","PC0167 Pancreatic Cancer","GSM3063785","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063785/suppl/GSM3063785_SH51T38_Cell1_20150624_1529_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063786","PC0196 Pancreatic Cancer","GSM3063786","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063786/suppl/GSM3063786_SH51T53_Cell2_20150624_1558_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063787","PC0223 Pancreatic Cancer","GSM3063787","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 81","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063787/suppl/GSM3063787_SH51T65_Cell1_20150626_1517_1Color_IntegratedResult.txt.gz","2565","81","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063788","PC0225 Pancreatic Cancer","GSM3063788","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063788/suppl/GSM3063788_SH54N13_Cell3_20150717_1414_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063789","PC0235 Pancreatic Cancer","GSM3063789","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 44","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063789/suppl/GSM3063789_SH51W02_Cell1_20150626_1529_1Color_IntegratedResult.txt.gz","2565","44","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063790","PC0284 Pancreatic Cancer","GSM3063790","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063790/suppl/GSM3063790_SH51W23_Cell2_20150626_1618_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063791","PC0291 Pancreatic Cancer","GSM3063791","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063791/suppl/GSM3063791_SH51W26_Cell1_20150626_1642_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063792","PC0302 Pancreatic Cancer","GSM3063792","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 52","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063792/suppl/GSM3063792_SH51W31_Cell4_20150630_1709_1Color_IntegratedResult.txt.gz","2565","52","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063793","PC0324 Pancreatic Cancer","GSM3063793","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063793/suppl/GSM3063793_SH54G32_Cell2_20150630_1547_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063794","PC0333 Pancreatic Cancer","GSM3063794","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063794/suppl/GSM3063794_SH54G34_Cell3_20150630_1556_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063795","PC0344 Pancreatic Cancer","GSM3063795","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063795/suppl/GSM3063795_SH54G38_Cell2_20150630_1607_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063796","PC0350 Pancreatic Cancer","GSM3063796","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063796/suppl/GSM3063796_SH54G39_Cell4_20150630_1613_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063797","PC0352 Pancreatic Cancer","GSM3063797","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 55","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063797/suppl/GSM3063797_SH54G40_Cell2_20150630_1615_1Color_IntegratedResult.txt.gz","2565","55","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063798","PC0387 Pancreatic Cancer","GSM3063798","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 49","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063798/suppl/GSM3063798_SH54G52_Cell1_20150702_1505_1Color_IntegratedResult.txt.gz","2565","49","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063799","PC0397 Pancreatic Cancer","GSM3063799","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063799/suppl/GSM3063799_SH54G55_Cell3_20150702_1515_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063800","PC0403 Pancreatic Cancer","GSM3063800","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 83","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063800/suppl/GSM3063800_SH54G59_Cell1_20150702_1521_1Color_IntegratedResult.txt.gz","2565","83","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063801","PC0408 Pancreatic Cancer","GSM3063801","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 60","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063801/suppl/GSM3063801_SH54G60_Cell2_20150702_1526_1Color_IntegratedResult.txt.gz","2565","60","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063802","PC0409 Pancreatic Cancer","GSM3063802","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 53","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063802/suppl/GSM3063802_SH54G60_Cell3_20150702_1527_1Color_IntegratedResult.txt.gz","2565","53","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063803","PC0418 Pancreatic Cancer","GSM3063803","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063803/suppl/GSM3063803_SH54N16_Cell3_20150717_1426_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063804","PC0447 Pancreatic Cancer","GSM3063804","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 52","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063804/suppl/GSM3063804_SH54L06_Cell1_20150702_1605_1Color_IntegratedResult.txt.gz","2565","52","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063805","PC0456 Pancreatic Cancer","GSM3063805","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 70","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063805/suppl/GSM3063805_SH54L13_Cell2_20150702_1614_1Color_IntegratedResult.txt.gz","2565","70","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063806","PC0460 Pancreatic Cancer","GSM3063806","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063806/suppl/GSM3063806_SH54L14_Cell2_20150703_1519_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063807","PC0493 Pancreatic Cancer","GSM3063807","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063807/suppl/GSM3063807_SH54L23_Cell3_20150703_1552_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063808","PC0512 Pancreatic Cancer","GSM3063808","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 44","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063808/suppl/GSM3063808_SH54L28_Cell2_20150703_1611_1Color_IntegratedResult.txt.gz","2565","44","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063809","PC0524 Pancreatic Cancer","GSM3063809","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 54","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063809/suppl/GSM3063809_SH54L31_Cell2_20150703_1623_1Color_IntegratedResult.txt.gz","2565","54","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063810","PC0543 Pancreatic Cancer","GSM3063810","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 65","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063810/suppl/GSM3063810_SH54L45_Cell1_20150707_1305_1Color_IntegratedResult.txt.gz","2565","65","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063811","PC0544 Pancreatic Cancer","GSM3063811","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 59","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063811/suppl/GSM3063811_SH54L45_Cell2_20150707_1306_1Color_IntegratedResult.txt.gz","2565","59","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063812","PC0588 Pancreatic Cancer","GSM3063812","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 52","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063812/suppl/GSM3063812_SH54N21_Cell1_20150717_1440_1Color_IntegratedResult.txt.gz","2565","52","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063813","PC0591 Pancreatic Cancer","GSM3063813","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063813/suppl/GSM3063813_SH54N21_Cell3_20150717_1442_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063814","PC0618 Pancreatic Cancer","GSM3063814","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063814/suppl/GSM3063814_SH54N22_Cell4_20150717_1447_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063815","PC0634 Pancreatic Cancer","GSM3063815","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063815/suppl/GSM3063815_SH54N23_Cell1_20150717_1448_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063816","PC0647 Pancreatic Cancer","GSM3063816","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063816/suppl/GSM3063816_SH56942_Cell2_20150820_1306_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063817","PC0669 Pancreatic Cancer","GSM3063817","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 68","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063817/suppl/GSM3063817_SH56844_Cell4_20150806_1645_1Color_IntegratedResult.txt.gz","2565","68","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063818","PC0670 Pancreatic Cancer","GSM3063818","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063818/suppl/GSM3063818_SH56845_Cell1_20150806_1646_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063819","PC0706 Pancreatic Cancer","GSM3063819","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063819/suppl/GSM3063819_SH56855_Cell1_20150811_1538_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063820","PC0714 Pancreatic Cancer","GSM3063820","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 55","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063820/suppl/GSM3063820_SH56943_Cell3_20150820_1311_1Color_IntegratedResult.txt.gz","2565","55","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063821","PC0764 Pancreatic Cancer","GSM3063821","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 63","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063821/suppl/GSM3063821_SH56903_Cell3_20150812_1520_1Color_IntegratedResult.txt.gz","2565","63","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063822","PC0801 Pancreatic Cancer","GSM3063822","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063822/suppl/GSM3063822_SH56914_Cell4_20150812_1557_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063823","PC0806 Pancreatic Cancer","GSM3063823","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 64","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063823/suppl/GSM3063823_SH56916_Cell1_20150812_1602_1Color_IntegratedResult.txt.gz","2565","64","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063824","PC0848 Pancreatic Cancer","GSM3063824","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Pancreatic Cancer","Sex: Male","age: 79","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063824/suppl/GSM3063824_SH56936_Cell3_20150813_1213_1Color_IntegratedResult.txt.gz","2565","79","uncertain","uncertain","uncertain","Pancreatic Cancer","Male"
"GSM3063825","PR0001 Prostate Cancer","GSM3063825","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 85","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063825/suppl/GSM3063825_SH63X33_Cell2_20160816_1559_1Color_IntegratedResult.txt.gz","2565","85","M0","N0","T3b","Prostate Cancer","Male"
"GSM3063826","PR0002 Prostate Cancer","GSM3063826","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063826/suppl/GSM3063826_SH63X33_Cell3_20160816_1600_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063827","PR0003 Prostate Cancer","GSM3063827","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063827/suppl/GSM3063827_SH63X33_Cell4_20160816_1601_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063828","PR0004 Prostate Cancer","GSM3063828","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063828/suppl/GSM3063828_SH63X34_Cell1_20160816_1602_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063829","PR0005 Prostate Cancer","GSM3063829","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063829/suppl/GSM3063829_SH63X34_Cell2_20160816_1603_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063830","PR0006 Prostate Cancer","GSM3063830","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 49","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063830/suppl/GSM3063830_SH63X34_Cell3_20160816_1604_1Color_IntegratedResult.txt.gz","2565","49","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063831","PR0007 Prostate Cancer","GSM3063831","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063831/suppl/GSM3063831_SH63X34_Cell4_20160816_1605_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063832","PR0008 Prostate Cancer","GSM3063832","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063832/suppl/GSM3063832_SH63Y42_Cell1_20160816_1606_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063833","PR0009 Prostate Cancer","GSM3063833","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063833/suppl/GSM3063833_SH63Y42_Cell2_20160816_1607_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063834","PR0013 Prostate Cancer","GSM3063834","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063834/suppl/GSM3063834_SH63Z37_Cell2_20160816_1611_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063835","PR0015 Prostate Cancer","GSM3063835","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063835/suppl/GSM3063835_SH63Z37_Cell4_20160816_1613_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063836","PR0016 Prostate Cancer","GSM3063836","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063836/suppl/GSM3063836_SH64716_Cell1_20160818_1538_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063837","PR0017 Prostate Cancer","GSM3063837","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063837/suppl/GSM3063837_SH64716_Cell2_20160818_1539_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063838","PR0018 Prostate Cancer","GSM3063838","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063838/suppl/GSM3063838_SH64716_Cell3_20160818_1540_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063839","PR0019 Prostate Cancer","GSM3063839","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063839/suppl/GSM3063839_SH64716_Cell4_20160818_1541_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063840","PR0020 Prostate Cancer","GSM3063840","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063840/suppl/GSM3063840_SH64725_Cell1_20160818_1542_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T3b","Prostate Cancer","Male"
"GSM3063841","PR0021 Prostate Cancer","GSM3063841","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T3b","cnstage: N1","cmstage: M1c","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063841/suppl/GSM3063841_SH64725_Cell2_20160818_1543_1Color_IntegratedResult.txt.gz","2565","78","M1c","N1","T3b","Prostate Cancer","Male"
"GSM3063842","PR0022 Prostate Cancer","GSM3063842","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 83","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063842/suppl/GSM3063842_SH64725_Cell3_20160818_1544_1Color_IntegratedResult.txt.gz","2565","83","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063843","PR0023 Prostate Cancer","GSM3063843","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063843/suppl/GSM3063843_SH64725_Cell4_20160818_1545_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063844","PR0024 Prostate Cancer","GSM3063844","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063844/suppl/GSM3063844_SH64742_Cell1_20160818_1546_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063845","PR0025 Prostate Cancer","GSM3063845","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063845/suppl/GSM3063845_SH64742_Cell2_20160818_1547_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063846","PR0026 Prostate Cancer","GSM3063846","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063846/suppl/GSM3063846_SH64742_Cell3_20160818_1548_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063847","PR0027 Prostate Cancer","GSM3063847","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063847/suppl/GSM3063847_SH64742_Cell4_20160818_1549_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063848","PR0028 Prostate Cancer","GSM3063848","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063848/suppl/GSM3063848_SH64748_Cell1_20160818_1550_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063849","PR0030 Prostate Cancer","GSM3063849","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063849/suppl/GSM3063849_SH64748_Cell3_20160818_1552_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063850","PR0031 Prostate Cancer","GSM3063850","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063850/suppl/GSM3063850_SH64748_Cell4_20160818_1553_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063851","PR0032 Prostate Cancer","GSM3063851","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063851/suppl/GSM3063851_SH64B11_Cell1_20160818_1554_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063852","PR0033 Prostate Cancer","GSM3063852","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063852/suppl/GSM3063852_SH64B11_Cell2_20160818_1555_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063853","PR0034 Prostate Cancer","GSM3063853","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T1c","cnstage: N0","cmstage: M1c","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063853/suppl/GSM3063853_SH64B11_Cell3_20160818_1556_1Color_IntegratedResult.txt.gz","2565","60","M1c","N0","T1c","Prostate Cancer","Male"
"GSM3063854","PR0035 Prostate Cancer","GSM3063854","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 83","ctstage: T4","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063854/suppl/GSM3063854_SH64B11_Cell4_20160818_1752_1Color_IntegratedResult.txt.gz","2565","83","M0","N0","T4","Prostate Cancer","Male"
"GSM3063855","PR0036 Prostate Cancer","GSM3063855","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T3a","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063855/suppl/GSM3063855_SH64B33_Cell1_20160818_1558_1Color_IntegratedResult.txt.gz","2565","67","M1b","N0","T3a","Prostate Cancer","Male"
"GSM3063856","PR0037 Prostate Cancer","GSM3063856","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 79","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063856/suppl/GSM3063856_SH64B33_Cell2_20160818_1559_1Color_IntegratedResult.txt.gz","2565","79","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063857","PR0038 Prostate Cancer","GSM3063857","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 81","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063857/suppl/GSM3063857_SH64B33_Cell3_20160818_1600_1Color_IntegratedResult.txt.gz","2565","81","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063858","PR0039 Prostate Cancer","GSM3063858","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063858/suppl/GSM3063858_SH64B33_Cell4_20160818_1601_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063859","PR0040 Prostate Cancer","GSM3063859","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063859/suppl/GSM3063859_SH64C16_Cell1_20160818_1602_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063860","PR0041 Prostate Cancer","GSM3063860","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063860/suppl/GSM3063860_SH64C16_Cell2_20160818_1603_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063861","PR0042 Prostate Cancer","GSM3063861","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 83","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063861/suppl/GSM3063861_SH64C16_Cell3_20160818_1604_1Color_IntegratedResult.txt.gz","2565","83","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063862","PR0043 Prostate Cancer","GSM3063862","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T3a","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063862/suppl/GSM3063862_SH64C16_Cell4_20160818_1605_1Color_IntegratedResult.txt.gz","2565","77","M0","N1","T3a","Prostate Cancer","Male"
"GSM3063863","PR0046 Prostate Cancer","GSM3063863","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063863/suppl/GSM3063863_SH64C19_Cell3_20160818_1608_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063864","PR0047 Prostate Cancer","GSM3063864","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063864/suppl/GSM3063864_SH64C19_Cell4_20160818_1609_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063865","PR0048 Prostate Cancer","GSM3063865","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063865/suppl/GSM3063865_SH64C20_Cell1_20160818_1610_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063866","PR0049 Prostate Cancer","GSM3063866","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 80","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063866/suppl/GSM3063866_SH64C20_Cell2_20160818_1611_1Color_IntegratedResult.txt.gz","2565","80","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063867","PR0050 Prostate Cancer","GSM3063867","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063867/suppl/GSM3063867_SH64C20_Cell3_20160818_1753_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063868","PR0051 Prostate Cancer","GSM3063868","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063868/suppl/GSM3063868_SH64C20_Cell4_20160818_1613_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063869","PR0052 Prostate Cancer","GSM3063869","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063869/suppl/GSM3063869_SH64L09_Cell1_20160818_1614_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063870","PR0053 Prostate Cancer","GSM3063870","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063870/suppl/GSM3063870_SH64L09_Cell2_20160818_1615_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063871","PR0054 Prostate Cancer","GSM3063871","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063871/suppl/GSM3063871_SH64L09_Cell3_20160818_1616_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063872","PR0055 Prostate Cancer","GSM3063872","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 85","ctstage: T3b","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063872/suppl/GSM3063872_SH64L09_Cell4_20160818_1617_1Color_IntegratedResult.txt.gz","2565","85","M1b","N0","T3b","Prostate Cancer","Male"
"GSM3063873","PR0056 Prostate Cancer","GSM3063873","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063873/suppl/GSM3063873_SH64R19_Cell1_20160818_1618_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063874","PR0057 Prostate Cancer","GSM3063874","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T1c","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063874/suppl/GSM3063874_SH64R19_Cell2_20160818_1619_1Color_IntegratedResult.txt.gz","2565","74","M1b","N0","T1c","Prostate Cancer","Male"
"GSM3063875","PR0058 Prostate Cancer","GSM3063875","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 50","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063875/suppl/GSM3063875_SH64R19_Cell3_20160818_1620_1Color_IntegratedResult.txt.gz","2565","50","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063876","PR0059 Prostate Cancer","GSM3063876","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063876/suppl/GSM3063876_SH64R19_Cell4_20160818_1621_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063877","PR0060 Prostate Cancer","GSM3063877","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063877/suppl/GSM3063877_SH64R52_Cell1_20160818_1622_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063878","PR0061 Prostate Cancer","GSM3063878","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 81","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063878/suppl/GSM3063878_SH64R52_Cell2_20160818_1623_1Color_IntegratedResult.txt.gz","2565","81","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063879","PR0062 Prostate Cancer","GSM3063879","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063879/suppl/GSM3063879_SH64R52_Cell3_20160818_1624_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063880","PR0063 Prostate Cancer","GSM3063880","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063880/suppl/GSM3063880_SH64R52_Cell4_20160818_1625_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063881","PR0064 Prostate Cancer","GSM3063881","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063881/suppl/GSM3063881_SH64R53_Cell1_20160818_1626_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T3b","Prostate Cancer","Male"
"GSM3063882","PR0065 Prostate Cancer","GSM3063882","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063882/suppl/GSM3063882_SH64R53_Cell2_20160818_1627_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063883","PR0066 Prostate Cancer","GSM3063883","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063883/suppl/GSM3063883_SH64R53_Cell3_20160818_1628_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063884","PR0067 Prostate Cancer","GSM3063884","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063884/suppl/GSM3063884_SH64R53_Cell4_20160818_1629_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063885","PR0068 Prostate Cancer","GSM3063885","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063885/suppl/GSM3063885_SH64R55_Cell1_20160818_1630_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063886","PR0069 Prostate Cancer","GSM3063886","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063886/suppl/GSM3063886_SH64R55_Cell2_20160818_1631_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063887","PR0070 Prostate Cancer","GSM3063887","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063887/suppl/GSM3063887_SH64R55_Cell3_20160818_1632_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063888","PR0071 Prostate Cancer","GSM3063888","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063888/suppl/GSM3063888_SH64R55_Cell4_20160818_1633_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063889","PR0072 Prostate Cancer","GSM3063889","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 58","ctstage: T3b","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063889/suppl/GSM3063889_SH64R56_Cell1_20160818_1634_1Color_IntegratedResult.txt.gz","2565","58","M1b","N1","T3b","Prostate Cancer","Male"
"GSM3063890","PR0073 Prostate Cancer","GSM3063890","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063890/suppl/GSM3063890_SH64R56_Cell2_20160818_1635_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063891","PR0074 Prostate Cancer","GSM3063891","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063891/suppl/GSM3063891_SH64R56_Cell3_20160818_1636_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063892","PR0075 Prostate Cancer","GSM3063892","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 55","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063892/suppl/GSM3063892_SH64R56_Cell4_20160818_1637_1Color_IntegratedResult.txt.gz","2565","55","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063893","PR0076 Prostate Cancer","GSM3063893","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T4","cnstage: N1","cmstage: M1a","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063893/suppl/GSM3063893_SH64R57_Cell1_20160818_1638_1Color_IntegratedResult.txt.gz","2565","74","M1a","N1","T4","Prostate Cancer","Male"
"GSM3063894","PR0077 Prostate Cancer","GSM3063894","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 85","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063894/suppl/GSM3063894_SH64R57_Cell2_20160818_1639_1Color_IntegratedResult.txt.gz","2565","85","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063895","PR0078 Prostate Cancer","GSM3063895","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063895/suppl/GSM3063895_SH64R57_Cell3_20160818_1640_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063896","PR0079 Prostate Cancer","GSM3063896","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063896/suppl/GSM3063896_SH64R57_Cell4_20160818_1641_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063897","PR0080 Prostate Cancer","GSM3063897","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063897/suppl/GSM3063897_SH64R58_Cell1_20160818_1642_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063898","PR0081 Prostate Cancer","GSM3063898","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T3b","cnstage: N1","cmstage: M1c","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063898/suppl/GSM3063898_SH64R58_Cell2_20160818_1643_1Color_IntegratedResult.txt.gz","2565","64","M1c","N1","T3b","Prostate Cancer","Male"
"GSM3063899","PR0083 Prostate Cancer","GSM3063899","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T1c","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063899/suppl/GSM3063899_SH66620_Cell1_20160915_1447_1Color_IntegratedResult.txt.gz","2565","74","M1b","N0","T1c","Prostate Cancer","Male"
"GSM3063900","PR0084 Prostate Cancer","GSM3063900","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063900/suppl/GSM3063900_SH66620_Cell2_20160915_1448_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063901","PR0085 Prostate Cancer","GSM3063901","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063901/suppl/GSM3063901_SH66620_Cell3_20160915_1449_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063902","PR0086 Prostate Cancer","GSM3063902","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063902/suppl/GSM3063902_SH64T01_Cell1_20160824_1505_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063903","PR0087 Prostate Cancer","GSM3063903","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063903/suppl/GSM3063903_SH64T01_Cell2_20160824_1506_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063904","PR0088 Prostate Cancer","GSM3063904","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063904/suppl/GSM3063904_SH66620_Cell4_20160915_1450_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063905","PR0089 Prostate Cancer","GSM3063905","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063905/suppl/GSM3063905_SH66621_Cell1_20160915_1451_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063906","PR0090 Prostate Cancer","GSM3063906","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 81","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063906/suppl/GSM3063906_SH66621_Cell2_20160915_1452_1Color_IntegratedResult.txt.gz","2565","81","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063907","PR0091 Prostate Cancer","GSM3063907","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 86","ctstage: T3b","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063907/suppl/GSM3063907_SH66621_Cell3_20160915_1453_1Color_IntegratedResult.txt.gz","2565","86","M1b","N0","T3b","Prostate Cancer","Male"
"GSM3063908","PR0092 Prostate Cancer","GSM3063908","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063908/suppl/GSM3063908_SH66621_Cell4_20160915_1454_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T2c","Prostate Cancer","Male"
"GSM3063909","PR0094 Prostate Cancer","GSM3063909","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063909/suppl/GSM3063909_SH66624_Cell1_20160915_1455_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063910","PR0096 Prostate Cancer","GSM3063910","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 58","ctstage: T3a","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063910/suppl/GSM3063910_SH66624_Cell3_20160915_1457_1Color_IntegratedResult.txt.gz","2565","58","M1b","N1","T3a","Prostate Cancer","Male"
"GSM3063911","PR0097 Prostate Cancer","GSM3063911","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063911/suppl/GSM3063911_SH66624_Cell4_20160915_1458_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063912","PR0098 Prostate Cancer","GSM3063912","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063912/suppl/GSM3063912_SH66625_Cell1_20160915_1459_1Color_IntegratedResult.txt.gz","2565","71","M1b","N0","T1c","Prostate Cancer","Male"
"GSM3063913","PR0099 Prostate Cancer","GSM3063913","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063913/suppl/GSM3063913_SH64T06_Cell2_20160824_1518_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063914","PR0100 Prostate Cancer","GSM3063914","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063914/suppl/GSM3063914_SH66625_Cell2_20160915_1500_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2c","Prostate Cancer","Male"
"GSM3063915","PR0101 Prostate Cancer","GSM3063915","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063915/suppl/GSM3063915_SH66625_Cell3_20160915_1501_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063916","PR0102 Prostate Cancer","GSM3063916","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063916/suppl/GSM3063916_SH66625_Cell4_20160915_1502_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063917","PR0103 Prostate Cancer","GSM3063917","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063917/suppl/GSM3063917_SH66626_Cell1_20160915_1503_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063918","PR0104 Prostate Cancer","GSM3063918","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T3a","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063918/suppl/GSM3063918_SH66626_Cell2_20160915_1504_1Color_IntegratedResult.txt.gz","2565","73","M0","N1","T3a","Prostate Cancer","Male"
"GSM3063919","PR0105 Prostate Cancer","GSM3063919","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T4","cnstage: N1","cmstage: M1a","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063919/suppl/GSM3063919_SH66626_Cell3_20160915_1505_1Color_IntegratedResult.txt.gz","2565","73","M1a","N1","T4","Prostate Cancer","Male"
"GSM3063920","PR0106 Prostate Cancer","GSM3063920","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063920/suppl/GSM3063920_SH64T09_Cell1_20160824_1525_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063921","PR0107 Prostate Cancer","GSM3063921","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063921/suppl/GSM3063921_SH66626_Cell4_20160915_1506_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063922","PR0108 Prostate Cancer","GSM3063922","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063922/suppl/GSM3063922_SH66627_Cell1_20160915_1507_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063923","PR0110 Prostate Cancer","GSM3063923","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063923/suppl/GSM3063923_SH66627_Cell3_20160915_1509_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T3b","Prostate Cancer","Male"
"GSM3063924","PR0111 Prostate Cancer","GSM3063924","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2c","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063924/suppl/GSM3063924_SH66627_Cell4_20160915_1510_1Color_IntegratedResult.txt.gz","2565","62","M1b","N0","T2c","Prostate Cancer","Male"
"GSM3063925","PR0113 Prostate Cancer","GSM3063925","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063925/suppl/GSM3063925_SH66628_Cell1_20160915_1511_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063926","PR0115 Prostate Cancer","GSM3063926","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063926/suppl/GSM3063926_SH66628_Cell3_20160915_1513_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063927","PR0119 Prostate Cancer","GSM3063927","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T3a","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063927/suppl/GSM3063927_SH66629_Cell3_20160915_1517_1Color_IntegratedResult.txt.gz","2565","75","M0","N1","T3a","Prostate Cancer","Male"
"GSM3063928","PR0121 Prostate Cancer","GSM3063928","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063928/suppl/GSM3063928_SH66630_Cell1_20160915_1519_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063929","PR0122 Prostate Cancer","GSM3063929","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063929/suppl/GSM3063929_SH64T14_Cell1_20160824_1541_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063930","PR0123 Prostate Cancer","GSM3063930","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063930/suppl/GSM3063930_SH64T14_Cell2_20160824_1542_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063931","PR0124 Prostate Cancer","GSM3063931","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063931/suppl/GSM3063931_SH66630_Cell2_20160915_1520_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063932","PR0125 Prostate Cancer","GSM3063932","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063932/suppl/GSM3063932_SH64T14_Cell4_20160824_1544_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063933","PR0126 Prostate Cancer","GSM3063933","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063933/suppl/GSM3063933_SH66630_Cell3_20160915_1521_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063934","PR0127 Prostate Cancer","GSM3063934","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063934/suppl/GSM3063934_SH66630_Cell4_20160915_1522_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063935","PR0128 Prostate Cancer","GSM3063935","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063935/suppl/GSM3063935_SH66631_Cell1_20160915_1523_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063936","PR0129 Prostate Cancer","GSM3063936","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063936/suppl/GSM3063936_SH66631_Cell2_20160915_1524_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063937","PR0130 Prostate Cancer","GSM3063937","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 58","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063937/suppl/GSM3063937_SH66631_Cell3_20160915_1525_1Color_IntegratedResult.txt.gz","2565","58","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063938","PR0132 Prostate Cancer","GSM3063938","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 84","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063938/suppl/GSM3063938_SH66632_Cell1_20160915_1527_1Color_IntegratedResult.txt.gz","2565","84","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063939","PR0133 Prostate Cancer","GSM3063939","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063939/suppl/GSM3063939_SH66632_Cell2_20160915_1528_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T3b","Prostate Cancer","Male"
"GSM3063940","PR0134 Prostate Cancer","GSM3063940","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063940/suppl/GSM3063940_SH66632_Cell3_20160915_1529_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063941","PR0135 Prostate Cancer","GSM3063941","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063941/suppl/GSM3063941_SH66632_Cell4_20160915_1530_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063942","PR0136 Prostate Cancer","GSM3063942","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 88","ctstage: T2c","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063942/suppl/GSM3063942_SH66633_Cell1_20160915_1531_1Color_IntegratedResult.txt.gz","2565","88","M1b","N0","T2c","Prostate Cancer","Male"
"GSM3063943","PR0137 Prostate Cancer","GSM3063943","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063943/suppl/GSM3063943_SH66633_Cell2_20160915_1532_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063944","PR0138 Prostate Cancer","GSM3063944","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063944/suppl/GSM3063944_SH64T19_Cell1_20160824_1557_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063945","PR0140 Prostate Cancer","GSM3063945","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T3a","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063945/suppl/GSM3063945_SH66633_Cell4_20160915_1534_1Color_IntegratedResult.txt.gz","2565","63","M1b","N1","T3a","Prostate Cancer","Male"
"GSM3063946","PR0141 Prostate Cancer","GSM3063946","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063946/suppl/GSM3063946_SH66634_Cell1_20160915_1535_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063947","PR0142 Prostate Cancer","GSM3063947","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T3b","cnstage: N0","cmstage: M1a","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063947/suppl/GSM3063947_SH66634_Cell2_20160915_1536_1Color_IntegratedResult.txt.gz","2565","64","M1a","N0","T3b","Prostate Cancer","Male"
"GSM3063948","PR0143 Prostate Cancer","GSM3063948","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063948/suppl/GSM3063948_SH66634_Cell3_20160915_1537_1Color_IntegratedResult.txt.gz","2565","71","M1b","N1","T1c","Prostate Cancer","Male"
"GSM3063949","PR0144 Prostate Cancer","GSM3063949","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063949/suppl/GSM3063949_SH66634_Cell4_20160915_1538_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063950","PR0145 Prostate Cancer","GSM3063950","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063950/suppl/GSM3063950_SH66635_Cell1_20160915_1539_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063951","PR0147 Prostate Cancer","GSM3063951","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063951/suppl/GSM3063951_SH64T22_Cell2_20160824_1606_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063952","PR0148 Prostate Cancer","GSM3063952","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063952/suppl/GSM3063952_SH64T22_Cell3_20160824_1607_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063953","PR0149 Prostate Cancer","GSM3063953","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 80","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063953/suppl/GSM3063953_SH64T22_Cell4_20160824_1608_1Color_IntegratedResult.txt.gz","2565","80","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063954","PR0150 Prostate Cancer","GSM3063954","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T4","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063954/suppl/GSM3063954_SH64T25_Cell1_20160824_1609_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T4","Prostate Cancer","Male"
"GSM3063955","PR0151 Prostate Cancer","GSM3063955","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063955/suppl/GSM3063955_SH64T25_Cell2_20160824_1610_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063956","PR0152 Prostate Cancer","GSM3063956","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063956/suppl/GSM3063956_SH64T25_Cell3_20160824_1611_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063957","PR0153 Prostate Cancer","GSM3063957","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 82","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063957/suppl/GSM3063957_SH66635_Cell2_20160915_1540_1Color_IntegratedResult.txt.gz","2565","82","M0","N0","T2c","Prostate Cancer","Male"
"GSM3063958","PR0154 Prostate Cancer","GSM3063958","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 92","ctstage: T3b","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063958/suppl/GSM3063958_SH64T26_Cell1_20160824_1613_1Color_IntegratedResult.txt.gz","2565","92","M0","N1","T3b","Prostate Cancer","Male"
"GSM3063959","PR0155 Prostate Cancer","GSM3063959","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063959/suppl/GSM3063959_SH64T26_Cell2_20160824_1614_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063960","PR0156 Prostate Cancer","GSM3063960","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063960/suppl/GSM3063960_SH64T26_Cell3_20160824_1615_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063961","PR0157 Prostate Cancer","GSM3063961","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063961/suppl/GSM3063961_SH64T26_Cell4_20160824_1616_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063962","PR0158 Prostate Cancer","GSM3063962","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063962/suppl/GSM3063962_SH64T27_Cell1_20160824_1617_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063963","PR0159 Prostate Cancer","GSM3063963","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063963/suppl/GSM3063963_SH64T27_Cell2_20160824_1618_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063964","PR0160 Prostate Cancer","GSM3063964","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 82","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063964/suppl/GSM3063964_SH64T27_Cell3_20160824_1619_1Color_IntegratedResult.txt.gz","2565","82","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063965","PR0161 Prostate Cancer","GSM3063965","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 83","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063965/suppl/GSM3063965_SH64T27_Cell4_20160824_1620_1Color_IntegratedResult.txt.gz","2565","83","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063966","PR0162 Prostate Cancer","GSM3063966","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063966/suppl/GSM3063966_SH64T28_Cell1_20160825_1118_1Color_IntegratedResult.txt.gz","2565","62","M1b","N0","T1c","Prostate Cancer","Male"
"GSM3063967","PR0163 Prostate Cancer","GSM3063967","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063967/suppl/GSM3063967_SH64T28_Cell2_20160825_1119_1Color_IntegratedResult.txt.gz","2565","57","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063968","PR0164 Prostate Cancer","GSM3063968","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 81","ctstage: T2c","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063968/suppl/GSM3063968_SH64T28_Cell3_20160825_1120_1Color_IntegratedResult.txt.gz","2565","81","M1b","N0","T2c","Prostate Cancer","Male"
"GSM3063969","PR0165 Prostate Cancer","GSM3063969","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063969/suppl/GSM3063969_SH64T28_Cell4_20160825_1121_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T3b","Prostate Cancer","Male"
"GSM3063970","PR0166 Prostate Cancer","GSM3063970","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063970/suppl/GSM3063970_SH64T29_Cell1_20160825_1122_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063971","PR0167 Prostate Cancer","GSM3063971","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T3a","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063971/suppl/GSM3063971_SH64T29_Cell2_20160825_1123_1Color_IntegratedResult.txt.gz","2565","72","M1b","N0","T3a","Prostate Cancer","Male"
"GSM3063972","PR0168 Prostate Cancer","GSM3063972","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 87","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063972/suppl/GSM3063972_SH64T29_Cell3_20160825_1124_1Color_IntegratedResult.txt.gz","2565","87","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063973","PR0170 Prostate Cancer","GSM3063973","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063973/suppl/GSM3063973_SH64T30_Cell1_20160825_1126_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063974","PR0171 Prostate Cancer","GSM3063974","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063974/suppl/GSM3063974_SH64T30_Cell2_20160825_1127_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063975","PR0172 Prostate Cancer","GSM3063975","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063975/suppl/GSM3063975_SH64T30_Cell3_20160825_1128_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063976","PR0173 Prostate Cancer","GSM3063976","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 81","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063976/suppl/GSM3063976_SH64T30_Cell4_20160825_1129_1Color_IntegratedResult.txt.gz","2565","81","M0","N0","T3b","Prostate Cancer","Male"
"GSM3063977","PR0174 Prostate Cancer","GSM3063977","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T4","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063977/suppl/GSM3063977_SH64T31_Cell1_20160825_1130_1Color_IntegratedResult.txt.gz","2565","74","M1b","N1","T4","Prostate Cancer","Male"
"GSM3063978","PR0175 Prostate Cancer","GSM3063978","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063978/suppl/GSM3063978_SH64T31_Cell2_20160825_1131_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063979","PR0176 Prostate Cancer","GSM3063979","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063979/suppl/GSM3063979_SH64T31_Cell3_20160825_1132_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063980","PR0177 Prostate Cancer","GSM3063980","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063980/suppl/GSM3063980_SH64T31_Cell4_20160825_1133_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063981","PR0178 Prostate Cancer","GSM3063981","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063981/suppl/GSM3063981_SH64T32_Cell1_20160825_1134_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063982","PR0180 Prostate Cancer","GSM3063982","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063982/suppl/GSM3063982_SH64T32_Cell3_20160825_1136_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063983","PR0181 Prostate Cancer","GSM3063983","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063983/suppl/GSM3063983_SH64T32_Cell4_20160825_1137_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063984","PR0182 Prostate Cancer","GSM3063984","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063984/suppl/GSM3063984_SH64T34_Cell1_20160825_1334_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063985","PR0183 Prostate Cancer","GSM3063985","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063985/suppl/GSM3063985_SH64T34_Cell2_20160825_1335_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063986","PR0184 Prostate Cancer","GSM3063986","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063986/suppl/GSM3063986_SH64T34_Cell3_20160825_1336_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063987","PR0186 Prostate Cancer","GSM3063987","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063987/suppl/GSM3063987_SH66159_Cell2_20160907_1543_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063988","PR0187 Prostate Cancer","GSM3063988","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063988/suppl/GSM3063988_SH66159_Cell3_20160907_1544_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063989","PR0188 Prostate Cancer","GSM3063989","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 88","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063989/suppl/GSM3063989_SH66159_Cell4_20160907_1545_1Color_IntegratedResult.txt.gz","2565","88","M0","N0","T2c","Prostate Cancer","Male"
"GSM3063990","PR0189 Prostate Cancer","GSM3063990","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063990/suppl/GSM3063990_SH66160_Cell1_20160907_1546_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063991","PR0190 Prostate Cancer","GSM3063991","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 54","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063991/suppl/GSM3063991_SH66160_Cell2_20160907_1547_1Color_IntegratedResult.txt.gz","2565","54","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063992","PR0193 Prostate Cancer","GSM3063992","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063992/suppl/GSM3063992_SH66161_Cell1_20160907_1550_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063993","PR0194 Prostate Cancer","GSM3063993","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063993/suppl/GSM3063993_SH66161_Cell2_20160907_1551_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3063994","PR0195 Prostate Cancer","GSM3063994","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063994/suppl/GSM3063994_SH66161_Cell3_20160907_1552_1Color_IntegratedResult.txt.gz","2565","57","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063995","PR0196 Prostate Cancer","GSM3063995","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063995/suppl/GSM3063995_SH66809_Cell1_20161004_1233_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2b","Prostate Cancer","Male"
"GSM3063996","PR0199 Prostate Cancer","GSM3063996","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063996/suppl/GSM3063996_SH66162_Cell3_20160907_1556_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T3a","Prostate Cancer","Male"
"GSM3063997","PR0200 Prostate Cancer","GSM3063997","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T4","cnstage: N1","cmstage: M1c","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063997/suppl/GSM3063997_SH66162_Cell4_20160907_1557_1Color_IntegratedResult.txt.gz","2565","57","M1c","N1","T4","Prostate Cancer","Male"
"GSM3063998","PR0201 Prostate Cancer","GSM3063998","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 50","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063998/suppl/GSM3063998_SH66201_Cell1_20160907_1558_1Color_IntegratedResult.txt.gz","2565","50","M0","N0","T2a","Prostate Cancer","Male"
"GSM3063999","PR0202 Prostate Cancer","GSM3063999","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3063nnn/GSM3063999/suppl/GSM3063999_SH66201_Cell2_20160907_1559_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064000","PR0203 Prostate Cancer","GSM3064000","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064000/suppl/GSM3064000_SH66201_Cell3_20160907_1600_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064001","PR0205 Prostate Cancer","GSM3064001","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 81","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064001/suppl/GSM3064001_SH66202_Cell1_20160907_1602_1Color_IntegratedResult.txt.gz","2565","81","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064002","PR0206 Prostate Cancer","GSM3064002","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064002/suppl/GSM3064002_SH66202_Cell2_20160907_1603_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064003","PR0207 Prostate Cancer","GSM3064003","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064003/suppl/GSM3064003_SH66202_Cell3_20160907_1604_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064004","PR0208 Prostate Cancer","GSM3064004","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064004/suppl/GSM3064004_SH66202_Cell4_20160907_1605_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064005","PR0209 Prostate Cancer","GSM3064005","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064005/suppl/GSM3064005_SH66203_Cell1_20160907_1606_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064006","PR0210 Prostate Cancer","GSM3064006","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064006/suppl/GSM3064006_SH66203_Cell2_20160907_1607_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064007","PR0211 Prostate Cancer","GSM3064007","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T3b","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064007/suppl/GSM3064007_SH66203_Cell3_20160907_1608_1Color_IntegratedResult.txt.gz","2565","78","M1b","N0","T3b","Prostate Cancer","Male"
"GSM3064008","PR0212 Prostate Cancer","GSM3064008","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 82","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064008/suppl/GSM3064008_SH66203_Cell4_20160907_1609_1Color_IntegratedResult.txt.gz","2565","82","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064009","PR0213 Prostate Cancer","GSM3064009","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064009/suppl/GSM3064009_SH66204_Cell1_20160907_1610_1Color_IntegratedResult.txt.gz","2565","62","M1b","N0","T1c","Prostate Cancer","Male"
"GSM3064010","PR0214 Prostate Cancer","GSM3064010","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064010/suppl/GSM3064010_SH66204_Cell2_20160907_1611_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064011","PR0215 Prostate Cancer","GSM3064011","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T1c","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064011/suppl/GSM3064011_SH66204_Cell3_20160907_1612_1Color_IntegratedResult.txt.gz","2565","60","M1b","N0","T1c","Prostate Cancer","Male"
"GSM3064012","PR0216 Prostate Cancer","GSM3064012","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T3a","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064012/suppl/GSM3064012_SH66204_Cell4_20160907_1613_1Color_IntegratedResult.txt.gz","2565","70","M1b","N1","T3a","Prostate Cancer","Male"
"GSM3064013","PR0217 Prostate Cancer","GSM3064013","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064013/suppl/GSM3064013_SH66205_Cell1_20160907_1614_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064014","PR0218 Prostate Cancer","GSM3064014","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064014/suppl/GSM3064014_SH66205_Cell2_20160907_1615_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064015","PR0219 Prostate Cancer","GSM3064015","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064015/suppl/GSM3064015_SH66205_Cell3_20160907_1616_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064016","PR0220 Prostate Cancer","GSM3064016","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064016/suppl/GSM3064016_SH66205_Cell4_20160907_1617_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064017","PR0221 Prostate Cancer","GSM3064017","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064017/suppl/GSM3064017_SH66206_Cell1_20160907_1618_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064018","PR0222 Prostate Cancer","GSM3064018","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064018/suppl/GSM3064018_SH66206_Cell2_20160907_1619_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064019","PR0223 Prostate Cancer","GSM3064019","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 82","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064019/suppl/GSM3064019_SH66206_Cell3_20160907_1620_1Color_IntegratedResult.txt.gz","2565","82","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064020","PR0224 Prostate Cancer","GSM3064020","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 80","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064020/suppl/GSM3064020_SH66206_Cell4_20160907_1621_1Color_IntegratedResult.txt.gz","2565","80","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064021","PR0225 Prostate Cancer","GSM3064021","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064021/suppl/GSM3064021_SH66207_Cell1_20160907_1622_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064022","PR0227 Prostate Cancer","GSM3064022","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064022/suppl/GSM3064022_SH66207_Cell3_20160907_1624_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064023","PR0228 Prostate Cancer","GSM3064023","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 82","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064023/suppl/GSM3064023_SH66207_Cell4_20160907_1625_1Color_IntegratedResult.txt.gz","2565","82","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064024","PR0229 Prostate Cancer","GSM3064024","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064024/suppl/GSM3064024_SH66208_Cell1_20160907_1626_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064025","PR0230 Prostate Cancer","GSM3064025","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064025/suppl/GSM3064025_SH66208_Cell2_20160907_1627_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064026","PR0231 Prostate Cancer","GSM3064026","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064026/suppl/GSM3064026_SH66208_Cell3_20160907_1628_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064027","PR0232 Prostate Cancer","GSM3064027","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064027/suppl/GSM3064027_SH66208_Cell4_20160907_1629_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064028","PR0233 Prostate Cancer","GSM3064028","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064028/suppl/GSM3064028_SH66809_Cell2_20161004_1234_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064029","PR0236 Prostate Cancer","GSM3064029","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064029/suppl/GSM3064029_SH66810_Cell1_20161004_1237_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064030","PR0237 Prostate Cancer","GSM3064030","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064030/suppl/GSM3064030_SH66210_Cell1_20160909_1534_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064031","PR0238 Prostate Cancer","GSM3064031","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064031/suppl/GSM3064031_SH66810_Cell2_20161004_1238_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064032","PR0239 Prostate Cancer","GSM3064032","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T3b","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064032/suppl/GSM3064032_SH66210_Cell3_20160909_1536_1Color_IntegratedResult.txt.gz","2565","61","M1b","N0","T3b","Prostate Cancer","Male"
"GSM3064033","PR0240 Prostate Cancer","GSM3064033","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 86","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064033/suppl/GSM3064033_SH66210_Cell4_20160909_1537_1Color_IntegratedResult.txt.gz","2565","86","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064034","PR0241 Prostate Cancer","GSM3064034","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064034/suppl/GSM3064034_SH66211_Cell1_20160909_1538_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064035","PR0243 Prostate Cancer","GSM3064035","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064035/suppl/GSM3064035_SH66211_Cell3_20160909_1540_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064036","PR0244 Prostate Cancer","GSM3064036","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 54","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064036/suppl/GSM3064036_SH66211_Cell4_20160909_1541_1Color_IntegratedResult.txt.gz","2565","54","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064037","PR0245 Prostate Cancer","GSM3064037","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064037/suppl/GSM3064037_SH66212_Cell1_20160909_1542_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064038","PR0246 Prostate Cancer","GSM3064038","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064038/suppl/GSM3064038_SH66212_Cell2_20160909_1543_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064039","PR0247 Prostate Cancer","GSM3064039","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064039/suppl/GSM3064039_SH66212_Cell3_20160909_1544_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064040","PR0249 Prostate Cancer","GSM3064040","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064040/suppl/GSM3064040_SH66213_Cell1_20160909_1546_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064041","PR0250 Prostate Cancer","GSM3064041","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2b","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064041/suppl/GSM3064041_SH66213_Cell2_20160909_1547_1Color_IntegratedResult.txt.gz","2565","63","M0","N1","T2b","Prostate Cancer","Male"
"GSM3064042","PR0251 Prostate Cancer","GSM3064042","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064042/suppl/GSM3064042_SH66213_Cell3_20160909_1548_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064043","PR0252 Prostate Cancer","GSM3064043","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 80","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064043/suppl/GSM3064043_SH66213_Cell4_20160909_1549_1Color_IntegratedResult.txt.gz","2565","80","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064044","PR0253 Prostate Cancer","GSM3064044","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064044/suppl/GSM3064044_SH66214_Cell1_20160909_1550_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064045","PR0254 Prostate Cancer","GSM3064045","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064045/suppl/GSM3064045_SH66214_Cell2_20160909_1551_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064046","PR0255 Prostate Cancer","GSM3064046","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064046/suppl/GSM3064046_SH66214_Cell3_20160909_1552_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064047","PR0256 Prostate Cancer","GSM3064047","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064047/suppl/GSM3064047_SH66214_Cell4_20160909_1553_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064048","PR0257 Prostate Cancer","GSM3064048","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064048/suppl/GSM3064048_SH66215_Cell1_20160909_1554_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064049","PR0258 Prostate Cancer","GSM3064049","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T2c","cnstage: N1","cmstage: M1a","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064049/suppl/GSM3064049_SH66215_Cell2_20160909_1555_1Color_IntegratedResult.txt.gz","2565","75","M1a","N1","T2c","Prostate Cancer","Male"
"GSM3064050","PR0259 Prostate Cancer","GSM3064050","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2c","cnstage: N1","cmstage: M1c","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064050/suppl/GSM3064050_SH66215_Cell3_20160909_1556_1Color_IntegratedResult.txt.gz","2565","62","M1c","N1","T2c","Prostate Cancer","Male"
"GSM3064051","PR0260 Prostate Cancer","GSM3064051","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064051/suppl/GSM3064051_SH66215_Cell4_20160909_1557_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064052","PR0261 Prostate Cancer","GSM3064052","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064052/suppl/GSM3064052_SH66216_Cell1_20160909_1558_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064053","PR0262 Prostate Cancer","GSM3064053","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064053/suppl/GSM3064053_SH66216_Cell2_20160909_1559_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064054","PR0263 Prostate Cancer","GSM3064054","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064054/suppl/GSM3064054_SH66216_Cell3_20160909_1600_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064055","PR0264 Prostate Cancer","GSM3064055","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064055/suppl/GSM3064055_SH66216_Cell4_20160909_1601_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064056","PR0265 Prostate Cancer","GSM3064056","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 84","ctstage: T2b","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064056/suppl/GSM3064056_SH66217_Cell1_20160909_1658_1Color_IntegratedResult.txt.gz","2565","84","M1b","N0","T2b","Prostate Cancer","Male"
"GSM3064057","PR0266 Prostate Cancer","GSM3064057","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064057/suppl/GSM3064057_SH66217_Cell2_20160909_1603_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064058","PR0267 Prostate Cancer","GSM3064058","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064058/suppl/GSM3064058_SH66217_Cell3_20160909_1604_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064059","PR0268 Prostate Cancer","GSM3064059","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T3b","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064059/suppl/GSM3064059_SH66217_Cell4_20160909_1605_1Color_IntegratedResult.txt.gz","2565","63","M1b","N1","T3b","Prostate Cancer","Male"
"GSM3064060","PR0270 Prostate Cancer","GSM3064060","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064060/suppl/GSM3064060_SH66218_Cell2_20160909_1607_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064061","PR0271 Prostate Cancer","GSM3064061","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T3b","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064061/suppl/GSM3064061_SH66218_Cell3_20160909_1608_1Color_IntegratedResult.txt.gz","2565","66","M1b","N1","T3b","Prostate Cancer","Male"
"GSM3064062","PR0272 Prostate Cancer","GSM3064062","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2c","cnstage: N0","cmstage: M1c","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064062/suppl/GSM3064062_SH66218_Cell4_20160909_1609_1Color_IntegratedResult.txt.gz","2565","70","M1c","N0","T2c","Prostate Cancer","Male"
"GSM3064063","PR0273 Prostate Cancer","GSM3064063","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064063/suppl/GSM3064063_SH66219_Cell1_20160909_1610_1Color_IntegratedResult.txt.gz","2565","57","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064064","PR0274 Prostate Cancer","GSM3064064","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 83","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064064/suppl/GSM3064064_SH66219_Cell2_20160909_1611_1Color_IntegratedResult.txt.gz","2565","83","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064065","PR0275 Prostate Cancer","GSM3064065","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2c","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064065/suppl/GSM3064065_SH66219_Cell3_20160909_1612_1Color_IntegratedResult.txt.gz","2565","68","M1b","N1","T2c","Prostate Cancer","Male"
"GSM3064066","PR0277 Prostate Cancer","GSM3064066","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064066/suppl/GSM3064066_SH66222_Cell1_20160909_1614_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064067","PR0278 Prostate Cancer","GSM3064067","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064067/suppl/GSM3064067_SH66222_Cell2_20160909_1615_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064068","PR0279 Prostate Cancer","GSM3064068","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064068/suppl/GSM3064068_SH66222_Cell3_20160909_1616_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064069","PR0280 Prostate Cancer","GSM3064069","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 58","ctstage: T2b","cnstage: N1","cmstage: M1a","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064069/suppl/GSM3064069_SH66222_Cell4_20160909_1617_1Color_IntegratedResult.txt.gz","2565","58","M1a","N1","T2b","Prostate Cancer","Male"
"GSM3064070","PR0281 Prostate Cancer","GSM3064070","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064070/suppl/GSM3064070_SH66223_Cell1_20160909_1618_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064071","PR0282 Prostate Cancer","GSM3064071","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064071/suppl/GSM3064071_SH66223_Cell2_20160909_1619_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064072","PR0283 Prostate Cancer","GSM3064072","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064072/suppl/GSM3064072_SH66223_Cell3_20160909_1620_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064073","PR0284 Prostate Cancer","GSM3064073","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064073/suppl/GSM3064073_SH66223_Cell4_20160909_1621_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064074","PR0286 Prostate Cancer","GSM3064074","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064074/suppl/GSM3064074_SH66225_Cell2_20160909_1623_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064075","PR0289 Prostate Cancer","GSM3064075","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064075/suppl/GSM3064075_SH66611_Cell1_20160913_1510_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064076","PR0290 Prostate Cancer","GSM3064076","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 80","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064076/suppl/GSM3064076_SH66810_Cell3_20161004_1239_1Color_IntegratedResult.txt.gz","2565","80","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064077","PR0291 Prostate Cancer","GSM3064077","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064077/suppl/GSM3064077_SH66611_Cell3_20160913_1512_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064078","PR0292 Prostate Cancer","GSM3064078","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T3b","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064078/suppl/GSM3064078_SH66611_Cell4_20160913_1513_1Color_IntegratedResult.txt.gz","2565","71","M1b","N1","T3b","Prostate Cancer","Male"
"GSM3064079","PR0293 Prostate Cancer","GSM3064079","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064079/suppl/GSM3064079_SH66612_Cell1_20160913_1514_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064080","PR0294 Prostate Cancer","GSM3064080","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064080/suppl/GSM3064080_SH66612_Cell2_20160913_1515_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064081","PR0295 Prostate Cancer","GSM3064081","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064081/suppl/GSM3064081_SH66612_Cell3_20160913_1516_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064082","PR0296 Prostate Cancer","GSM3064082","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064082/suppl/GSM3064082_SH66612_Cell4_20160913_1517_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064083","PR0298 Prostate Cancer","GSM3064083","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064083/suppl/GSM3064083_SH66615_Cell2_20160913_1519_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064084","PR0299 Prostate Cancer","GSM3064084","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064084/suppl/GSM3064084_SH66615_Cell3_20160913_1520_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064085","PR0300 Prostate Cancer","GSM3064085","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064085/suppl/GSM3064085_SH66615_Cell4_20160913_1521_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064086","PR0301 Prostate Cancer","GSM3064086","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064086/suppl/GSM3064086_SH66617_Cell1_20160913_1522_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064087","PR0302 Prostate Cancer","GSM3064087","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064087/suppl/GSM3064087_SH66617_Cell2_20160913_1523_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064088","PR0303 Prostate Cancer","GSM3064088","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064088/suppl/GSM3064088_SH66617_Cell3_20160913_1524_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064089","PR0304 Prostate Cancer","GSM3064089","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064089/suppl/GSM3064089_SH66617_Cell4_20160913_1525_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064090","PR0305 Prostate Cancer","GSM3064090","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064090/suppl/GSM3064090_SH66618_Cell1_20160913_1526_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064091","PR0308 Prostate Cancer","GSM3064091","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064091/suppl/GSM3064091_SH66618_Cell4_20160913_1529_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064092","PR0309 Prostate Cancer","GSM3064092","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064092/suppl/GSM3064092_SH66619_Cell1_20160913_1530_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064093","PR0310 Prostate Cancer","GSM3064093","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 84","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064093/suppl/GSM3064093_SH66619_Cell2_20160913_1531_1Color_IntegratedResult.txt.gz","2565","84","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064094","PR0311 Prostate Cancer","GSM3064094","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2c","cnstage: N0","cmstage: M1a","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064094/suppl/GSM3064094_SH66619_Cell3_20160913_1532_1Color_IntegratedResult.txt.gz","2565","66","M1a","N0","T2c","Prostate Cancer","Male"
"GSM3064095","PR0312 Prostate Cancer","GSM3064095","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064095/suppl/GSM3064095_SH66811_Cell1_20161004_1241_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064096","PR0313 Prostate Cancer","GSM3064096","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064096/suppl/GSM3064096_SH66811_Cell2_20161004_1242_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064097","PR0316 Prostate Cancer","GSM3064097","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 52","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064097/suppl/GSM3064097_SH66636_Cell2_20160915_1544_1Color_IntegratedResult.txt.gz","2565","52","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064098","PR0317 Prostate Cancer","GSM3064098","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064098/suppl/GSM3064098_SH66636_Cell3_20160915_1545_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064099","PR0318 Prostate Cancer","GSM3064099","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064099/suppl/GSM3064099_SH66636_Cell4_20160915_1546_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064100","PR0319 Prostate Cancer","GSM3064100","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 79","ctstage: T1c","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064100/suppl/GSM3064100_SH66637_Cell1_20160915_1547_1Color_IntegratedResult.txt.gz","2565","79","M1b","N1","T1c","Prostate Cancer","Male"
"GSM3064101","PR0320 Prostate Cancer","GSM3064101","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064101/suppl/GSM3064101_SH66637_Cell2_20160915_1548_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064102","PR0321 Prostate Cancer","GSM3064102","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2c","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064102/suppl/GSM3064102_SH66637_Cell3_20160915_1549_1Color_IntegratedResult.txt.gz","2565","68","M0","N1","T2c","Prostate Cancer","Male"
"GSM3064103","PR0322 Prostate Cancer","GSM3064103","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064103/suppl/GSM3064103_SH66637_Cell4_20160915_1550_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064104","PR0323 Prostate Cancer","GSM3064104","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064104/suppl/GSM3064104_SH66638_Cell1_20160915_1551_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064105","PR0325 Prostate Cancer","GSM3064105","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064105/suppl/GSM3064105_SH66638_Cell3_20160915_1553_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064106","PR0326 Prostate Cancer","GSM3064106","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064106/suppl/GSM3064106_SH66638_Cell4_20160915_1554_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064107","PR0327 Prostate Cancer","GSM3064107","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 80","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064107/suppl/GSM3064107_SH66639_Cell1_20160915_1555_1Color_IntegratedResult.txt.gz","2565","80","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064108","PR0328 Prostate Cancer","GSM3064108","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064108/suppl/GSM3064108_SH66639_Cell2_20160915_1556_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064109","PR0329 Prostate Cancer","GSM3064109","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064109/suppl/GSM3064109_SH66639_Cell3_20160915_1557_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064110","PR0330 Prostate Cancer","GSM3064110","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064110/suppl/GSM3064110_SH66639_Cell4_20160915_1558_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064111","PR0331 Prostate Cancer","GSM3064111","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064111/suppl/GSM3064111_SH66641_Cell1_20160915_1603_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064112","PR0332 Prostate Cancer","GSM3064112","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064112/suppl/GSM3064112_SH66641_Cell2_20160915_1604_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064113","PR0333 Prostate Cancer","GSM3064113","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064113/suppl/GSM3064113_SH66641_Cell3_20160915_1605_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064114","PR0334 Prostate Cancer","GSM3064114","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064114/suppl/GSM3064114_SH66641_Cell4_20160915_1606_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064115","PR0335 Prostate Cancer","GSM3064115","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064115/suppl/GSM3064115_SH66642_Cell1_20160915_1559_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064116","PR0336 Prostate Cancer","GSM3064116","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064116/suppl/GSM3064116_SH66642_Cell2_20160915_1600_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064117","PR0338 Prostate Cancer","GSM3064117","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064117/suppl/GSM3064117_SH66642_Cell4_20160915_1602_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064118","PR0341 Prostate Cancer","GSM3064118","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064118/suppl/GSM3064118_SH66643_Cell3_20160916_1528_1Color_IntegratedResult.txt.gz","2565","57","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064119","PR0343 Prostate Cancer","GSM3064119","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T3a","cnstage: N1","cmstage: M1a","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064119/suppl/GSM3064119_SH66644_Cell1_20160916_1530_1Color_IntegratedResult.txt.gz","2565","69","M1a","N1","T3a","Prostate Cancer","Male"
"GSM3064120","PR0346 Prostate Cancer","GSM3064120","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064120/suppl/GSM3064120_SH66644_Cell4_20160916_1533_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064121","PR0347 Prostate Cancer","GSM3064121","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064121/suppl/GSM3064121_SH66645_Cell1_20160916_1534_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064122","PR0348 Prostate Cancer","GSM3064122","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064122/suppl/GSM3064122_SH66645_Cell2_20160916_1535_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064123","PR0349 Prostate Cancer","GSM3064123","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064123/suppl/GSM3064123_SH66645_Cell3_20160916_1536_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064124","PR0350 Prostate Cancer","GSM3064124","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064124/suppl/GSM3064124_SH66645_Cell4_20160916_1537_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064125","PR0351 Prostate Cancer","GSM3064125","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064125/suppl/GSM3064125_SH66646_Cell1_20160916_1727_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064126","PR0352 Prostate Cancer","GSM3064126","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 55","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064126/suppl/GSM3064126_SH66646_Cell2_20160916_1539_1Color_IntegratedResult.txt.gz","2565","55","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064127","PR0353 Prostate Cancer","GSM3064127","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 53","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064127/suppl/GSM3064127_SH66646_Cell3_20160916_1540_1Color_IntegratedResult.txt.gz","2565","53","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064128","PR0354 Prostate Cancer","GSM3064128","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T3b","cnstage: N1","cmstage: M1c","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064128/suppl/GSM3064128_SH66646_Cell4_20160916_1541_1Color_IntegratedResult.txt.gz","2565","64","M1c","N1","T3b","Prostate Cancer","Male"
"GSM3064129","PR0356 Prostate Cancer","GSM3064129","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 84","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064129/suppl/GSM3064129_SH66647_Cell2_20160916_1543_1Color_IntegratedResult.txt.gz","2565","84","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064130","PR0357 Prostate Cancer","GSM3064130","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064130/suppl/GSM3064130_SH66647_Cell3_20160916_1544_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064131","PR0358 Prostate Cancer","GSM3064131","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064131/suppl/GSM3064131_SH66811_Cell3_20161004_1243_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064132","PR0359 Prostate Cancer","GSM3064132","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064132/suppl/GSM3064132_SH66648_Cell1_20160916_1546_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064133","PR0360 Prostate Cancer","GSM3064133","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064133/suppl/GSM3064133_SH66648_Cell2_20160916_1547_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064134","PR0361 Prostate Cancer","GSM3064134","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064134/suppl/GSM3064134_SH66648_Cell3_20160916_1548_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064135","PR0362 Prostate Cancer","GSM3064135","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 83","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064135/suppl/GSM3064135_SH66648_Cell4_20160916_1549_1Color_IntegratedResult.txt.gz","2565","83","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064136","PR0363 Prostate Cancer","GSM3064136","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064136/suppl/GSM3064136_SH66649_Cell1_20160916_1550_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064137","PR0364 Prostate Cancer","GSM3064137","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064137/suppl/GSM3064137_SH66649_Cell2_20160916_1551_1Color_IntegratedResult.txt.gz","2565","57","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064138","PR0365 Prostate Cancer","GSM3064138","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 54","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064138/suppl/GSM3064138_SH66649_Cell3_20160916_1552_1Color_IntegratedResult.txt.gz","2565","54","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064139","PR0367 Prostate Cancer","GSM3064139","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064139/suppl/GSM3064139_SH66650_Cell1_20160916_1554_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064140","PR0368 Prostate Cancer","GSM3064140","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064140/suppl/GSM3064140_SH66650_Cell2_20160916_1555_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064141","PR0369 Prostate Cancer","GSM3064141","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064141/suppl/GSM3064141_SH66650_Cell3_20160916_1556_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064142","PR0372 Prostate Cancer","GSM3064142","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064142/suppl/GSM3064142_SH66651_Cell2_20160916_1559_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064143","PR0374 Prostate Cancer","GSM3064143","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064143/suppl/GSM3064143_SH66651_Cell4_20160916_1601_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064144","PR0375 Prostate Cancer","GSM3064144","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064144/suppl/GSM3064144_SH66652_Cell1_20160916_1602_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064145","PR0376 Prostate Cancer","GSM3064145","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064145/suppl/GSM3064145_SH66652_Cell2_20160916_1603_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064146","PR0377 Prostate Cancer","GSM3064146","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064146/suppl/GSM3064146_SH66652_Cell3_20160916_1604_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064147","PR0379 Prostate Cancer","GSM3064147","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064147/suppl/GSM3064147_SH66655_Cell1_20160916_1606_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064148","PR0380 Prostate Cancer","GSM3064148","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064148/suppl/GSM3064148_SH66812_Cell2_20161004_1246_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064149","PR0381 Prostate Cancer","GSM3064149","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064149/suppl/GSM3064149_SH66655_Cell3_20160916_1608_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064150","PR0382 Prostate Cancer","GSM3064150","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064150/suppl/GSM3064150_SH66655_Cell4_20160916_1609_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064151","PR0383 Prostate Cancer","GSM3064151","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064151/suppl/GSM3064151_SH66812_Cell3_20161004_1247_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064152","PR0385 Prostate Cancer","GSM3064152","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 84","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064152/suppl/GSM3064152_SH66656_Cell3_20160916_1612_1Color_IntegratedResult.txt.gz","2565","84","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064153","PR0386 Prostate Cancer","GSM3064153","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064153/suppl/GSM3064153_SH66813_Cell1_20161004_1249_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064154","PR0387 Prostate Cancer","GSM3064154","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 55","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064154/suppl/GSM3064154_SH66657_Cell1_20160916_1614_1Color_IntegratedResult.txt.gz","2565","55","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064155","PR0389 Prostate Cancer","GSM3064155","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T4","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064155/suppl/GSM3064155_SH66657_Cell3_20160916_1616_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T4","Prostate Cancer","Male"
"GSM3064156","PR0390 Prostate Cancer","GSM3064156","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064156/suppl/GSM3064156_SH66657_Cell4_20160916_1728_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064157","PR0391 Prostate Cancer","GSM3064157","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064157/suppl/GSM3064157_SH66813_Cell2_20161004_1250_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064158","PR0395 Prostate Cancer","GSM3064158","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064158/suppl/GSM3064158_SH66659_Cell1_20160916_1622_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064159","PR0396 Prostate Cancer","GSM3064159","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064159/suppl/GSM3064159_SH66659_Cell2_20160916_1623_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064160","PR0397 Prostate Cancer","GSM3064160","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064160/suppl/GSM3064160_SH66659_Cell3_20160916_1624_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064161","PR0398 Prostate Cancer","GSM3064161","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 82","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064161/suppl/GSM3064161_SH66659_Cell4_20160916_1625_1Color_IntegratedResult.txt.gz","2565","82","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064162","PR0399 Prostate Cancer","GSM3064162","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 58","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064162/suppl/GSM3064162_SH66660_Cell1_20160916_1626_1Color_IntegratedResult.txt.gz","2565","58","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064163","PR0401 Prostate Cancer","GSM3064163","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064163/suppl/GSM3064163_SH66660_Cell3_20160916_1628_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064164","PR0402 Prostate Cancer","GSM3064164","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064164/suppl/GSM3064164_SH66660_Cell4_20160916_1629_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064165","PR0403 Prostate Cancer","GSM3064165","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064165/suppl/GSM3064165_SH66661_Cell1_20160916_1630_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064166","PR0404 Prostate Cancer","GSM3064166","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 51","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064166/suppl/GSM3064166_SH66661_Cell2_20160916_1631_1Color_IntegratedResult.txt.gz","2565","51","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064167","PR0407 Prostate Cancer","GSM3064167","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064167/suppl/GSM3064167_SH66662_Cell1_20160916_1634_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064168","PR0409 Prostate Cancer","GSM3064168","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064168/suppl/GSM3064168_SH66662_Cell3_20160916_1636_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064169","PR0410 Prostate Cancer","GSM3064169","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2c","cnstage: N0","cmstage: M1c","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064169/suppl/GSM3064169_SH66662_Cell4_20160916_1637_1Color_IntegratedResult.txt.gz","2565","69","M1c","N0","T2c","Prostate Cancer","Male"
"GSM3064170","PR0411 Prostate Cancer","GSM3064170","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064170/suppl/GSM3064170_SH66663_Cell1_20160916_1638_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064171","PR0412 Prostate Cancer","GSM3064171","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064171/suppl/GSM3064171_SH66663_Cell2_20160916_1639_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064172","PR0415 Prostate Cancer","GSM3064172","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064172/suppl/GSM3064172_SH66701_Cell1_20160916_1642_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064173","PR0416 Prostate Cancer","GSM3064173","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064173/suppl/GSM3064173_SH66701_Cell2_20160916_1643_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064174","PR0417 Prostate Cancer","GSM3064174","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064174/suppl/GSM3064174_SH66701_Cell3_20160916_1644_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064175","PR0419 Prostate Cancer","GSM3064175","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064175/suppl/GSM3064175_SH66703_Cell1_20160921_1446_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064176","PR0420 Prostate Cancer","GSM3064176","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064176/suppl/GSM3064176_SH66703_Cell2_20160921_1447_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064177","PR0422 Prostate Cancer","GSM3064177","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 55","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064177/suppl/GSM3064177_SH66703_Cell4_20160921_1449_1Color_IntegratedResult.txt.gz","2565","55","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064178","PR0423 Prostate Cancer","GSM3064178","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064178/suppl/GSM3064178_SH66815_Cell1_20161004_1253_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064179","PR0425 Prostate Cancer","GSM3064179","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064179/suppl/GSM3064179_SH66704_Cell3_20160921_1452_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064180","PR0427 Prostate Cancer","GSM3064180","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064180/suppl/GSM3064180_SH66705_Cell1_20160921_1454_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064181","PR0428 Prostate Cancer","GSM3064181","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064181/suppl/GSM3064181_SH66705_Cell2_20160921_1455_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064182","PR0429 Prostate Cancer","GSM3064182","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064182/suppl/GSM3064182_SH66705_Cell3_20160921_1456_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064183","PR0431 Prostate Cancer","GSM3064183","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 54","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064183/suppl/GSM3064183_SH66707_Cell1_20160921_1458_1Color_IntegratedResult.txt.gz","2565","54","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064184","PR0432 Prostate Cancer","GSM3064184","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064184/suppl/GSM3064184_SH66707_Cell2_20160921_1459_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064185","PR0433 Prostate Cancer","GSM3064185","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 82","ctstage: T1c","cnstage: N1","cmstage: M1a","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064185/suppl/GSM3064185_SH66707_Cell3_20160921_1500_1Color_IntegratedResult.txt.gz","2565","82","M1a","N1","T1c","Prostate Cancer","Male"
"GSM3064186","PR0434 Prostate Cancer","GSM3064186","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064186/suppl/GSM3064186_SH66707_Cell4_20160921_1501_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064187","PR0436 Prostate Cancer","GSM3064187","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064187/suppl/GSM3064187_SH66708_Cell2_20160921_1503_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064188","PR0437 Prostate Cancer","GSM3064188","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064188/suppl/GSM3064188_SH66708_Cell3_20160921_1504_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064189","PR0439 Prostate Cancer","GSM3064189","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064189/suppl/GSM3064189_SH66709_Cell1_20160921_1506_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064190","PR0440 Prostate Cancer","GSM3064190","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064190/suppl/GSM3064190_SH66709_Cell2_20160921_1507_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064191","PR0442 Prostate Cancer","GSM3064191","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064191/suppl/GSM3064191_SH66709_Cell4_20160921_1509_1Color_IntegratedResult.txt.gz","2565","57","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064192","PR0443 Prostate Cancer","GSM3064192","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064192/suppl/GSM3064192_SH66710_Cell1_20160921_1510_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064193","PR0444 Prostate Cancer","GSM3064193","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 55","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064193/suppl/GSM3064193_SH66710_Cell2_20160921_1511_1Color_IntegratedResult.txt.gz","2565","55","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064194","PR0446 Prostate Cancer","GSM3064194","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064194/suppl/GSM3064194_SH66710_Cell4_20160921_1513_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064195","PR0447 Prostate Cancer","GSM3064195","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064195/suppl/GSM3064195_SH66712_Cell1_20160921_1514_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064196","PR0448 Prostate Cancer","GSM3064196","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064196/suppl/GSM3064196_SH66712_Cell2_20160921_1515_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064197","PR0449 Prostate Cancer","GSM3064197","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064197/suppl/GSM3064197_SH66712_Cell3_20160921_1516_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064198","PR0450 Prostate Cancer","GSM3064198","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064198/suppl/GSM3064198_SH66712_Cell4_20160921_1517_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064199","PR0451 Prostate Cancer","GSM3064199","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064199/suppl/GSM3064199_SH66713_Cell1_20160921_1518_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064200","PR0454 Prostate Cancer","GSM3064200","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064200/suppl/GSM3064200_SH66713_Cell4_20160921_1521_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064201","PR0455 Prostate Cancer","GSM3064201","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064201/suppl/GSM3064201_SH66714_Cell1_20160921_1522_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064202","PR0456 Prostate Cancer","GSM3064202","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064202/suppl/GSM3064202_SH66714_Cell2_20160921_1523_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064203","PR0457 Prostate Cancer","GSM3064203","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064203/suppl/GSM3064203_SH66714_Cell3_20160921_1524_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064204","PR0458 Prostate Cancer","GSM3064204","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064204/suppl/GSM3064204_SH66714_Cell4_20160921_1525_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064205","PR0459 Prostate Cancer","GSM3064205","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T3b","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064205/suppl/GSM3064205_SH66715_Cell1_20160921_1526_1Color_IntegratedResult.txt.gz","2565","65","M1b","N0","T3b","Prostate Cancer","Male"
"GSM3064206","PR0460 Prostate Cancer","GSM3064206","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064206/suppl/GSM3064206_SH66715_Cell2_20160921_1527_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064207","PR0461 Prostate Cancer","GSM3064207","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064207/suppl/GSM3064207_SH66715_Cell3_20160921_1528_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064208","PR0462 Prostate Cancer","GSM3064208","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064208/suppl/GSM3064208_SH66715_Cell4_20160921_1529_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064209","PR0463 Prostate Cancer","GSM3064209","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064209/suppl/GSM3064209_SH66717_Cell1_20160921_1530_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064210","PR0465 Prostate Cancer","GSM3064210","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064210/suppl/GSM3064210_SH66717_Cell3_20160921_1532_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064211","PR0467 Prostate Cancer","GSM3064211","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064211/suppl/GSM3064211_SH66718_Cell1_20160921_1534_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064212","PR0468 Prostate Cancer","GSM3064212","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064212/suppl/GSM3064212_SH66718_Cell2_20160921_1535_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064213","PR0469 Prostate Cancer","GSM3064213","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 50","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064213/suppl/GSM3064213_SH66718_Cell3_20160921_1536_1Color_IntegratedResult.txt.gz","2565","50","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064214","PR0472 Prostate Cancer","GSM3064214","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064214/suppl/GSM3064214_SH66719_Cell2_20160921_1539_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064215","PR0473 Prostate Cancer","GSM3064215","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 81","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064215/suppl/GSM3064215_SH66719_Cell3_20160921_1540_1Color_IntegratedResult.txt.gz","2565","81","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064216","PR0474 Prostate Cancer","GSM3064216","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064216/suppl/GSM3064216_SH66719_Cell4_20160921_1541_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064217","PR0475 Prostate Cancer","GSM3064217","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 79","ctstage: T4","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064217/suppl/GSM3064217_SH66720_Cell1_20160921_1542_1Color_IntegratedResult.txt.gz","2565","79","M1b","N1","T4","Prostate Cancer","Male"
"GSM3064218","PR0476 Prostate Cancer","GSM3064218","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T3b","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064218/suppl/GSM3064218_SH66720_Cell2_20160921_1543_1Color_IntegratedResult.txt.gz","2565","57","M1b","N1","T3b","Prostate Cancer","Male"
"GSM3064219","PR0477 Prostate Cancer","GSM3064219","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064219/suppl/GSM3064219_SH66720_Cell3_20160921_1544_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064220","PR0478 Prostate Cancer","GSM3064220","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 53","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064220/suppl/GSM3064220_SH66720_Cell4_20160921_1545_1Color_IntegratedResult.txt.gz","2565","53","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064221","PR0479 Prostate Cancer","GSM3064221","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064221/suppl/GSM3064221_SH66721_Cell1_20160921_1546_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064222","PR0480 Prostate Cancer","GSM3064222","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064222/suppl/GSM3064222_SH66721_Cell2_20160921_1547_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064223","PR0481 Prostate Cancer","GSM3064223","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064223/suppl/GSM3064223_SH66721_Cell3_20160921_1548_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064224","PR0482 Prostate Cancer","GSM3064224","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064224/suppl/GSM3064224_SH66721_Cell4_20160921_1549_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064225","PR0485 Prostate Cancer","GSM3064225","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064225/suppl/GSM3064225_SH66722_Cell3_20160921_1552_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064226","PR0486 Prostate Cancer","GSM3064226","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064226/suppl/GSM3064226_SH66815_Cell4_20161004_1256_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064227","PR0488 Prostate Cancer","GSM3064227","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064227/suppl/GSM3064227_SH66725_Cell2_20160921_1555_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064228","PR0489 Prostate Cancer","GSM3064228","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064228/suppl/GSM3064228_SH66816_Cell1_20161004_1257_1Color_IntegratedResult.txt.gz","2565","57","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064229","PR0490 Prostate Cancer","GSM3064229","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064229/suppl/GSM3064229_SH66816_Cell2_20161004_1258_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064230","PR0491 Prostate Cancer","GSM3064230","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064230/suppl/GSM3064230_SH66726_Cell1_20160921_1558_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064231","PR0493 Prostate Cancer","GSM3064231","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064231/suppl/GSM3064231_SH66726_Cell3_20160921_1600_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064232","PR0495 Prostate Cancer","GSM3064232","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 84","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064232/suppl/GSM3064232_SH66727_Cell1_20160921_1602_1Color_IntegratedResult.txt.gz","2565","84","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064233","PR0498 Prostate Cancer","GSM3064233","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2c","cnstage: N1","cmstage: M1c","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064233/suppl/GSM3064233_SH66727_Cell4_20160921_1605_1Color_IntegratedResult.txt.gz","2565","66","M1c","N1","T2c","Prostate Cancer","Male"
"GSM3064234","PR0499 Prostate Cancer","GSM3064234","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064234/suppl/GSM3064234_SH66729_Cell1_20160927_1459_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064235","PR0500 Prostate Cancer","GSM3064235","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064235/suppl/GSM3064235_SH66729_Cell2_20160927_1500_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064236","PR0501 Prostate Cancer","GSM3064236","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064236/suppl/GSM3064236_SH66729_Cell3_20160927_1501_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064237","PR0502 Prostate Cancer","GSM3064237","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064237/suppl/GSM3064237_SH66816_Cell3_20161004_1259_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064238","PR0504 Prostate Cancer","GSM3064238","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064238/suppl/GSM3064238_SH66730_Cell2_20160927_1504_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064239","PR0505 Prostate Cancer","GSM3064239","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064239/suppl/GSM3064239_SH66730_Cell3_20160927_1505_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064240","PR0506 Prostate Cancer","GSM3064240","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 86","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064240/suppl/GSM3064240_SH66817_Cell1_20161004_1301_1Color_IntegratedResult.txt.gz","2565","86","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064241","PR0507 Prostate Cancer","GSM3064241","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064241/suppl/GSM3064241_SH66731_Cell1_20160927_1507_1Color_IntegratedResult.txt.gz","2565","70","M1b","N1","T1c","Prostate Cancer","Male"
"GSM3064242","PR0508 Prostate Cancer","GSM3064242","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 84","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064242/suppl/GSM3064242_SH66731_Cell2_20160927_1508_1Color_IntegratedResult.txt.gz","2565","84","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064243","PR0509 Prostate Cancer","GSM3064243","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064243/suppl/GSM3064243_SH66731_Cell3_20160927_1509_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064244","PR0510 Prostate Cancer","GSM3064244","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T4","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064244/suppl/GSM3064244_SH66731_Cell4_20160927_1510_1Color_IntegratedResult.txt.gz","2565","61","M1b","N1","T4","Prostate Cancer","Male"
"GSM3064245","PR0511 Prostate Cancer","GSM3064245","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064245/suppl/GSM3064245_SH66732_Cell1_20160927_1511_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064246","PR0512 Prostate Cancer","GSM3064246","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064246/suppl/GSM3064246_SH66732_Cell2_20160927_1512_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064247","PR0513 Prostate Cancer","GSM3064247","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064247/suppl/GSM3064247_SH66732_Cell3_20160927_1513_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064248","PR0515 Prostate Cancer","GSM3064248","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064248/suppl/GSM3064248_SH66733_Cell1_20160927_1515_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064249","PR0516 Prostate Cancer","GSM3064249","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064249/suppl/GSM3064249_SH66733_Cell2_20160927_1516_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064250","PR0517 Prostate Cancer","GSM3064250","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064250/suppl/GSM3064250_SH66817_Cell3_20161004_1303_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064251","PR0519 Prostate Cancer","GSM3064251","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 54","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064251/suppl/GSM3064251_SH66734_Cell1_20160927_1519_1Color_IntegratedResult.txt.gz","2565","54","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064252","PR0520 Prostate Cancer","GSM3064252","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064252/suppl/GSM3064252_SH66734_Cell2_20160927_1520_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064253","PR0521 Prostate Cancer","GSM3064253","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064253/suppl/GSM3064253_SH66734_Cell3_20160927_1521_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064254","PR0522 Prostate Cancer","GSM3064254","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 50","ctstage: T3a","cnstage: N0","cmstage: M1c","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064254/suppl/GSM3064254_SH66734_Cell4_20160927_1522_1Color_IntegratedResult.txt.gz","2565","50","M1c","N0","T3a","Prostate Cancer","Male"
"GSM3064255","PR0524 Prostate Cancer","GSM3064255","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064255/suppl/GSM3064255_SH66735_Cell2_20160927_1524_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064256","PR0525 Prostate Cancer","GSM3064256","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T4","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064256/suppl/GSM3064256_SH66735_Cell3_20160927_1525_1Color_IntegratedResult.txt.gz","2565","64","M1b","N1","T4","Prostate Cancer","Male"
"GSM3064257","PR0526 Prostate Cancer","GSM3064257","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064257/suppl/GSM3064257_SH66735_Cell4_20160927_1526_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064258","PR0527 Prostate Cancer","GSM3064258","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064258/suppl/GSM3064258_SH66736_Cell1_20160927_1527_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064259","PR0528 Prostate Cancer","GSM3064259","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064259/suppl/GSM3064259_SH66736_Cell2_20160927_1528_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064260","PR0529 Prostate Cancer","GSM3064260","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064260/suppl/GSM3064260_SH66736_Cell3_20160927_1529_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064261","PR0530 Prostate Cancer","GSM3064261","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064261/suppl/GSM3064261_SH66736_Cell4_20160927_1530_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064262","PR0531 Prostate Cancer","GSM3064262","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064262/suppl/GSM3064262_SH66737_Cell1_20160927_1531_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064263","PR0532 Prostate Cancer","GSM3064263","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 54","ctstage: T4","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064263/suppl/GSM3064263_SH66737_Cell2_20160927_1532_1Color_IntegratedResult.txt.gz","2565","54","M1b","N1","T4","Prostate Cancer","Male"
"GSM3064264","PR0533 Prostate Cancer","GSM3064264","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064264/suppl/GSM3064264_SH66737_Cell3_20160927_1533_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064265","PR0535 Prostate Cancer","GSM3064265","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064265/suppl/GSM3064265_SH66739_Cell1_20160927_1535_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064266","PR0536 Prostate Cancer","GSM3064266","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064266/suppl/GSM3064266_SH66739_Cell2_20160927_1536_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064267","PR0537 Prostate Cancer","GSM3064267","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064267/suppl/GSM3064267_SH66739_Cell3_20160927_1537_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064268","PR0538 Prostate Cancer","GSM3064268","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064268/suppl/GSM3064268_SH66739_Cell4_20160927_1538_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064269","PR0539 Prostate Cancer","GSM3064269","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064269/suppl/GSM3064269_SH66740_Cell1_20160927_1539_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064270","PR0540 Prostate Cancer","GSM3064270","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064270/suppl/GSM3064270_SH66740_Cell2_20160927_1540_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064271","PR0541 Prostate Cancer","GSM3064271","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064271/suppl/GSM3064271_SH66740_Cell3_20160927_1541_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064272","PR0542 Prostate Cancer","GSM3064272","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T3a","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064272/suppl/GSM3064272_SH66740_Cell4_20160927_1542_1Color_IntegratedResult.txt.gz","2565","62","M1b","N1","T3a","Prostate Cancer","Male"
"GSM3064273","PR0543 Prostate Cancer","GSM3064273","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064273/suppl/GSM3064273_SH66741_Cell1_20160927_1543_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064274","PR0544 Prostate Cancer","GSM3064274","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064274/suppl/GSM3064274_SH66741_Cell2_20160927_1544_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064275","PR0545 Prostate Cancer","GSM3064275","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T3a","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064275/suppl/GSM3064275_SH66741_Cell3_20160927_1545_1Color_IntegratedResult.txt.gz","2565","65","M1b","N1","T3a","Prostate Cancer","Male"
"GSM3064276","PR0546 Prostate Cancer","GSM3064276","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064276/suppl/GSM3064276_SH66741_Cell4_20160927_1546_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064277","PR0547 Prostate Cancer","GSM3064277","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064277/suppl/GSM3064277_SH66742_Cell1_20160927_1547_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064278","PR0549 Prostate Cancer","GSM3064278","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064278/suppl/GSM3064278_SH66742_Cell3_20160927_1549_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064279","PR0550 Prostate Cancer","GSM3064279","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 79","ctstage: T3a","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064279/suppl/GSM3064279_SH66742_Cell4_20160927_1550_1Color_IntegratedResult.txt.gz","2565","79","M1b","N1","T3a","Prostate Cancer","Male"
"GSM3064280","PR0551 Prostate Cancer","GSM3064280","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064280/suppl/GSM3064280_SH66743_Cell1_20160927_1551_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064281","PR0552 Prostate Cancer","GSM3064281","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 81","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064281/suppl/GSM3064281_SH66743_Cell2_20160927_1552_1Color_IntegratedResult.txt.gz","2565","81","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064282","PR0553 Prostate Cancer","GSM3064282","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064282/suppl/GSM3064282_SH66743_Cell3_20160927_1553_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064283","PR0554 Prostate Cancer","GSM3064283","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064283/suppl/GSM3064283_SH66743_Cell4_20160927_1554_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064284","PR0555 Prostate Cancer","GSM3064284","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064284/suppl/GSM3064284_SH66744_Cell1_20160927_1555_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064285","PR0556 Prostate Cancer","GSM3064285","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064285/suppl/GSM3064285_SH66744_Cell2_20160927_1556_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064286","PR0557 Prostate Cancer","GSM3064286","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064286/suppl/GSM3064286_SH66744_Cell3_20160927_1557_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064287","PR0559 Prostate Cancer","GSM3064287","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064287/suppl/GSM3064287_SH66745_Cell1_20160927_1559_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064288","PR0561 Prostate Cancer","GSM3064288","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 86","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064288/suppl/GSM3064288_SH66745_Cell3_20160927_1601_1Color_IntegratedResult.txt.gz","2565","86","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064289","PR0562 Prostate Cancer","GSM3064289","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064289/suppl/GSM3064289_SH66745_Cell4_20160927_1602_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064290","PR0563 Prostate Cancer","GSM3064290","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064290/suppl/GSM3064290_SH66746_Cell1_20160927_1603_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064291","PR0564 Prostate Cancer","GSM3064291","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064291/suppl/GSM3064291_SH66746_Cell2_20160927_1604_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064292","PR0565 Prostate Cancer","GSM3064292","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T3a","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064292/suppl/GSM3064292_SH66746_Cell3_20160927_1605_1Color_IntegratedResult.txt.gz","2565","73","M1b","N0","T3a","Prostate Cancer","Male"
"GSM3064293","PR0566 Prostate Cancer","GSM3064293","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064293/suppl/GSM3064293_SH66746_Cell4_20160927_1606_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064294","PR0567 Prostate Cancer","GSM3064294","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 48","ctstage: T3a","cnstage: N1","cmstage: M1a","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064294/suppl/GSM3064294_SH66747_Cell1_20160927_1607_1Color_IntegratedResult.txt.gz","2565","48","M1a","N1","T3a","Prostate Cancer","Male"
"GSM3064295","PR0569 Prostate Cancer","GSM3064295","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064295/suppl/GSM3064295_SH66747_Cell3_20160927_1609_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064296","PR0570 Prostate Cancer","GSM3064296","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 55","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064296/suppl/GSM3064296_SH66747_Cell4_20160927_1610_1Color_IntegratedResult.txt.gz","2565","55","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064297","PR0571 Prostate Cancer","GSM3064297","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 52","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064297/suppl/GSM3064297_SH66748_Cell1_20160927_1611_1Color_IntegratedResult.txt.gz","2565","52","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064298","PR0573 Prostate Cancer","GSM3064298","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064298/suppl/GSM3064298_SH66748_Cell3_20160927_1613_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064299","PR0575 Prostate Cancer","GSM3064299","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064299/suppl/GSM3064299_SH66749_Cell1_20160927_1615_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064300","PR0576 Prostate Cancer","GSM3064300","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064300/suppl/GSM3064300_SH66749_Cell2_20160927_1616_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064301","PR0577 Prostate Cancer","GSM3064301","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T3a","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064301/suppl/GSM3064301_SH66749_Cell3_20160927_1617_1Color_IntegratedResult.txt.gz","2565","60","M0","N1","T3a","Prostate Cancer","Male"
"GSM3064302","PR0578 Prostate Cancer","GSM3064302","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064302/suppl/GSM3064302_SH66750_Cell1_20160930_1526_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064303","PR0580 Prostate Cancer","GSM3064303","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064303/suppl/GSM3064303_SH66931_Cell1_20161019_1135_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064304","PR0581 Prostate Cancer","GSM3064304","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064304/suppl/GSM3064304_SH66750_Cell4_20160930_1529_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064305","PR0584 Prostate Cancer","GSM3064305","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064305/suppl/GSM3064305_SH66751_Cell3_20160930_1532_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064306","PR0586 Prostate Cancer","GSM3064306","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064306/suppl/GSM3064306_SH66752_Cell1_20160930_1534_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064307","PR0589 Prostate Cancer","GSM3064307","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T4","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064307/suppl/GSM3064307_SH66752_Cell4_20160930_1537_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T4","Prostate Cancer","Male"
"GSM3064308","PR0591 Prostate Cancer","GSM3064308","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 58","ctstage: T3a","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064308/suppl/GSM3064308_SH66754_Cell2_20160930_1539_1Color_IntegratedResult.txt.gz","2565","58","M1b","N1","T3a","Prostate Cancer","Male"
"GSM3064309","PR0593 Prostate Cancer","GSM3064309","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064309/suppl/GSM3064309_SH66754_Cell4_20160930_1541_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064310","PR0594 Prostate Cancer","GSM3064310","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064310/suppl/GSM3064310_SH66755_Cell1_20160930_1542_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064311","PR0595 Prostate Cancer","GSM3064311","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064311/suppl/GSM3064311_SH66755_Cell2_20160930_1543_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064312","PR0596 Prostate Cancer","GSM3064312","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064312/suppl/GSM3064312_SH66755_Cell3_20160930_1544_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064313","PR0598 Prostate Cancer","GSM3064313","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064313/suppl/GSM3064313_SH66756_Cell1_20160930_1546_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064314","PR0601 Prostate Cancer","GSM3064314","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064314/suppl/GSM3064314_SH66756_Cell4_20160930_1549_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064315","PR0602 Prostate Cancer","GSM3064315","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064315/suppl/GSM3064315_SH66757_Cell1_20160930_1550_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064316","PR0604 Prostate Cancer","GSM3064316","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064316/suppl/GSM3064316_SH66757_Cell3_20160930_1552_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064317","PR0605 Prostate Cancer","GSM3064317","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064317/suppl/GSM3064317_SH66757_Cell4_20160930_1553_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064318","PR0606 Prostate Cancer","GSM3064318","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064318/suppl/GSM3064318_SH66758_Cell1_20160930_1554_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064319","PR0608 Prostate Cancer","GSM3064319","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064319/suppl/GSM3064319_SH66758_Cell3_20160930_1556_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064320","PR0609 Prostate Cancer","GSM3064320","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064320/suppl/GSM3064320_SH66758_Cell4_20160930_1934_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064321","PR0610 Prostate Cancer","GSM3064321","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064321/suppl/GSM3064321_SH66759_Cell1_20160930_1935_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064322","PR0611 Prostate Cancer","GSM3064322","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064322/suppl/GSM3064322_SH66759_Cell2_20160930_1559_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064323","PR0612 Prostate Cancer","GSM3064323","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064323/suppl/GSM3064323_SH66759_Cell3_20160930_1600_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064324","PR0615 Prostate Cancer","GSM3064324","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064324/suppl/GSM3064324_SH66760_Cell2_20160930_1936_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064325","PR0618 Prostate Cancer","GSM3064325","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T3b","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064325/suppl/GSM3064325_SH66931_Cell3_20161019_1137_1Color_IntegratedResult.txt.gz","2565","60","M0","N1","T3b","Prostate Cancer","Male"
"GSM3064326","PR0619 Prostate Cancer","GSM3064326","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064326/suppl/GSM3064326_SH66761_Cell2_20160930_1607_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064327","PR0621 Prostate Cancer","GSM3064327","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064327/suppl/GSM3064327_SH66761_Cell4_20160930_1609_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064328","PR0624 Prostate Cancer","GSM3064328","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064328/suppl/GSM3064328_SH66762_Cell3_20160930_1612_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064329","PR0627 Prostate Cancer","GSM3064329","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064329/suppl/GSM3064329_SH66801_Cell2_20160930_1615_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064330","PR0628 Prostate Cancer","GSM3064330","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064330/suppl/GSM3064330_SH66801_Cell3_20160930_1616_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064331","PR0630 Prostate Cancer","GSM3064331","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064331/suppl/GSM3064331_SH66802_Cell1_20160930_1618_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064332","PR0631 Prostate Cancer","GSM3064332","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064332/suppl/GSM3064332_SH66802_Cell2_20160930_1619_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064333","PR0632 Prostate Cancer","GSM3064333","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064333/suppl/GSM3064333_SH66802_Cell3_20160930_1620_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064334","PR0633 Prostate Cancer","GSM3064334","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064334/suppl/GSM3064334_SH66802_Cell4_20160930_1621_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064335","PR0634 Prostate Cancer","GSM3064335","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064335/suppl/GSM3064335_SH66803_Cell1_20160930_1622_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064336","PR0635 Prostate Cancer","GSM3064336","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 81","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064336/suppl/GSM3064336_SH66803_Cell2_20160930_1623_1Color_IntegratedResult.txt.gz","2565","81","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064337","PR0636 Prostate Cancer","GSM3064337","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064337/suppl/GSM3064337_SH66803_Cell3_20160930_1624_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064338","PR0637 Prostate Cancer","GSM3064338","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064338/suppl/GSM3064338_SH66803_Cell4_20160930_1625_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064339","PR0638 Prostate Cancer","GSM3064339","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064339/suppl/GSM3064339_SH66804_Cell1_20160930_1626_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064340","PR0639 Prostate Cancer","GSM3064340","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064340/suppl/GSM3064340_SH66804_Cell2_20160930_1627_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064341","PR0640 Prostate Cancer","GSM3064341","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064341/suppl/GSM3064341_SH66804_Cell3_20160930_1628_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064342","PR0641 Prostate Cancer","GSM3064342","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064342/suppl/GSM3064342_SH66804_Cell4_20160930_1629_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064343","PR0642 Prostate Cancer","GSM3064343","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064343/suppl/GSM3064343_SH66805_Cell1_20160930_1630_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064344","PR0643 Prostate Cancer","GSM3064344","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064344/suppl/GSM3064344_SH66805_Cell2_20160930_1938_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064345","PR0645 Prostate Cancer","GSM3064345","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064345/suppl/GSM3064345_SH66805_Cell4_20160930_1939_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064346","PR0646 Prostate Cancer","GSM3064346","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T4","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064346/suppl/GSM3064346_SH66806_Cell1_20160930_1634_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T4","Prostate Cancer","Male"
"GSM3064347","PR0648 Prostate Cancer","GSM3064347","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064347/suppl/GSM3064347_SH66806_Cell3_20160930_1636_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064348","PR0650 Prostate Cancer","GSM3064348","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064348/suppl/GSM3064348_SH66807_Cell1_20160930_1638_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064349","PR0651 Prostate Cancer","GSM3064349","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064349/suppl/GSM3064349_SH66807_Cell2_20160930_1639_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064350","PR0652 Prostate Cancer","GSM3064350","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064350/suppl/GSM3064350_SH66807_Cell3_20160930_1640_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064351","PR0653 Prostate Cancer","GSM3064351","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064351/suppl/GSM3064351_SH66807_Cell4_20160930_1641_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064352","PR0658 Prostate Cancer","GSM3064352","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064352/suppl/GSM3064352_SH66931_Cell4_20161019_1138_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064353","PR0659 Prostate Cancer","GSM3064353","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 53","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064353/suppl/GSM3064353_SH66818_Cell2_20161004_1312_1Color_IntegratedResult.txt.gz","2565","53","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064354","PR0660 Prostate Cancer","GSM3064354","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064354/suppl/GSM3064354_SH66932_Cell1_20161019_1139_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064355","PR0662 Prostate Cancer","GSM3064355","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 55","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064355/suppl/GSM3064355_SH66932_Cell3_20161019_1141_1Color_IntegratedResult.txt.gz","2565","55","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064356","PR0664 Prostate Cancer","GSM3064356","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064356/suppl/GSM3064356_SH66819_Cell3_20161004_1317_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064357","PR0665 Prostate Cancer","GSM3064357","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064357/suppl/GSM3064357_SH66819_Cell4_20161004_1318_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064358","PR0667 Prostate Cancer","GSM3064358","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064358/suppl/GSM3064358_SH66820_Cell2_20161004_1320_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064359","PR0668 Prostate Cancer","GSM3064359","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064359/suppl/GSM3064359_SH66820_Cell3_20161004_1321_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064360","PR0669 Prostate Cancer","GSM3064360","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064360/suppl/GSM3064360_SH66932_Cell4_20161019_1142_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064361","PR0670 Prostate Cancer","GSM3064361","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064361/suppl/GSM3064361_SH66821_Cell1_20161004_1323_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064362","PR0671 Prostate Cancer","GSM3064362","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064362/suppl/GSM3064362_SH66821_Cell2_20161004_1324_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064363","PR0672 Prostate Cancer","GSM3064363","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064363/suppl/GSM3064363_SH66933_Cell1_20161019_1143_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064364","PR0674 Prostate Cancer","GSM3064364","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064364/suppl/GSM3064364_SH66822_Cell1_20161004_1327_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064365","PR0675 Prostate Cancer","GSM3064365","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064365/suppl/GSM3064365_SH66822_Cell2_20161004_1328_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064366","PR0676 Prostate Cancer","GSM3064366","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064366/suppl/GSM3064366_SH66822_Cell3_20161004_1329_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064367","PR0677 Prostate Cancer","GSM3064367","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064367/suppl/GSM3064367_SH66933_Cell3_20161019_1145_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064368","PR0678 Prostate Cancer","GSM3064368","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064368/suppl/GSM3064368_SH66823_Cell1_20161004_1331_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064369","PR0679 Prostate Cancer","GSM3064369","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064369/suppl/GSM3064369_SH66823_Cell2_20161004_1332_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064370","PR0681 Prostate Cancer","GSM3064370","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064370/suppl/GSM3064370_SH66933_Cell4_20161019_1146_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064371","PR0682 Prostate Cancer","GSM3064371","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064371/suppl/GSM3064371_SH66825_Cell1_20161004_1335_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064372","PR0685 Prostate Cancer","GSM3064372","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064372/suppl/GSM3064372_SH66825_Cell4_20161004_1338_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064373","PR0687 Prostate Cancer","GSM3064373","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064373/suppl/GSM3064373_SH66826_Cell2_20161004_1340_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064374","PR0689 Prostate Cancer","GSM3064374","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064374/suppl/GSM3064374_SH66826_Cell4_20161004_1342_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064375","PR0690 Prostate Cancer","GSM3064375","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064375/suppl/GSM3064375_SH66827_Cell1_20161004_1343_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064376","PR0691 Prostate Cancer","GSM3064376","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064376/suppl/GSM3064376_SH66827_Cell2_20161004_1344_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064377","PR0692 Prostate Cancer","GSM3064377","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064377/suppl/GSM3064377_SH66827_Cell3_20161004_1345_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064378","PR0693 Prostate Cancer","GSM3064378","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064378/suppl/GSM3064378_SH66827_Cell4_20161004_1346_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064379","PR0694 Prostate Cancer","GSM3064379","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064379/suppl/GSM3064379_SH66828_Cell1_20161004_1347_1Color_IntegratedResult.txt.gz","2565","57","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064380","PR0695 Prostate Cancer","GSM3064380","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064380/suppl/GSM3064380_SH66828_Cell2_20161004_1348_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064381","PR0697 Prostate Cancer","GSM3064381","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064381/suppl/GSM3064381_SH66828_Cell4_20161004_1350_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064382","PR0699 Prostate Cancer","GSM3064382","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 52","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064382/suppl/GSM3064382_SH66829_Cell2_20161004_1352_1Color_IntegratedResult.txt.gz","2565","52","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064383","PR0700 Prostate Cancer","GSM3064383","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 84","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064383/suppl/GSM3064383_SH66829_Cell3_20161004_1353_1Color_IntegratedResult.txt.gz","2565","84","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064384","PR0701 Prostate Cancer","GSM3064384","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 79","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064384/suppl/GSM3064384_SH66829_Cell4_20161004_1354_1Color_IntegratedResult.txt.gz","2565","79","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064385","PR0702 Prostate Cancer","GSM3064385","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064385/suppl/GSM3064385_SH66830_Cell1_20161004_1355_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064386","PR0703 Prostate Cancer","GSM3064386","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 50","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064386/suppl/GSM3064386_SH66830_Cell2_20161004_1356_1Color_IntegratedResult.txt.gz","2565","50","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064387","PR0704 Prostate Cancer","GSM3064387","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064387/suppl/GSM3064387_SH66830_Cell3_20161004_1357_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064388","PR0705 Prostate Cancer","GSM3064388","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064388/suppl/GSM3064388_SH66830_Cell4_20161004_1358_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064389","PR0706 Prostate Cancer","GSM3064389","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064389/suppl/GSM3064389_SH66831_Cell1_20161013_1456_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064390","PR0707 Prostate Cancer","GSM3064390","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064390/suppl/GSM3064390_SH66831_Cell2_20161013_1457_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064391","PR0708 Prostate Cancer","GSM3064391","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064391/suppl/GSM3064391_SH66831_Cell3_20161013_1458_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064392","PR0709 Prostate Cancer","GSM3064392","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064392/suppl/GSM3064392_SH66831_Cell4_20161013_1459_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064393","PR0710 Prostate Cancer","GSM3064393","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T3a","cnstage: N1","cmstage: M1c","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064393/suppl/GSM3064393_SH66833_Cell1_20161013_1500_1Color_IntegratedResult.txt.gz","2565","77","M1c","N1","T3a","Prostate Cancer","Male"
"GSM3064394","PR0711 Prostate Cancer","GSM3064394","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T4","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064394/suppl/GSM3064394_SH66833_Cell2_20161013_1501_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T4","Prostate Cancer","Male"
"GSM3064395","PR0712 Prostate Cancer","GSM3064395","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064395/suppl/GSM3064395_SH66833_Cell3_20161013_1502_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064396","PR0713 Prostate Cancer","GSM3064396","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064396/suppl/GSM3064396_SH66833_Cell4_20161013_1503_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064397","PR0714 Prostate Cancer","GSM3064397","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064397/suppl/GSM3064397_SH66834_Cell1_20161013_1504_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064398","PR0715 Prostate Cancer","GSM3064398","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064398/suppl/GSM3064398_SH66834_Cell2_20161013_1505_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064399","PR0716 Prostate Cancer","GSM3064399","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064399/suppl/GSM3064399_SH66834_Cell3_20161013_1506_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064400","PR0717 Prostate Cancer","GSM3064400","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064400/suppl/GSM3064400_SH66834_Cell4_20161013_1507_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064401","PR0718 Prostate Cancer","GSM3064401","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064401/suppl/GSM3064401_SH66835_Cell1_20161013_1508_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064402","PR0719 Prostate Cancer","GSM3064402","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064402/suppl/GSM3064402_SH66835_Cell2_20161013_1509_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064403","PR0720 Prostate Cancer","GSM3064403","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064403/suppl/GSM3064403_SH66835_Cell3_20161013_1510_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064404","PR0721 Prostate Cancer","GSM3064404","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 82","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064404/suppl/GSM3064404_SH66835_Cell4_20161013_1511_1Color_IntegratedResult.txt.gz","2565","82","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064405","PR0722 Prostate Cancer","GSM3064405","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 54","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064405/suppl/GSM3064405_SH66836_Cell1_20161013_1512_1Color_IntegratedResult.txt.gz","2565","54","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064406","PR0723 Prostate Cancer","GSM3064406","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T1c","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064406/suppl/GSM3064406_SH66836_Cell2_20161013_1513_1Color_IntegratedResult.txt.gz","2565","72","M0","N1","T1c","Prostate Cancer","Male"
"GSM3064407","PR0724 Prostate Cancer","GSM3064407","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064407/suppl/GSM3064407_SH66836_Cell3_20161013_1514_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064408","PR0725 Prostate Cancer","GSM3064408","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064408/suppl/GSM3064408_SH66836_Cell4_20161013_1515_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064409","PR0726 Prostate Cancer","GSM3064409","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064409/suppl/GSM3064409_SH66837_Cell1_20161013_1516_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064410","PR0727 Prostate Cancer","GSM3064410","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064410/suppl/GSM3064410_SH66837_Cell2_20161013_1517_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064411","PR0728 Prostate Cancer","GSM3064411","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064411/suppl/GSM3064411_SH66837_Cell3_20161013_1518_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064412","PR0729 Prostate Cancer","GSM3064412","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064412/suppl/GSM3064412_SH66837_Cell4_20161013_1519_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064413","PR0730 Prostate Cancer","GSM3064413","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 53","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064413/suppl/GSM3064413_SH66840_Cell1_20161013_1520_1Color_IntegratedResult.txt.gz","2565","53","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064414","PR0731 Prostate Cancer","GSM3064414","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064414/suppl/GSM3064414_SH66840_Cell2_20161013_1521_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064415","PR0734 Prostate Cancer","GSM3064415","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064415/suppl/GSM3064415_SH66841_Cell1_20161013_1524_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064416","PR0735 Prostate Cancer","GSM3064416","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 84","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064416/suppl/GSM3064416_SH66841_Cell2_20161013_1525_1Color_IntegratedResult.txt.gz","2565","84","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064417","PR0736 Prostate Cancer","GSM3064417","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 55","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064417/suppl/GSM3064417_SH66841_Cell3_20161013_1526_1Color_IntegratedResult.txt.gz","2565","55","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064418","PR0737 Prostate Cancer","GSM3064418","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 51","ctstage: T4","cnstage: N1","cmstage: M1a","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064418/suppl/GSM3064418_SH66841_Cell4_20161013_1527_1Color_IntegratedResult.txt.gz","2565","51","M1a","N1","T4","Prostate Cancer","Male"
"GSM3064419","PR0738 Prostate Cancer","GSM3064419","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064419/suppl/GSM3064419_SH66842_Cell1_20161013_1528_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064420","PR0739 Prostate Cancer","GSM3064420","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064420/suppl/GSM3064420_SH66842_Cell2_20161013_1529_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064421","PR0740 Prostate Cancer","GSM3064421","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064421/suppl/GSM3064421_SH66842_Cell3_20161013_1530_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064422","PR0742 Prostate Cancer","GSM3064422","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064422/suppl/GSM3064422_SH66843_Cell1_20161013_1532_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064423","PR0743 Prostate Cancer","GSM3064423","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064423/suppl/GSM3064423_SH66843_Cell2_20161013_1533_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064424","PR0744 Prostate Cancer","GSM3064424","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064424/suppl/GSM3064424_SH66843_Cell3_20161013_1534_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064425","PR0745 Prostate Cancer","GSM3064425","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 52","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064425/suppl/GSM3064425_SH66843_Cell4_20161013_1535_1Color_IntegratedResult.txt.gz","2565","52","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064426","PR0748 Prostate Cancer","GSM3064426","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 53","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064426/suppl/GSM3064426_SH66845_Cell3_20161013_1538_1Color_IntegratedResult.txt.gz","2565","53","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064427","PR0749 Prostate Cancer","GSM3064427","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064427/suppl/GSM3064427_SH66845_Cell4_20161013_1539_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064428","PR0751 Prostate Cancer","GSM3064428","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 39","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064428/suppl/GSM3064428_SH66846_Cell2_20161013_1541_1Color_IntegratedResult.txt.gz","2565","39","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064429","PR0752 Prostate Cancer","GSM3064429","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064429/suppl/GSM3064429_SH66846_Cell3_20161013_1542_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064430","PR0753 Prostate Cancer","GSM3064430","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064430/suppl/GSM3064430_SH66846_Cell4_20161013_1543_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064431","PR0755 Prostate Cancer","GSM3064431","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064431/suppl/GSM3064431_SH66847_Cell2_20161013_1545_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064432","PR0756 Prostate Cancer","GSM3064432","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064432/suppl/GSM3064432_SH66847_Cell3_20161013_1546_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064433","PR0758 Prostate Cancer","GSM3064433","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2b","cnstage: N0","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064433/suppl/GSM3064433_SH66848_Cell1_20161013_1548_1Color_IntegratedResult.txt.gz","2565","72","M1b","N0","T2b","Prostate Cancer","Male"
"GSM3064434","PR0759 Prostate Cancer","GSM3064434","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064434/suppl/GSM3064434_SH66848_Cell2_20161013_1549_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064435","PR0760 Prostate Cancer","GSM3064435","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064435/suppl/GSM3064435_SH66848_Cell3_20161013_1550_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064436","PR0762 Prostate Cancer","GSM3064436","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064436/suppl/GSM3064436_SH66849_Cell1_20161013_1552_1Color_IntegratedResult.txt.gz","2565","62","M0","N1","T1c","Prostate Cancer","Male"
"GSM3064437","PR0763 Prostate Cancer","GSM3064437","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064437/suppl/GSM3064437_SH66849_Cell2_20161013_1553_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064438","PR0764 Prostate Cancer","GSM3064438","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064438/suppl/GSM3064438_SH66849_Cell3_20161013_1554_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064439","PR0766 Prostate Cancer","GSM3064439","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 53","ctstage: T3a","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064439/suppl/GSM3064439_SH66850_Cell1_20161013_1556_1Color_IntegratedResult.txt.gz","2565","53","M0","N1","T3a","Prostate Cancer","Male"
"GSM3064440","PR0767 Prostate Cancer","GSM3064440","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064440/suppl/GSM3064440_SH66850_Cell2_20161013_1557_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064441","PR0768 Prostate Cancer","GSM3064441","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064441/suppl/GSM3064441_SH66850_Cell3_20161013_1558_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064442","PR0769 Prostate Cancer","GSM3064442","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064442/suppl/GSM3064442_SH66850_Cell4_20161013_1559_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064443","PR0770 Prostate Cancer","GSM3064443","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064443/suppl/GSM3064443_SH66851_Cell1_20161013_1600_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064444","PR0771 Prostate Cancer","GSM3064444","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 79","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064444/suppl/GSM3064444_SH66851_Cell2_20161013_1601_1Color_IntegratedResult.txt.gz","2565","79","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064445","PR0773 Prostate Cancer","GSM3064445","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T1c","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064445/suppl/GSM3064445_SH66851_Cell4_20161013_1603_1Color_IntegratedResult.txt.gz","2565","74","M0","N1","T1c","Prostate Cancer","Male"
"GSM3064446","PR0776 Prostate Cancer","GSM3064446","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064446/suppl/GSM3064446_SH66852_Cell3_20161013_1606_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064447","PR0778 Prostate Cancer","GSM3064447","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064447/suppl/GSM3064447_SH66853_Cell1_20161013_1608_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064448","PR0780 Prostate Cancer","GSM3064448","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064448/suppl/GSM3064448_SH66853_Cell3_20161013_1610_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064449","PR0781 Prostate Cancer","GSM3064449","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064449/suppl/GSM3064449_SH66853_Cell4_20161013_1611_1Color_IntegratedResult.txt.gz","2565","57","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064450","PR0782 Prostate Cancer","GSM3064450","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064450/suppl/GSM3064450_SH66854_Cell1_20161013_1612_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064451","PR0783 Prostate Cancer","GSM3064451","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064451/suppl/GSM3064451_SH66854_Cell2_20161013_1613_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064452","PR0786 Prostate Cancer","GSM3064452","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064452/suppl/GSM3064452_SH66855_Cell1_20161014_1530_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064453","PR0789 Prostate Cancer","GSM3064453","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064453/suppl/GSM3064453_SH66946_Cell4_20161028_1726_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064454","PR0790 Prostate Cancer","GSM3064454","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064454/suppl/GSM3064454_SH66856_Cell1_20161014_1534_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064455","PR0791 Prostate Cancer","GSM3064455","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 58","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064455/suppl/GSM3064455_SH66856_Cell2_20161014_1535_1Color_IntegratedResult.txt.gz","2565","58","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064456","PR0792 Prostate Cancer","GSM3064456","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064456/suppl/GSM3064456_SH66948_Cell1_20161028_1547_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064457","PR0793 Prostate Cancer","GSM3064457","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064457/suppl/GSM3064457_SH66948_Cell2_20161028_1548_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064458","PR0794 Prostate Cancer","GSM3064458","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064458/suppl/GSM3064458_SH66857_Cell1_20161014_1538_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064459","PR0795 Prostate Cancer","GSM3064459","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064459/suppl/GSM3064459_SH66857_Cell2_20161014_1539_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064460","PR0797 Prostate Cancer","GSM3064460","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064460/suppl/GSM3064460_SH66857_Cell4_20161014_1541_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064461","PR0800 Prostate Cancer","GSM3064461","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064461/suppl/GSM3064461_SH66858_Cell3_20161014_1544_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064462","PR0802 Prostate Cancer","GSM3064462","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064462/suppl/GSM3064462_SH66859_Cell1_20161014_1546_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064463","PR0805 Prostate Cancer","GSM3064463","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064463/suppl/GSM3064463_SH66948_Cell4_20161028_1550_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064464","PR0806 Prostate Cancer","GSM3064464","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 58","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064464/suppl/GSM3064464_SH66860_Cell1_20161014_1550_1Color_IntegratedResult.txt.gz","2565","58","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064465","PR0807 Prostate Cancer","GSM3064465","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064465/suppl/GSM3064465_SH66860_Cell2_20161014_1551_1Color_IntegratedResult.txt.gz","2565","57","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064466","PR0808 Prostate Cancer","GSM3064466","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064466/suppl/GSM3064466_SH66949_Cell1_20161028_1551_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064467","PR0809 Prostate Cancer","GSM3064467","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064467/suppl/GSM3064467_SH66860_Cell4_20161014_1553_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064468","PR0810 Prostate Cancer","GSM3064468","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064468/suppl/GSM3064468_SH66861_Cell1_20161014_1554_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064469","PR0811 Prostate Cancer","GSM3064469","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 52","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064469/suppl/GSM3064469_SH66861_Cell2_20161014_1555_1Color_IntegratedResult.txt.gz","2565","52","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064470","PR0812 Prostate Cancer","GSM3064470","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064470/suppl/GSM3064470_SH66861_Cell3_20161014_1556_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064471","PR0813 Prostate Cancer","GSM3064471","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064471/suppl/GSM3064471_SH66861_Cell4_20161014_1557_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064472","PR0815 Prostate Cancer","GSM3064472","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064472/suppl/GSM3064472_SH66862_Cell2_20161014_1559_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064473","PR0817 Prostate Cancer","GSM3064473","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 54","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064473/suppl/GSM3064473_SH66862_Cell4_20161014_1601_1Color_IntegratedResult.txt.gz","2565","54","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064474","PR0818 Prostate Cancer","GSM3064474","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064474/suppl/GSM3064474_SH66863_Cell1_20161014_1602_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064475","PR0819 Prostate Cancer","GSM3064475","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064475/suppl/GSM3064475_SH66863_Cell2_20161014_1603_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064476","PR0820 Prostate Cancer","GSM3064476","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064476/suppl/GSM3064476_SH66863_Cell3_20161014_1604_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064477","PR0821 Prostate Cancer","GSM3064477","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 58","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064477/suppl/GSM3064477_SH66863_Cell4_20161014_1605_1Color_IntegratedResult.txt.gz","2565","58","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064478","PR0823 Prostate Cancer","GSM3064478","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064478/suppl/GSM3064478_SH66903_Cell2_20161014_1607_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064479","PR0825 Prostate Cancer","GSM3064479","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064479/suppl/GSM3064479_SH66903_Cell4_20161014_1609_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064480","PR0828 Prostate Cancer","GSM3064480","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064480/suppl/GSM3064480_SH66904_Cell3_20161014_1612_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064481","PR0829 Prostate Cancer","GSM3064481","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 55","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064481/suppl/GSM3064481_SH66949_Cell2_20161028_1552_1Color_IntegratedResult.txt.gz","2565","55","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064482","PR0833 Prostate Cancer","GSM3064482","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064482/suppl/GSM3064482_SH66905_Cell4_20161014_1617_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064483","PR0834 Prostate Cancer","GSM3064483","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064483/suppl/GSM3064483_SH66906_Cell1_20161014_1618_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064484","PR0838 Prostate Cancer","GSM3064484","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064484/suppl/GSM3064484_SH66907_Cell1_20161014_1622_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064485","PR0840 Prostate Cancer","GSM3064485","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064485/suppl/GSM3064485_SH66907_Cell3_20161014_1624_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064486","PR0845 Prostate Cancer","GSM3064486","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064486/suppl/GSM3064486_SH66908_Cell4_20161014_1629_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064487","PR0846 Prostate Cancer","GSM3064487","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 51","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064487/suppl/GSM3064487_SH66909_Cell1_20161014_1630_1Color_IntegratedResult.txt.gz","2565","51","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064488","PR0847 Prostate Cancer","GSM3064488","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064488/suppl/GSM3064488_SH66909_Cell2_20161014_1631_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064489","PR0849 Prostate Cancer","GSM3064489","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064489/suppl/GSM3064489_SH66909_Cell4_20161014_1633_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064490","PR0850 Prostate Cancer","GSM3064490","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064490/suppl/GSM3064490_SH66910_Cell1_20161014_1634_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064491","PR0851 Prostate Cancer","GSM3064491","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064491/suppl/GSM3064491_SH66910_Cell2_20161014_1635_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064492","PR0853 Prostate Cancer","GSM3064492","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064492/suppl/GSM3064492_SH66910_Cell4_20161014_1637_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064493","PR0856 Prostate Cancer","GSM3064493","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064493/suppl/GSM3064493_SH66911_Cell3_20161014_1640_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064494","PR0857 Prostate Cancer","GSM3064494","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 54","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064494/suppl/GSM3064494_SH66911_Cell4_20161014_1641_1Color_IntegratedResult.txt.gz","2565","54","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064495","PR0859 Prostate Cancer","GSM3064495","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064495/suppl/GSM3064495_SH66912_Cell2_20161014_1643_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064496","PR0860 Prostate Cancer","GSM3064496","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064496/suppl/GSM3064496_SH66912_Cell3_20161014_1644_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064497","PR0862 Prostate Cancer","GSM3064497","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064497/suppl/GSM3064497_SH66913_Cell1_20161014_1646_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064498","PR0863 Prostate Cancer","GSM3064498","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064498/suppl/GSM3064498_SH66913_Cell2_20161014_1647_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064499","PR0864 Prostate Cancer","GSM3064499","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064499/suppl/GSM3064499_SH66913_Cell3_20161014_1648_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064500","PR0866 Prostate Cancer","GSM3064500","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064500/suppl/GSM3064500_SH66914_Cell1_20161019_1426_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064501","PR0870 Prostate Cancer","GSM3064501","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064501/suppl/GSM3064501_SH66915_Cell1_20161019_1430_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064502","PR0871 Prostate Cancer","GSM3064502","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064502/suppl/GSM3064502_SH66950_Cell2_20161028_1556_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064503","PR0872 Prostate Cancer","GSM3064503","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 54","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064503/suppl/GSM3064503_SH66915_Cell3_20161019_1432_1Color_IntegratedResult.txt.gz","2565","54","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064504","PR0879 Prostate Cancer","GSM3064504","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064504/suppl/GSM3064504_SH66917_Cell2_20161019_1439_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064505","PR0881 Prostate Cancer","GSM3064505","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064505/suppl/GSM3064505_SH66917_Cell4_20161019_1441_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064506","PR0882 Prostate Cancer","GSM3064506","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064506/suppl/GSM3064506_SH66918_Cell1_20161019_1442_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064507","PR0885 Prostate Cancer","GSM3064507","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064507/suppl/GSM3064507_SH66918_Cell4_20161019_1445_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064508","PR0886 Prostate Cancer","GSM3064508","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064508/suppl/GSM3064508_SH66919_Cell1_20161019_1446_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064509","PR0887 Prostate Cancer","GSM3064509","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064509/suppl/GSM3064509_SH66950_Cell4_20161028_1558_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064510","PR0889 Prostate Cancer","GSM3064510","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064510/suppl/GSM3064510_SH66919_Cell4_20161019_1449_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064511","PR0890 Prostate Cancer","GSM3064511","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064511/suppl/GSM3064511_SH66920_Cell1_20161019_1450_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064512","PR0892 Prostate Cancer","GSM3064512","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 52","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064512/suppl/GSM3064512_SH66920_Cell3_20161019_1452_1Color_IntegratedResult.txt.gz","2565","52","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064513","PR0894 Prostate Cancer","GSM3064513","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064513/suppl/GSM3064513_SH66921_Cell1_20161019_1454_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064514","PR0896 Prostate Cancer","GSM3064514","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 58","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064514/suppl/GSM3064514_SH66921_Cell3_20161019_1456_1Color_IntegratedResult.txt.gz","2565","58","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064515","PR0897 Prostate Cancer","GSM3064515","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T4","cnstage: N1","cmstage: M1a","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064515/suppl/GSM3064515_SH66951_Cell1_20161028_1559_1Color_IntegratedResult.txt.gz","2565","68","M1a","N1","T4","Prostate Cancer","Male"
"GSM3064516","PR0898 Prostate Cancer","GSM3064516","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064516/suppl/GSM3064516_SH66922_Cell1_20161019_1458_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064517","PR0900 Prostate Cancer","GSM3064517","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064517/suppl/GSM3064517_SH66922_Cell3_20161019_1500_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064518","PR0902 Prostate Cancer","GSM3064518","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064518/suppl/GSM3064518_SH66923_Cell1_20161019_1502_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064519","PR0903 Prostate Cancer","GSM3064519","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064519/suppl/GSM3064519_SH66923_Cell2_20161019_1503_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064520","PR0904 Prostate Cancer","GSM3064520","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064520/suppl/GSM3064520_SH66923_Cell3_20161019_1504_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064521","PR0906 Prostate Cancer","GSM3064521","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064521/suppl/GSM3064521_SH66924_Cell1_20161019_1506_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064522","PR0907 Prostate Cancer","GSM3064522","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064522/suppl/GSM3064522_SH66924_Cell2_20161019_1507_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064523","PR0908 Prostate Cancer","GSM3064523","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064523/suppl/GSM3064523_SH66924_Cell3_20161019_1508_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064524","PR0909 Prostate Cancer","GSM3064524","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064524/suppl/GSM3064524_SH66924_Cell4_20161019_1509_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064525","PR0910 Prostate Cancer","GSM3064525","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064525/suppl/GSM3064525_SH66925_Cell1_20161019_1510_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064526","PR0911 Prostate Cancer","GSM3064526","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064526/suppl/GSM3064526_SH66925_Cell2_20161019_1511_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064527","PR0912 Prostate Cancer","GSM3064527","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064527/suppl/GSM3064527_SH66925_Cell3_20161019_1512_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064528","PR0913 Prostate Cancer","GSM3064528","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064528/suppl/GSM3064528_SH66925_Cell4_20161019_1513_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064529","PR0915 Prostate Cancer","GSM3064529","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064529/suppl/GSM3064529_SH66926_Cell2_20161019_1515_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064530","PR0916 Prostate Cancer","GSM3064530","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T3b","cnstage: N1","cmstage: M1b","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064530/suppl/GSM3064530_SH66926_Cell3_20161019_1516_1Color_IntegratedResult.txt.gz","2565","65","M1b","N1","T3b","Prostate Cancer","Male"
"GSM3064531","PR0917 Prostate Cancer","GSM3064531","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064531/suppl/GSM3064531_SH66926_Cell4_20161019_1517_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064532","PR0918 Prostate Cancer","GSM3064532","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064532/suppl/GSM3064532_SH66928_Cell1_20161019_1518_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064533","PR0919 Prostate Cancer","GSM3064533","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064533/suppl/GSM3064533_SH66928_Cell2_20161019_1519_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064534","PR0920 Prostate Cancer","GSM3064534","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064534/suppl/GSM3064534_SH66951_Cell2_20161028_1600_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064535","PR0921 Prostate Cancer","GSM3064535","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064535/suppl/GSM3064535_SH66928_Cell4_20161019_1521_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064536","PR0923 Prostate Cancer","GSM3064536","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064536/suppl/GSM3064536_SH66927_Cell2_20161019_1523_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064537","PR0924 Prostate Cancer","GSM3064537","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064537/suppl/GSM3064537_SH66927_Cell3_20161019_1524_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064538","PR0925 Prostate Cancer","GSM3064538","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064538/suppl/GSM3064538_SH66927_Cell4_20161019_1525_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064539","PR0926 Prostate Cancer","GSM3064539","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064539/suppl/GSM3064539_SH66929_Cell1_20161019_1526_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064540","PR0927 Prostate Cancer","GSM3064540","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064540/suppl/GSM3064540_SH66929_Cell2_20161019_1527_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064541","PR0929 Prostate Cancer","GSM3064541","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064541/suppl/GSM3064541_SH66929_Cell4_20161019_1529_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064542","PR0930 Prostate Cancer","GSM3064542","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064542/suppl/GSM3064542_SH66930_Cell1_20161019_1530_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064543","PR0931 Prostate Cancer","GSM3064543","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064543/suppl/GSM3064543_SH66930_Cell2_20161019_1531_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064544","PR0932 Prostate Cancer","GSM3064544","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 74","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064544/suppl/GSM3064544_SH66930_Cell3_20161019_1532_1Color_IntegratedResult.txt.gz","2565","74","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064545","PR0934 Prostate Cancer","GSM3064545","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064545/suppl/GSM3064545_SH66934_Cell1_20161020_1218_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064546","PR0935 Prostate Cancer","GSM3064546","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064546/suppl/GSM3064546_SH66934_Cell2_20161020_1219_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064547","PR0936 Prostate Cancer","GSM3064547","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 78","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064547/suppl/GSM3064547_SH66934_Cell3_20161020_1220_1Color_IntegratedResult.txt.gz","2565","78","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064548","PR0938 Prostate Cancer","GSM3064548","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064548/suppl/GSM3064548_SH66936_Cell1_20161020_1222_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064549","PR0939 Prostate Cancer","GSM3064549","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064549/suppl/GSM3064549_SH66936_Cell2_20161020_1223_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064550","PR0940 Prostate Cancer","GSM3064550","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064550/suppl/GSM3064550_SH66936_Cell3_20161020_1224_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064551","PR0941 Prostate Cancer","GSM3064551","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064551/suppl/GSM3064551_SH66936_Cell4_20161020_1225_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064552","PR0942 Prostate Cancer","GSM3064552","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064552/suppl/GSM3064552_SH66938_Cell1_20161020_1226_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064553","PR0943 Prostate Cancer","GSM3064553","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064553/suppl/GSM3064553_SH66938_Cell2_20161020_1227_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064554","PR0944 Prostate Cancer","GSM3064554","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064554/suppl/GSM3064554_SH66938_Cell3_20161020_1228_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064555","PR0945 Prostate Cancer","GSM3064555","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064555/suppl/GSM3064555_SH66938_Cell4_20161020_1229_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064556","PR0947 Prostate Cancer","GSM3064556","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064556/suppl/GSM3064556_SH66939_Cell2_20161020_1231_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064557","PR0948 Prostate Cancer","GSM3064557","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064557/suppl/GSM3064557_SH66939_Cell3_20161020_1232_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064558","PR0950 Prostate Cancer","GSM3064558","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064558/suppl/GSM3064558_SH66940_Cell1_20161020_1234_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064559","PR0951 Prostate Cancer","GSM3064559","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064559/suppl/GSM3064559_SH66940_Cell2_20161020_1235_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064560","PR0952 Prostate Cancer","GSM3064560","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064560/suppl/GSM3064560_SH66940_Cell3_20161020_1236_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064561","PR0954 Prostate Cancer","GSM3064561","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 54","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064561/suppl/GSM3064561_SH66941_Cell1_20161020_1238_1Color_IntegratedResult.txt.gz","2565","54","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064562","PR0955 Prostate Cancer","GSM3064562","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064562/suppl/GSM3064562_SH66941_Cell2_20161020_1239_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064563","PR0956 Prostate Cancer","GSM3064563","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064563/suppl/GSM3064563_SH66941_Cell3_20161020_1240_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064564","PR0958 Prostate Cancer","GSM3064564","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064564/suppl/GSM3064564_SH66942_Cell1_20161020_1242_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064565","PR0959 Prostate Cancer","GSM3064565","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064565/suppl/GSM3064565_SH66942_Cell2_20161020_1243_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064566","PR0960 Prostate Cancer","GSM3064566","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064566/suppl/GSM3064566_SH66942_Cell3_20161020_1244_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064567","PR0961 Prostate Cancer","GSM3064567","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064567/suppl/GSM3064567_SH66942_Cell4_20161020_1245_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064568","PR0962 Prostate Cancer","GSM3064568","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 61","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064568/suppl/GSM3064568_SH66943_Cell1_20161020_1246_1Color_IntegratedResult.txt.gz","2565","61","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064569","PR0964 Prostate Cancer","GSM3064569","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064569/suppl/GSM3064569_SH66943_Cell3_20161020_1248_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064570","PR0966 Prostate Cancer","GSM3064570","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 44","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064570/suppl/GSM3064570_SH66944_Cell1_20161020_1250_1Color_IntegratedResult.txt.gz","2565","44","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064571","PR0967 Prostate Cancer","GSM3064571","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064571/suppl/GSM3064571_SH66944_Cell2_20161020_1251_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064572","PR0968 Prostate Cancer","GSM3064572","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 77","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064572/suppl/GSM3064572_SH66944_Cell3_20161020_1252_1Color_IntegratedResult.txt.gz","2565","77","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064573","PR0969 Prostate Cancer","GSM3064573","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T2a","cnstage: N1","cmstage: M1a","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064573/suppl/GSM3064573_SH66944_Cell4_20161020_1253_1Color_IntegratedResult.txt.gz","2565","76","M1a","N1","T2a","Prostate Cancer","Male"
"GSM3064574","PR0970 Prostate Cancer","GSM3064574","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 68","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064574/suppl/GSM3064574_SH66945_Cell1_20161020_1254_1Color_IntegratedResult.txt.gz","2565","68","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064575","PR0971 Prostate Cancer","GSM3064575","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064575/suppl/GSM3064575_SH66945_Cell2_20161020_1255_1Color_IntegratedResult.txt.gz","2565","57","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064576","PR0972 Prostate Cancer","GSM3064576","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064576/suppl/GSM3064576_SH66945_Cell3_20161020_1256_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064577","PR0973 Prostate Cancer","GSM3064577","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 54","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064577/suppl/GSM3064577_SH66945_Cell4_20161020_1257_1Color_IntegratedResult.txt.gz","2565","54","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064578","PR0975 Prostate Cancer","GSM3064578","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064578/suppl/GSM3064578_SH66951_Cell4_20161028_1602_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064579","PR0976 Prostate Cancer","GSM3064579","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064579/suppl/GSM3064579_SH66952_Cell1_20161028_1603_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064580","PR0977 Prostate Cancer","GSM3064580","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064580/suppl/GSM3064580_SH66952_Cell2_20161028_1727_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064581","PR0978 Prostate Cancer","GSM3064581","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064581/suppl/GSM3064581_SH66952_Cell3_20161028_1605_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064582","PR0979 Prostate Cancer","GSM3064582","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064582/suppl/GSM3064582_SH66952_Cell4_20161028_1606_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064583","PR0980 Prostate Cancer","GSM3064583","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064583/suppl/GSM3064583_SH66953_Cell1_20161028_1607_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064584","PR0981 Prostate Cancer","GSM3064584","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064584/suppl/GSM3064584_SH66953_Cell2_20161028_1608_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064585","PR0982 Prostate Cancer","GSM3064585","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064585/suppl/GSM3064585_SH66953_Cell3_20161028_1728_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064586","PR0983 Prostate Cancer","GSM3064586","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T3b","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064586/suppl/GSM3064586_SH66953_Cell4_20161028_1610_1Color_IntegratedResult.txt.gz","2565","69","M0","N1","T3b","Prostate Cancer","Male"
"GSM3064587","PR0984 Prostate Cancer","GSM3064587","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064587/suppl/GSM3064587_SH66955_Cell1_20161028_1611_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064588","PR0985 Prostate Cancer","GSM3064588","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064588/suppl/GSM3064588_SH66955_Cell2_20161028_1612_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064589","PR0986 Prostate Cancer","GSM3064589","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 67","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064589/suppl/GSM3064589_SH66955_Cell3_20161028_1613_1Color_IntegratedResult.txt.gz","2565","67","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064590","PR0987 Prostate Cancer","GSM3064590","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064590/suppl/GSM3064590_SH66955_Cell4_20161028_1614_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064591","PR0989 Prostate Cancer","GSM3064591","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 55","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064591/suppl/GSM3064591_SH67M43_Cell2_20161116_1710_1Color_IntegratedResult.txt.gz","2565","55","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064592","PR0990 Prostate Cancer","GSM3064592","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 56","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064592/suppl/GSM3064592_SH66956_Cell3_20161028_1617_1Color_IntegratedResult.txt.gz","2565","56","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064593","PR0993 Prostate Cancer","GSM3064593","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064593/suppl/GSM3064593_SH66957_Cell2_20161028_1620_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064594","PR0994 Prostate Cancer","GSM3064594","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064594/suppl/GSM3064594_SH66957_Cell3_20161028_1621_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064595","PR0995 Prostate Cancer","GSM3064595","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064595/suppl/GSM3064595_SH66957_Cell4_20161028_1622_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064596","PR0996 Prostate Cancer","GSM3064596","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064596/suppl/GSM3064596_SH66958_Cell1_20161028_1623_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064597","PR0999 Prostate Cancer","GSM3064597","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 60","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064597/suppl/GSM3064597_SH66958_Cell4_20161028_1626_1Color_IntegratedResult.txt.gz","2565","60","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064598","PR1001 Prostate Cancer","GSM3064598","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 76","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064598/suppl/GSM3064598_SH66959_Cell2_20161028_1628_1Color_IntegratedResult.txt.gz","2565","76","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064599","PR1002 Prostate Cancer","GSM3064599","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064599/suppl/GSM3064599_SH66959_Cell3_20161028_1629_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064600","PR1003 Prostate Cancer","GSM3064600","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T3b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064600/suppl/GSM3064600_SH67M43_Cell3_20161116_1711_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T3b","Prostate Cancer","Male"
"GSM3064601","PR1004 Prostate Cancer","GSM3064601","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064601/suppl/GSM3064601_SH66961_Cell1_20161028_1631_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064602","PR1006 Prostate Cancer","GSM3064602","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064602/suppl/GSM3064602_SH66961_Cell3_20161028_1633_1Color_IntegratedResult.txt.gz","2565","59","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064603","PR1007 Prostate Cancer","GSM3064603","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 58","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064603/suppl/GSM3064603_SH66961_Cell4_20161028_1634_1Color_IntegratedResult.txt.gz","2565","58","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064604","PR1008 Prostate Cancer","GSM3064604","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 75","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064604/suppl/GSM3064604_SH66962_Cell1_20161028_1635_1Color_IntegratedResult.txt.gz","2565","75","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064605","PR1009 Prostate Cancer","GSM3064605","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064605/suppl/GSM3064605_SH66962_Cell2_20161028_1636_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064606","PR1010 Prostate Cancer","GSM3064606","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064606/suppl/GSM3064606_SH66962_Cell3_20161028_1637_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064607","PR1011 Prostate Cancer","GSM3064607","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T3a","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064607/suppl/GSM3064607_SH66962_Cell4_20161028_1638_1Color_IntegratedResult.txt.gz","2565","66","M0","N1","T3a","Prostate Cancer","Male"
"GSM3064608","PR1012 Prostate Cancer","GSM3064608","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064608/suppl/GSM3064608_SH66963_Cell1_20161028_1643_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064609","PR1013 Prostate Cancer","GSM3064609","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064609/suppl/GSM3064609_SH66963_Cell2_20161028_1644_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064610","PR1014 Prostate Cancer","GSM3064610","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T2b","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064610/suppl/GSM3064610_SH67M43_Cell4_20161116_1712_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T2b","Prostate Cancer","Male"
"GSM3064611","PR1015 Prostate Cancer","GSM3064611","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064611/suppl/GSM3064611_SH66963_Cell4_20161028_1646_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064612","PR1016 Prostate Cancer","GSM3064612","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064612/suppl/GSM3064612_SH66D02_Cell1_20161028_1639_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064613","PR1019 Prostate Cancer","GSM3064613","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064613/suppl/GSM3064613_SH66D02_Cell4_20161028_1642_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064614","PR1021 Prostate Cancer","GSM3064614","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064614/suppl/GSM3064614_SH66D03_Cell2_20161028_1648_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064615","PR1025 Prostate Cancer","GSM3064615","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 65","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064615/suppl/GSM3064615_SH66D04_Cell2_20161031_1027_1Color_IntegratedResult.txt.gz","2565","65","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064616","PR1027 Prostate Cancer","GSM3064616","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 71","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064616/suppl/GSM3064616_SH66D04_Cell4_20161028_1654_1Color_IntegratedResult.txt.gz","2565","71","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064617","PR1028 Prostate Cancer","GSM3064617","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064617/suppl/GSM3064617_SH66D05_Cell1_20161028_1655_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064618","PR1029 Prostate Cancer","GSM3064618","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 66","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064618/suppl/GSM3064618_SH66D05_Cell2_20161028_1656_1Color_IntegratedResult.txt.gz","2565","66","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064619","PR1030 Prostate Cancer","GSM3064619","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064619/suppl/GSM3064619_SH66D05_Cell3_20161028_1657_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064620","PR1031 Prostate Cancer","GSM3064620","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 64","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064620/suppl/GSM3064620_SH66D05_Cell4_20161028_1658_1Color_IntegratedResult.txt.gz","2565","64","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064621","PR1032 Prostate Cancer","GSM3064621","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 63","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064621/suppl/GSM3064621_SH66D06_Cell1_20161028_1659_1Color_IntegratedResult.txt.gz","2565","63","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064622","PR1033 Prostate Cancer","GSM3064622","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 72","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064622/suppl/GSM3064622_SH66D06_Cell2_20161028_1700_1Color_IntegratedResult.txt.gz","2565","72","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064623","PR1034 Prostate Cancer","GSM3064623","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 53","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064623/suppl/GSM3064623_SH66D06_Cell3_20161028_1701_1Color_IntegratedResult.txt.gz","2565","53","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064624","PR1035 Prostate Cancer","GSM3064624","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 57","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064624/suppl/GSM3064624_SH66D06_Cell4_20161028_1702_1Color_IntegratedResult.txt.gz","2565","57","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064625","PR1036 Prostate Cancer","GSM3064625","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064625/suppl/GSM3064625_SH67M03_Cell1_20161101_1423_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064626","PR1037 Prostate Cancer","GSM3064626","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T3a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064626/suppl/GSM3064626_SH67M03_Cell2_20161101_1424_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T3a","Prostate Cancer","Male"
"GSM3064627","PR1038 Prostate Cancer","GSM3064627","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 69","ctstage: T2c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064627/suppl/GSM3064627_SH67M03_Cell3_20161101_1425_1Color_IntegratedResult.txt.gz","2565","69","M0","N0","T2c","Prostate Cancer","Male"
"GSM3064628","PR1039 Prostate Cancer","GSM3064628","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 59","ctstage: T1c","cnstage: N1","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064628/suppl/GSM3064628_SH67M03_Cell4_20161101_1426_1Color_IntegratedResult.txt.gz","2565","59","M0","N1","T1c","Prostate Cancer","Male"
"GSM3064629","PR1040 Prostate Cancer","GSM3064629","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 62","ctstage: T2a","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064629/suppl/GSM3064629_SH67M04_Cell1_20161101_1427_1Color_IntegratedResult.txt.gz","2565","62","M0","N0","T2a","Prostate Cancer","Male"
"GSM3064630","PR1041 Prostate Cancer","GSM3064630","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 70","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064630/suppl/GSM3064630_SH67M04_Cell2_20161101_1428_1Color_IntegratedResult.txt.gz","2565","70","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064631","PR1042 Prostate Cancer","GSM3064631","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 81","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064631/suppl/GSM3064631_SH67M04_Cell3_20161101_1429_1Color_IntegratedResult.txt.gz","2565","81","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064632","PR1043 Prostate Cancer","GSM3064632","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064632/suppl/GSM3064632_SH67M04_Cell4_20161101_1430_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064633","PR1044 Prostate Cancer","GSM3064633","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Prostate Cancer","Sex: Male","age: 73","ctstage: T1c","cnstage: N0","cmstage: M0","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064633/suppl/GSM3064633_SH67M05_Cell1_20161101_1431_1Color_IntegratedResult.txt.gz","2565","73","M0","N0","T1c","Prostate Cancer","Male"
"GSM3064634","SA0055 Sarcoma","GSM3064634","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064634/suppl/GSM3064634_SH59Q53_Cell3_20160113_1620_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064635","SA0063 Sarcoma","GSM3064635","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 74","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064635/suppl/GSM3064635_SH59Q55_Cell3_20160113_1519_1Color_IntegratedResult.txt.gz","2565","74","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064636","SA0094 Sarcoma","GSM3064636","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 51","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064636/suppl/GSM3064636_SH59Q64_Cell1_20160113_1549_1Color_IntegratedResult.txt.gz","2565","51","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064637","SA0105 Sarcoma","GSM3064637","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 36","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064637/suppl/GSM3064637_SH59W02_Cell3_20160113_1559_1Color_IntegratedResult.txt.gz","2565","36","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064638","SA0108 Sarcoma","GSM3064638","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 45","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064638/suppl/GSM3064638_SH59W03_Cell2_20160113_1602_1Color_IntegratedResult.txt.gz","2565","45","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064639","SA0123 Sarcoma","GSM3064639","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 47","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064639/suppl/GSM3064639_SH59W06_Cell1_20160113_1613_1Color_IntegratedResult.txt.gz","2565","47","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064640","SA0167 Sarcoma","GSM3064640","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 77","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064640/suppl/GSM3064640_SH59W15_Cell1_20160114_1521_1Color_IntegratedResult.txt.gz","2565","77","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064641","SA0181 Sarcoma","GSM3064641","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064641/suppl/GSM3064641_SH59W17_Cell4_20160114_1532_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064642","SA0183 Sarcoma","GSM3064642","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064642/suppl/GSM3064642_SH59W18_Cell2_20160114_1534_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064643","SA0187 Sarcoma","GSM3064643","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 44","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064643/suppl/GSM3064643_SH59W19_Cell2_20160114_1538_1Color_IntegratedResult.txt.gz","2565","44","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064644","SA0202 Sarcoma","GSM3064644","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 41","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064644/suppl/GSM3064644_SH59W23_Cell3_20160114_1551_1Color_IntegratedResult.txt.gz","2565","41","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064645","SA0215 Sarcoma","GSM3064645","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 49","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064645/suppl/GSM3064645_SH59W26_Cell2_20160114_1602_1Color_IntegratedResult.txt.gz","2565","49","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064646","SA0267 Sarcoma","GSM3064646","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 25","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064646/suppl/GSM3064646_SH59W40_Cell2_20160115_1558_1Color_IntegratedResult.txt.gz","2565","25","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064647","SA0268 Sarcoma","GSM3064647","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 57","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064647/suppl/GSM3064647_SH59W40_Cell3_20160115_1559_1Color_IntegratedResult.txt.gz","2565","57","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064648","SA0279 Sarcoma","GSM3064648","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 50","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064648/suppl/GSM3064648_SH59W43_Cell1_20160115_1609_1Color_IntegratedResult.txt.gz","2565","50","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064649","SA0280 Sarcoma","GSM3064649","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 78","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064649/suppl/GSM3064649_SH59W43_Cell2_20160115_1610_1Color_IntegratedResult.txt.gz","2565","78","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064650","SA0282 Sarcoma","GSM3064650","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 48","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064650/suppl/GSM3064650_SH59W43_Cell4_20160115_1612_1Color_IntegratedResult.txt.gz","2565","48","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064651","SA0287 Sarcoma","GSM3064651","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064651/suppl/GSM3064651_SH59W46_Cell1_20160115_1617_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064652","SA0294 Sarcoma","GSM3064652","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 37","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064652/suppl/GSM3064652_SH59W47_Cell3_20160115_1623_1Color_IntegratedResult.txt.gz","2565","37","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064653","SA0298 Sarcoma","GSM3064653","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064653/suppl/GSM3064653_SH59W48_Cell3_20160115_1627_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064654","SA0301 Sarcoma","GSM3064654","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 79","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064654/suppl/GSM3064654_SH59W49_Cell2_20160115_1630_1Color_IntegratedResult.txt.gz","2565","79","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064655","SA0302 Sarcoma","GSM3064655","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 75","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064655/suppl/GSM3064655_SH59W49_Cell3_20160115_1631_1Color_IntegratedResult.txt.gz","2565","75","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064656","SA0305 Sarcoma","GSM3064656","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064656/suppl/GSM3064656_SH59W50_Cell2_20160115_1634_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064657","SA0310 Sarcoma","GSM3064657","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 45","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064657/suppl/GSM3064657_SH59W51_Cell3_20160115_1639_1Color_IntegratedResult.txt.gz","2565","45","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064658","SA0324 Sarcoma","GSM3064658","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 69","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064658/suppl/GSM3064658_SH59W55_Cell1_20160119_1537_1Color_IntegratedResult.txt.gz","2565","69","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064659","SA0326 Sarcoma","GSM3064659","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064659/suppl/GSM3064659_SH59W55_Cell3_20160119_1539_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064660","SA0329 Sarcoma","GSM3064660","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 73","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064660/suppl/GSM3064660_SH59W56_Cell2_20160119_1542_1Color_IntegratedResult.txt.gz","2565","73","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064661","SA0331 Sarcoma","GSM3064661","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064661/suppl/GSM3064661_SH59W56_Cell4_20160119_1544_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064662","SA0341 Sarcoma","GSM3064662","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064662/suppl/GSM3064662_SH59W59_Cell2_20160119_1554_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064663","SA0342 Sarcoma","GSM3064663","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 58","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064663/suppl/GSM3064663_SH59W59_Cell3_20160119_1555_1Color_IntegratedResult.txt.gz","2565","58","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064664","SA0353 Sarcoma","GSM3064664","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064664/suppl/GSM3064664_SH59W62_Cell1_20160119_1605_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064665","SA0364 Sarcoma","GSM3064665","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 59","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064665/suppl/GSM3064665_SH59X02_Cell4_20160119_1616_1Color_IntegratedResult.txt.gz","2565","59","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064666","SA0368 Sarcoma","GSM3064666","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 36","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064666/suppl/GSM3064666_SH59X03_Cell4_20160119_1620_1Color_IntegratedResult.txt.gz","2565","36","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064667","SA0369 Sarcoma","GSM3064667","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 67","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064667/suppl/GSM3064667_SH59X04_Cell1_20160119_1621_1Color_IntegratedResult.txt.gz","2565","67","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064668","SA0378 Sarcoma","GSM3064668","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 25","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064668/suppl/GSM3064668_SH59X06_Cell1_20160119_1629_1Color_IntegratedResult.txt.gz","2565","25","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064669","SA0384 Sarcoma","GSM3064669","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 20","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064669/suppl/GSM3064669_SH59X07_Cell3_20160119_1635_1Color_IntegratedResult.txt.gz","2565","20","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064670","SA0394 Sarcoma","GSM3064670","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 25","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064670/suppl/GSM3064670_SH59X09_Cell4_20160119_1644_1Color_IntegratedResult.txt.gz","2565","25","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064671","SA0468 Sarcoma","GSM3064671","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 71","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064671/suppl/GSM3064671_SH59X28_Cell2_20160121_1622_1Color_IntegratedResult.txt.gz","2565","71","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064672","SA0835 Sarcoma","GSM3064672","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 52","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064672/suppl/GSM3064672_SH51P33_Cell2_20150604_1215_1Color_IntegratedResult.txt.gz","2565","52","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064673","SA0863 Sarcoma","GSM3064673","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 62","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064673/suppl/GSM3064673_SH59Q26_Cell3_20151225_1122_1Color_IntegratedResult.txt.gz","2565","62","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064674","SA0868 Sarcoma","GSM3064674","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 56","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064674/suppl/GSM3064674_SH57Y49_Cell3_20151209_1203_1Color_IntegratedResult.txt.gz","2565","56","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064675","SA0878 Sarcoma","GSM3064675","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 22","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064675/suppl/GSM3064675_SH4YT39_Cell4_20150520_1559_1Color_IntegratedResult.txt.gz","2565","22","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064676","SA0887 Sarcoma","GSM3064676","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 85","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064676/suppl/GSM3064676_SH4YT54_Cell2_20150521_1557_1Color_IntegratedResult.txt.gz","2565","85","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064677","SA0922 Sarcoma","GSM3064677","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 56","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064677/suppl/GSM3064677_SH51840_Cell1_20150521_1632_1Color_IntegratedResult.txt.gz","2565","56","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064678","SA0923 Sarcoma","GSM3064678","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 30","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064678/suppl/GSM3064678_SH51840_Cell2_20150521_1633_1Color_IntegratedResult.txt.gz","2565","30","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064679","SA0944 Sarcoma","GSM3064679","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 41","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064679/suppl/GSM3064679_SH51847_Cell3_20150521_1654_1Color_IntegratedResult.txt.gz","2565","41","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064680","SA0967 Sarcoma","GSM3064680","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 31","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064680/suppl/GSM3064680_SH51856_Cell2_20150522_1507_1Color_IntegratedResult.txt.gz","2565","31","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064681","SA0976 Sarcoma","GSM3064681","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 66","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064681/suppl/GSM3064681_SH51858_Cell3_20150522_1516_1Color_IntegratedResult.txt.gz","2565","66","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064682","SA0981 Sarcoma","GSM3064682","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 61","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064682/suppl/GSM3064682_SH51P47_Cell4_20150604_1233_1Color_IntegratedResult.txt.gz","2565","61","uncertain","uncertain","uncertain","Sarcoma","Male"
"GSM3064683","SA1001 Sarcoma","GSM3064683","Public on Mar 01 2019","Mar 23 2018","Mar 01 2019","RNA","1","serum","Homo sapiens","disease state: Sarcoma","Sex: Male","age: 72","ctstage: uncertain","cnstage: uncertain","cmstage: uncertain","total RNA","Total RNA was extracted each from 300uL serum samples using 3D-Gene® RNA extraction reagent from liquid sample kit (Toray Industries, Inc.).","Cy5","miRNA was labeled using 3D-Gene® miRNA Labeling kit in accordance with the manufacturer's instructions.","9606","Hybridized for 16 h at 32 ºC with rotary shaker (250 rpm). Hybridization buffer and washing protocol was attached in the 3D-Gene® miRNA oligo chip kit.","3D-Gene® Scanner (Toray Industries, Inc.) was used for scanning. Images were quantified using Extraction version 2.0.0.6 (Toray Industries, Inc.).","The presence of miRNA was determined based on a corresponding microarray signal of greater than [the mean + 2 × standard deviation] of the negative controls signal, of which the top and bottom ranked ones by signal intensity were removed. Once a miRNA was considered present, the mean signal of the negative controls of which the top and bottom 5% ranked by signal intensity were removed was subtracted from the miRNA signal. When the signal value was negative (or undetEsophageal Cancerted) after background subtraction, the value was replaced by 0.1 on a base 2 logarithm scale.","GPL21263","Ichikawa,,Makiko","makiko.ichikawa.d3@mail.toray","New Frontiers Research Laboratories","Toray Industries, Inc.","6-10-1","Kamakura","Kanagawa","248-0036","Japan","ftp://ftp.ncbi.nlm.nih.gov/geo/samples/GSM3064nnn/GSM3064683/suppl/GSM3064683_SH51903_Cell4_20150522_1541_1Color_IntegratedResult.txt.gz","2565","72","uncertain","uncertain","uncertain","Sarcoma","Male"
